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ABSTRACT
The purpose of this thesis was to obtain some insight into the role of genetic 
changes in progression of human colorectal cancer. Two approaches were adopted: (i), 
determination of frequency and nature of mutations in Ki-ras and (ii), determination of 
the nature and extent of genetic aberrations, at chromosomal level, in advanced colorectal 
cancer. The main theme of the work was the use of paired tumour samples from the same 
patients in an attempt to measure the extent of genetic heterogeneity and clonal diversity 
between primary tumours and their synchronous metastases.
For Ki-ras gene, I have determined the point mutations occurring in codons 12 
and 13 of exon 1 of the Ki-ras gene in 78 patients with colorectal carcinoma (31 Dukes’ 
A and B, 21 Dukes’ C, 26 Dukes’ D) by allele specific oligonucleotide hybridisation and 
sequencing. Duplicate samples of invasive primary carcinoma, adjacent normal tissue 
and available lymph node and liver metastases from the same patients were 
microdissected from paraffin sections. There were no differences in incidence of Ki-ras 
mutations between primary carcinomas and secondary deposits: 26 of 78 (33%) primary 
carcinomas, 10 of 32 (31%) lymph node metastases, and 10 of 26 (38%) liver metastases. 
Multiple sampling revealed frequent heterogeneity within carcinomas: 9 of 26 primaries 
with Kl-ras mutations also contained areas of carcinoma with only the wild-type gene, 
implying that Ki-ras mutation, even when present in a colonic carcinoma, may not have 
been necessary for establishing the malignant phenotype. Also, 2 of 26 (8%) Dukes’ D 
patients had a mutation in their primary carcinoma but none in liver metastases and 6 of 
47 (13%) Dukes’ C and D patients had mutations in liver or lymph-node metastases but 
none in the primary carcinoma. Mutation of codon 12 from GGT (glycine) to GTT 
(valine) was more prevalent in primary and metastatic deposits of Dukes’ C/D 
carcinomas (p=0.01) than in primary carcinomas from Dukes’ A/B patients. Mutations of 
codon 12 to GAT, AGT, GCT and codon 13 GGC to GAC were also found, but no 
correlation with carcinoma aggressiveness was apparent. Follow-up of 71/78 patients (up 
to 12 years) revealed decreased overall survival (P=0.001) in patients with the GGT to 
GTT transversion in codon 12, even when the analysis was restricted to Dukes’ D cases, 
supporting the suggestion that this mutation may confer a more aggressive phenotype in 
colorectal carcinoma.
I then wanted to determine whether the correlation between valine-12 mutant Ki- 
RAS and tumour aggressiveness observed in vivo could be reflected in vitro. For this, 
Rat-1 fibroblasts transfected with valine-12 or aspartate-12 mutant or wild-type Ki-ras 
gene were assessed in terms of transformation, VEGF production and in vitro invasion. 
Both mutants demonstrated equal abilities to transform Rat-1 cells and induce VEGF 
production while cells expressing the wild-type Ki-Ras protein failed to do so. Clones of 
Rat-1 cells expressing valine-12 mutant Ki-Ras protein demonstrated increased ability to 
invade matrigel and to stimulate stromelysin-1 production compared to cells expressing 
aspartate-12 mutant Ki-Ras.
A central question in the role of mutant Ras protein in tumour biology is why 
should one particular mutation be associated with aggressive behaviour while the other is 
not? To address this question, I have used molecular modelling on the wild type, valine- 
12 and aspartate-12 Ras molecules and shown there to be a significant conformational 
differences in the GTP-bound state between the two mutants involving the effector
I
binding domain of Ras. These ‘topographic’ differences could be responsible for the 
different biological activities between the two mutants.
It is arguable, based on both in vivo and in vitro work, that the biological effects 
of the two different Ki-ras mutations cannot be assumed to be the same and the use of 
valine-12 mutant Ki-ras as a clinical marker for worse prognosis should be considered.
To determine the extent of heterogeneity between primary tumours and their 
synchronous metastases and to ascertain the role of genetic aberrations, other than Ki-ras 
mutations, in the metastatic process, I have analysed 26 tumours from 12 patients with 
metastatic colorectal adenocarcinoma by Comparative Genomic Hybridisation (CGH). 
Primary tumours and their lymph node metastases from five Dukes’ C patients and 
primary tumours and their liver metastases from seven Dukes’ D patients were used to 
assess the extent of genetic differences between primary and secondary colorectal 
carcinomas from the same patients, to assess the degree of clonal divergence and genetic 
heterogeneity in metastatic colorectal cancer, and to determine differences in genetic 
imbalances between Dukes' C and D stage tumours. The results show that the same 
genetic aberrations were frequently found in the primary tumours and their metastases. 
However, metastases frequently contained genetic aberrations not found in the 
corresponding primary tumours. The comparison of Dukes’ stages C and D revealed 
genetic aberrations common to both. However, reduced copy number of chromosome arm 
17p (5/5 versus 0/7; p=0.001) was significantly associated with Dukes’ stage C and 
lymph node metastases, while increased copy number of chromosome arms 6p (6/7 
versus 0/5; p=0.007), 8q(6/7 versus 1/5; p>0.05), and 17q (5/7 versus 0/5; p=0.027) were 
more associated with Dukes’ stage D and liver metastases. These results establish a 
repertoire of chromosomal alterations associated with metastatic colorectal cancer, and 
suggest that Dukes' C (lymph node metastasis) tumours are not always simply an earlier 
stage of Dukes' D (liver metastasis) tumours and, thus, in some instances at least, they are 
distinct forms of the disease.
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INTRODUCTION
CHAPTER 1. COLORECTAL CANCER
1.1. Epidemiology
Colorectal carcinoma is a common malignancy. It is the second most 
common malignancy in women and the third most common in men in the West of 
Scotland (Coleman et al., 1993). 31000 new cases of colorectal cancer and 18000 
deaths are registered in the United Kingdom per annum. The peak incidence of 
colorectal cancer is 60-80 years. Colonic primary tumours outnumber rectal
tumours by almost 2 to 1. For colon cancer, there is a female-to-male
predominance of 4:3, while for rectal cancer there is a male-to-female
predominance of 4:3. Colorectal cancer is predominantly a disease of the
developed countries, and is rare in Africa and Asia. However, immigrants from 
low incidence countries to countries with high incidence of the disease acquire the 
risk of the indigenous population, which stress the importance of environmental 
factors in the aetiology of the disease. Diet may account for the marked 
geographical variation in incidence. This is presumed to be due to changes in the 
bowel flora which produce carcinogen from ingested food, the effect being 
exacerbated by the slow bowel transit time seen in people taking a low-fibre diet.
In the majority of patients with colorectal cancer, the disease arises 
sporadically from pre-malignant adenomas, while in 1-15 % of patients there 
seems to be a hereditary predisposition to colorectal cancer. Familial adenomatous 
polyposis (FAP) is inherited in an autosomal dominant fashion and has been 
shown to involve germline mutations and deletions of both APC  alleles located on 
chromosome 5q21-q22 (Powell et al., 1993), which almost always result in a
1
truncated APC protein (Nagase and Nakamura, 1993). Individuals with FAP 
develop numerous pre-neoplastic polyps in the colon and rectum at a relatively 
young age of which a subset invariably progresses to malignant cancer if not 
surgically removed. Patients with FAP may also present with tumours in other 
regions of the gastrointestinal tract, brain, thyroid, and elsewhere (Burt, 1991).
Hereditary non-polyposis coli (HNPCC) is another autosomal dominant 
hereditary disease. Individuals with the disease are prone to develop right-sided 
colorectal cancer at a young age but without the formation of adenomas (Aaltonen 
et al., 1993). Interestingly, HNPCC is also associated with development of 
carcinoma of the endometrium, ovary, breast, stomach and urinary tract (Lin et al., 
1998). Mutation or deletion of mismatch repair genes MLH1 and MSH2 have 
been associated with development of HNPCC (Leach et al., 1993; Liu et al., 
1996).
Studies of these familial syndromes have provided unique insights into 
both inherited and sporadic forms of human tumours and stress the important 
contribution of genetic aberrations in the development of colorectal and other 
cancers. Indeed, more than 80 % of sporadic colorectal cancers and the adenomas 
from which these cancers are derived carry genetic alterations in the APC  gene 
(Jen et al., 1994; Smith et al., 1993). Also, more than 13 % of sporadic colorectal 
cancers harbour defective mismatch repair genes MSH2 and MLH1 (Aaltonen et 
al., 1993; Ionov et al., 1993; Thibodeau et al., 1993). Interestingly, like HNPCC, 
the mismatch repair deficient tumours involve mainly the right or ascending colon 
and have diploid to near diploid chromosomal content.
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1.2. Dukes' classification
In 1932 Cuthbert Dukes described a system for staging rectal cancer. The 
staging system associated the clinical-pathological behaviour of rectal tumours 
with prognosis (Figure 1). When the tumour is confined entirely within the wall of 
the bowel (Dukes’ A) more than 90 % of patients can be cured by surgery alone. 
Penetration through the muscularis propria (Dukes’ B) worsens the prognosis, 
and when there is metastasis to the lymph nodes (Dukes’ C) the outlook 
deteriorates further so that two-thirds of the affected patients die of the disease 
within five years. When distant metastases to the liver are present (Dukes' D) 
most patients will die by the end of the first year (Dukes, 1932).
In recent years, Dukes' classification has undergone a number of 
modifications including the incorporation of colon cancer (Hermanek, 1995). The 
most widely used version is the Astler-Coller modification. In this system, stage A 
tumours are confined to the mucosa. Stage B is subdivided into B1 and B2 
depending on whether or not the outer muscle layer, the muscularis propria has 
been breached. Stage C is spread to the lymph nodes with subdivision into Cl and 
C2 depending on whether or not the bowel wall has been breached or whether the 
apical lymph node is involved (C2). Stage D is spread of the tumour to distant 
organs. The Gunderson and Sosin modification includes a B3 and C3 category 
depending on whether or not the tumour or lymph nodes involves other organs or 
structures, which are still removable en bloc at operation or if the tumour has 
perforated the serosa (B3). The TNM classification and the UICC are other 
staging systems (Table 1).
3
Table 1: Dukes', Astler-Coller, TNM and UICC staging systems for 
colorectal cancer
Dukes Astler-Coller TNM I W ^ I
A A T1N0M0 Stage I
B B1 T2N0M0
B2 T3N0M0 Stage II
B3a T4N0M0
C Cl T1-2N1-3M0 Stage III
C2 T3N1-3M0
C 3a T4N1-3M0
D D T any, N any, M l Stage IV
a B3 and C3 according to the Gunderson and Sosin modification.
The notion that colorectal cancer progresses in defined stages makes it an 
appealing tumour for correlating the genetic alterations with a particular Dukes' 
stage. However, it is important to note that there is considerable variation in the 
clinical course among patients with apparently equivalent stages of the disease. 
For example, 20-50% of patients without clinical evidence of metastasis die 
within five years from recurrent disease (Kune et al., 1990; Ovaska et al., 1990) 
because either they have been miss-classified as harbouring early tumours (Caplin 
et al., 1998) or the patients have micrometastasis (occult metastasis) that are 
undetectable using current routine pathological methods. In addition, these 
classification systems fail to explain why some early staged colorectal cancers 
reoccur and/or metastasise. Thus, the identification of markers of aggressiveness 
and metastases will not only have significant benefits in identifying patients at 
high risk of metastases but could also aid our understanding of the molecular 
bases of the metastatic process.
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Figure 1: Modified D ukes’ staging
Colorectal cancer staging is classified according to the extent of infiltration 
o f  the submucosa, muscularis propria and serosa (T l-4 )  and the presence ( Nl )  or 
absence of involved regional lymph nodes (NO) and distant metastatic deposits (M 
0-1). Staging is significant in determining 5-year survival. The letters A, B, C and 
D indicate Dukes’ stage. The tumour, lymph nodes and liver metastasis are 
coloured purple.
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1.3. Genetic alterations associated with progression of adenoma to 
carcinoma
Tumour progression implies the gradual transition of a localised, slow 
growing tumour to an invasive, metastatic cancer. Colorectal carcinomas arise 
usually from adenomas. The patterns and frequencies of four different genetic 
abnormalities (losses in 5q, 17p, 18q and mutations of ras genes) were analysed in 
a study by Vogelstein et al. (1988). In this study, adenomas with different sizes 
and forms (class I-III) were compared with carcinomas from different patients in 
an attempt to delineate genetic alterations associated with progression of 
adenomas to carcinomas. Deletions involving 5q chromosome were found in 29% 
of class II adenomas and 35% of carcinomas, indicating early involvement of 
genes on this chromosome arm in tumour progression. A specific region of 
chromosome 18q was found to be deleted in 47% of late adenomas (class III) and 
73% of carcinomas, indicating that this genetic aberration occurred late in the 
progression sequence. In addition, deletions involving 17p were most frequent in 
carcinomas (75%) and were rarely found in early adenomas (although present in 
24% of late adenomas). Mutant ras genes were found in 12% of class I adenomas, 
42%-57% of class II-III adenomas respectively and in 47% of carcinomas, 
indicating that ras mutation occurs early in the progression sequence. The authors 
concluded that the four molecular alterations accumulated in a fashion that 
paralleled the clinical progression of tumours and that there appears to be a 
preferred sequence of genetic changes that leads to progression in colorectal 
cancer (Figure 2). However, it was also evident from analysis of separate regions 
of adenomatous and carcinomatous tissue from the same patients that loss of 17p
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could occur early, while in another patient ras mutation appeared late in this 
sequence, which led the authors to conclude that it is not the sequential genetic 
aberration of particular genes in any given order that is of prime importance, 
rather it is the overall accumulation of genetic aberrations (Fearon and Vogelstein, 
1990). Thus, while only 9% of class I adenomas accumulated more than two of 
the four genetic aberrations, 40% of carcinomas have accumulated more than two 
genetic aberrations. However, no single aberration was found in all tumours, 
regardless of stage. Moreover, all four genetic aberrations were only found in 10% 
of carcinomas. Therefore, the represented model of colorectal cancer progression 
is misleading in that there is no rigid requirement for each genetic step to occur at 
a precisely pre-determined step in tumour progression.
The accumulation of various genetic aberrations during progression from 
adenoma to carcinoma has been confirmed by various methodologies, including 
CGH (Ried et al., 1996), chromosome banding analysis (Bardi et al., 1993, 1995; 
Muleris et al., 1994), DNA content and interphase cytogenetics (Herbergs et al., 
1994).
Recently, Boland et al. (1995) analysed multiple microdissected 
adenomatous and carcinomatous regions from the same tumours and have shown 
that deletions involving 5q occurred very early in the progression sequence and 
that 18q deletions were found in all stages of the progression sequence. Also, 17p 
deletions were frequent in grade III adenomas (Figure 3b). Thus, the genetic 
aberrations involved in the evolutionary sequence occurred at a somewhat earlier 
histologic stage than in Vogelstein’s study (Boland et al., 1995). More important
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Figure 2: Multistep model o f colon cancer progression
Progression of colorectal cancer involves several genetic and epigenetic 
alterations, which have been associated with specific steps along the progression 
sequence. See section 1.3 for details.
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is the evidence that high-grade adenomas were heterogenous with respect to the 
LOH on the three chromosomes analysed, whereas carcinomas were homogenous 
(Figure 3). Thus, if adenomas are made up of a mixture of subclones (as the 
authors have shown), each with different patterns of genetic imbalances, this 
could make it practically difficult to detect the subclone that progressed to 
carcinoma (because it could be a minority population). Also, the fact that not all 
adenomas progress to carcinomas and adenomas that do not progress might have a 
different genetic imbalances to those that do progress to carcinoma (Giaretti, 
1994; Giaretti and Santi, 1990; Morris et al., 1996), when such adenomas are 
included in cancer progression studies they could cause a significant dilutional or 
masking effects on the overall genetic aberration involved in cancer progression. 
Taken together, it is possible that the genetic aberrations involved in carcinoma 
progression could be present in adenomas but are not amenable to detection 
bescause of the reasons stated above. Indeed, not only has the study of Boland et 
al. (1995) shown that LOH involving 17p occurred earlier in the progression 
sequence, but another study has shown that a considerable number of dysplastic 
adenomas have chromosomal rearrangements leading to the appearance of 
aberrations previously have been found frequent in carcinomas, including gains in 
8q, 13q and loss of 17p (Bomme et al., 1994). Nevertheless, the tumour 
progression model does provide a concept upon which to found further studies on 
the process of carcinogenesis. More attention, however, should be paid to the 
choice of methodologies and standardisation of tumour materials in future studies.
To date, the genetic alterations associated with progression of in situ 
carcinomas to invasive and metastatic carcinomas are not well understood. In 
Vogelstein’s model, these aberrations were labelled as "other alterations". Many
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studies have concentrated on few genes associated with the metastatic phenotype 
because there appear to be a lack of guidance as to "where to look" in the genome 
for genetic events associated with the metastatic process. Moreover, studies 
designed to show the role of single or few genes in the metastatic process are 
bound to fail in showing such an association. For example, this is evident from 
the contradictory findings in the literature regarding, for example, the role of 
single genes in the metastatic process. Although single gene aberrations could be 
playing a significant part in the metastatic process, when studied in isolation their 
significance to the metastatic process become obscure because metastasis is a 
multi-step process involving the interaction of many genetic and epigenetic 
phenomenon. Therefore, the development of wide-scanning genome 
methodologies such as CGH and RDA could offer a great insight in narrowing 
down areas of the genome and in elucidating the combination of genetic events 
involved in the multi-step process of metastasis.
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Figure 3: Comparison o f the genetic alterations in the multistep progression 
model as viewed by Vogelstein et al. (A) with those found by Boland et a l (B)
Solid arrows indicate the point at which the specific aberration has 
occurred in the progression sequence and the direction indicates increased 
frequency of the aberration. The dotted arrow indicates that the genetic aberration 
was found in all stages of the progression sequence with similar frequency. See 
section 1.3 for details.
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CHAPTER 2. THE METASTATIC PROCESS
2.1. An overview of the metastatic process
Metastasis is defined as the ability of primary tumours to form tumour 
deposits distant to their site of origin. It is this process that distinguishes benign 
from malignant tumours. Metastasis is not a unique phenomenon to tumours. A 
closer look at foetal development, the immune system surveillance, and placental 
development reveals the ability of these systems to invade and metastasise. 
Physiologically, this process is strictly controlled. In tumours, however, 
metastasis is under no such physiological controls.
Metastasis is a multi-step process (Figure 4). A selected clone of cells 
growing in the primary tumour has to detach from the tumour mass and invade 
through a thick layer of connective tissue known as the basement membrane 
(BM). This process involves the production of a collection of proteolytic enzymes 
capable of destroying collagen type IV and other proteins and carbohydrate 
polymers, which are the main constituents of the BM. This process is discussed in 
section 2.3.2. The metastatic cells then reach blood or lymphatic vessels by which 
they are transported to distant sites. The tumour cells then extravasate from the 
vessels to colonize distant organs as micrometastases. Micrometastases have been 
substantially documented in early stages of colorectal cancer (Adell et al., 1996; 
Greenson et al., 1994; Hayashi et al., 1995; Jeffers et al., 1994; Nakamori et al., 
1997). Although only 1% of micrometastases can eventually give rise to clinically 
detectable tumours (Luzzi et al., 1998), a recent study has shown that the five-year 
survival rate decreased from 91 % to 50 % in patients with colorectal cancer
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Figure 4: Sequential steps involved in the metastatic process
Blue cells represent the original founding clone. The light red cells 
represent the em ergence o f a clone or clones o f cells with invasive and m etastatic 
potential, which later dom inate the tum our mass (dark red cells). The biological 
processes im portant to each step are also noted.
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lymph node micrometastases, while patients without lymph node micrometastases 
had a significantly better prognosis (Liefers et al., 1998).
Metastasis is therefore a complex process involving multiple steps and 
requiring the expression of multiple unrelated genes. A successful metastatic cell 
should have a complete set of abnormally expressed genes where each gene or a 
combination of genes is required to complete single steps in the metastatic 
cascade. The process of blood vessel formation or angiogenesis and adhesion of 
tumour cells to distant vessels are described in sections 2.6 and 2.2.3 respectively.
Metastasis is an inefficient process. Metastatic tumour cells are typically 
cleared from the host biphasically. The initial phase (6-24 hours), represents an 
exponential decline of cell numbers due to mechanical trauma, oxygen toxicity 
and clearance by the immune system. The second more gradual decline phase 
represents cell death at colonized sites (Weiss, 1990). However, recent evidence 
from intravital videomicroscopy, have strongly proposed that the major cause of 
metastasis inefficiency is failure of cells to grow in distant sites post-extravasation 
(Chambers et al., 1995; Koop et al., 1996).
The liver represents the major site for metastasis in colorectal cancer. 
However, metastasis to the lung, brain and bone is not uncommon. 
Haemodynamic considerations could explain the involvement of the liver in the 
majority of metastases, since the liver represents the first capillary bed 
encountered by metastatic colorectal cancer cells. Similarly, tumours in the lower 
rectum a re . more likely to metastasize to the lung since the lower rectum 
principally drains into the systemic circulation via the inferior vena cava. 
Although haemodynamic distribution contributes to the formation of metastases 
by mechanical trapping, it fails to account for liver, instead of the expected lung,
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colonization after intravenous injections of tumour cells in mice. The preference 
to metastasize to specific organs is well documented. Indeed, this 'soil 
phenomenon' was first described by Pagets as far as a century ago.
Tumour cells "the seeds" also posses genetic or epigenetic characteristics 
that allow them to colonize distant organs. This has been elegantly shown by Kuo 
et al., (1995). The authors have demonstrated that cells from metastatic colorectal 
tumours were able to colonize the liver after directly injecting or implanting the 
tumours on it, while non-metastatic tumours failed to colonize the liver. The 
authors argued that the genetic characteristics of tumour cells were of prime 
importance in successful colonization of distant sites. Indeed, this thesis is 
devoted to pinpointing genetic alterations in colorectal cancer associated with the 
metastatic process.
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2.2. The role o f cell adhesion molecules in metastasis
2.2.1. Cadherin
The cadherins comprise a family of calcium-dependent adhesion receptors 
that are usually employed in homotypic cell-cell adhesion (Suzuki, 1997). 
Cadherins superfamily can be divided into two subgroups based on their 
association with cytoskeletal components (Arnaout, 1993).
The first group includes the N, P, R, B, and E cadherins. This group 
localises in adherence-type junctions, and can form linkage to the actin part of the 
cytoskeleton. The second comprise a group of desmosome-associated cadherins 
known as desmogleins and desmocollins that can form linkages to intermediate 
filaments (Mechanic et al., 1991). The best characterised cadherins are E- 
cadherin (Uvomorulin) found commonly on epithelial cells, N-cadherin found on 
neural cells (Ozawa and Kemler, 1992), and P-cadherin of placental cells (Nose et 
al., 1987).
The structure of a typical cadherin molecule consists of an amino-terminal 
external domain having five tandem repeats that mediate homotypic interaction 
with another cadherin molecule on adjacent cell via calcium ions, a single 
transmembrane segment, and a cytoplasmic carboxy-terminal domain of about 
150 amino acids of variable length. The carboxy-terminal domain plays a crucial 
part in attaching and stabilising cadherins to the actin filament indirectly via 
intracellular proteins known as catenins (Gumbiner and McCrea, 1993).
The catenins are members of the armadillo family of proteins. P-catenin 
binds direcly to a specific 72 amino acid region in the cytoplasmic domain of
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cadherins and serves as a bridge for a-catenin association with cadherins. a- 
catenin links cadherins to the actin cytoskeleton, while y-catenin appears to 
weakly associate on the periphery of this complex (Aberle et al., 1996). The 
linkage to the actin cytoskeleton is essential for the adhesion function of cadherins 
(Aberle et al., 1996). In addition to its function in adhesion, p-catenin serves as a 
signal transduction molecule by forming complexes with the Tcf-Lef family of 
trascription factors (Behrens et al., 1996). The p-catenin-Tcf complex 
transactivates downstream genes that inhibit apoptosis and increase cell 
proliferation (Peifer, 1997; Rubinfeld et al., 1997).
APC interacts with p-catenin and serves in its degradation, thus decreasing 
the cytoplasmic pool of p-catenin. Recently, it has been shown that the APC 
protein down regulates the transcriptional activity of p-catenin-Tcf complex in 
colorectal tumours (Korinek et al., 1997; Morin et al., 1997). Moreover, ectopic 
expression of wild-type APC eliminates excess p-catenin from APC-defective 
melanoma cells (Rubinfeld et al., 1997). These results indicate that APC plays an 
essential role in clearance of p-catenin from the cytoplasm and that P-catenin 
acquires oncogenic activity when it is mutated or when it is upregulated by 
inactivation of APC as seen in patients with familial and sporadic colorectal 
cancer. This is in keeping with the gatekeeper function of the APC protein.
The phosphorylation status of cadherins and p-catenin may influence 
adhesive function of cadherins as well. For example, v-Src tyrosine 
phosphorylation of these proteins have been demonstrated to disrupt E- and N- 
cadherins mediated adhesion (Behrens et al., 1993; Takeda et al., 1995). Also, p- 
catenin can directly complex with the proto-oncogene c-erbB-2 and the EGF
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receptor, the disruption of this complex has been shown to suppress the invasion 
and metastasis of cancer cells (Shibata et al., 1996). Moreover, activation of the 
EGF and HGF receptor tyrosine kinases induces tyrosine phosphorylation of p- 
catenin, and correlates with decreased cell-cell adhesion and increased cell 
migration (Shibamoto et al., 1994).
There is mounting in vivo and in vitro evidence to support the 
involvement of cadherin mediated adhesion in invasion and metastasis. In vitro 
studies, utilising either the collagen matrix gel assays or the chick heart fragment 
invasion assays, have shown that transfection of invading cells with E-cadherin 
renders them non-invasive, while transfection of anti-sense E-cadherin into E- 
cadherin expressing cells or neutralising E-cadherin by antibodies renders them 
invasive (Vleminckx et al., 1991). Studies of tumours from patients presenting 
with breast, gastric, or head and neck squamous cell cancers indicate that loss or 
reduced E-cadherin expression correlates with invasive tumours (Oka et al., 1993; 
Schipper et al., 1991). Similarly, loss of E-cadherin and inceased stability of |3- 
catenin has been shown to be frequent in colorectal cancers (Dorudi et al., 1993; 
Hiscox and Jiang, 1997). Moreover, the loss of E-cadherin has been shown to 
correlate with Dukes' progression (Mohri, 1997).
In the cadherin-catenin system, cadherins seem to localise P-catenin to the 
cytosol of the cell. Increased nuclear and decreased cytosolic p-catenin is 
associated with colorectal carcinoma and increasing degree of dysplasia in 
adenomas (Hao et al., 1997). Indeed, this is in line with the metastatic suppressor 
function of cadherins, since inactivation of this system induces dissociation of 
cell-cell adhesion and increases the metastatic potential of cancer cells. Therefore, 
the amount of cytoplasmic P-catenin is likely to be regulated by its binding to
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APC or to the adhesion apparatus. In tumour cells, inactivation of the APC  gene 
through mutation or deletion, and alterations of the adhesion apparatus by 
increased tyrosine phosphorylation could serve to stabilise p-catenin. Recently, p- 
catenin has been shown to activate transcription from the cyclin D1 promoter, 
which contains sequences related to TCF/LEF (Tetsu and McCormick 1999). The 
authors hypothesise that p-catenin accumulation may contribute to neoplastic 
transformation by causing accumulation of cyclin D l.
2.2.2. Integrins
Integrins are a large family of heterodimeric integral plasma membrane 
cell surface receptors that mediate cell-matrix and cell-cell interaction (Hynes, 
1992). Such interactions are involved in a wide variety of physiological processes 
including regulation of cellular function during embryonic development, wound 
healing, inflammation, cell growth, and metastasis (Giancotti and Mainiero, 
1994).
Each integrin heterodimer is composed of an a  and a p subunit, of size 
ranges 120-180KD and 90-110KD respectively. To date, there are 16 distinct a  
subunits and 8  p subunits which variously combine to form 22 receptor types, For 
example, Pi subunit can form heterodimers with many types of a  subunits each 
characterised by a distinct, although largely overlapping, ligand-binding 
specificity. Similarly, the a  subunit can dimerize with many types of P subunits 
(Hynes, 1992). This property is useful for a motile cell because some integrins can 
functionally substitute for others when the cell encounters different matrix 
proteins along its journey. A further level of complexity is introduced by
19
alternative splicing of some a  subunits (Hogervorst et al., 1991) and p subunits 
(Altruda et al., 1990).
Both a  and p subunits are transmembrane glycoproteins with large 
globular amino-terminal extracellular domains that bind principally RGD or other 
sequences in the extracellular matrix or ICAMS on other cells (Pierschbacher and 
Ruoslahti, 1984; Pierschbacher and Ruoslahti, 1984). Each subunit provides a thin 
leg that transverse the plasma membrane and end in a relatively small cytoplasmic 
tail of less than 60 amino acids (Tamura et al., 1990). P4 integrin subunit is an 
exception to this general rule because it has a cytoplasmic domain of about 1 0 0 0  
amino acids (Hogervorst et al., 1990). The cytoplasmic domain of the p subunit 
interacts with talin which in turn interacts with vinculin and thereby paxillin 
(Lewis and Schwartz, 1995). Vinculin and paxillin interact with the actin 
cytoskeleton thus attaching the extracellular matrix via integrin heterodimer to the 
cytoskeleton.
Integrins differ from other cell adhesion molecules in that they bind their 
ligand with low affinity. However, clustering integrins increases the strength of 
binding to their ligand as seen in focal adhesions. This is a useful characteristic 
for motile cells, because in this way cells can bind simultaneously but weakly to 
large number of matrix molecules and still have the opportunity to explore their 
environment without losing all attachment to it by building or breaking down 
focal contacts. Strong binding of the receptors to their ligand would reduce or 
abolish cell motility (Palecek et al., 1996). This problem is avoided when the 
attachment depends on multiple weak adhesions.
It is now becoming clear that integrins have functions other than merely 
attaching cells to the extracellular matrix. Integrins play a crucial part in
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modulating cellular responses to growth factors and extracellular matrix by 
transmitting signals, a process known as “outside-in” integrin signalling. Upon 
binding to the extracellular matrix, integrins are activated by conformational 
change " affinity modulation" or through integrin clustering " avidity modulation". 
The mechanistic details of the down stream signalling is still scanty, but involves 
the recruitment of a distinct quarternary signalling molecules (ILK, FAK, C-SRC, 
pl30CAS and paxillin) to focal adhesions whose assembly is normally initiated by 
autophosphorylation of FAK. This results in activation of the MAPK pathway via 
RAS (Clark and Hynes, 1996; Wary et al., 1996), or RAS independent pathway 
directly via RAF-1 (Chen et al., 1996), or via PI3K-PKC-RAF-1 pathway (Clark 
and Hynes, 1996).
Cell growth requires both growth factors and anchorage to the 
extracellular matrix. It is becoming evident that integrin-dependent adhesions 
often have a major role in potentiating the efficiency of growth factor signalling 
through RTKs and MAPK cascade "collaborative signalling". For example, by 
comparing suspension cells with integrin-anchored cells, the former was found to 
have impaired MEK and MAPK kinases (Lin et al., 1997). Also, both integrin 
clustering and stimulation of growth factor receptors enhanced auto 
phosphorylation of the corresponding growth factor receptor (Schneller et al., 
1997; Yamada, 1997). Thus, it is not surprising that cells would use both 
positional information via integrin, as well as information about the availability of 
growth factors, to determine the appropriate time to enter the cell cycle. However, 
tumours activated by various co-operating oncogenes could circumvent the need 
for integrin anchorage-dependant growth by constitutively activating any of the 
kinases involved in the integrin pathway. For example, recent data have indicated
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that a constitutively active form of FAK can promote anchorage-independent 
survival and growth in epithelial cells (Frisch et al., 1996). Also, FAK expression 
was found to be elevated in highly malignant tumours compared to normal tissue 
(Weiner et al., 1993). Moreover, transformation of cells by v-src overrides the 
requirement of attachment to the extracellular matrix leading to anchorage- 
independent growth by constitutively activating FAK or by phosphorylating its 
substrates (Guan and Shalloway, 1992).
Integrins affinity to the extracellular matrix could also be modulated from 
within the cell in a process known as “inside-out” integrin signalling. This 
phenomenon is important since it allows the cell to modulate its adhesion in 
response to intracellular signals, as in cell division, where the cell loses its 
attachment to the extracellular matrix (see section 3.5.1 for details).
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2.3. The role of cell invasion and motility in metastasis
2.3.1. Extracellular Matrix Degrading Enzymes
The ECM defines boundaries between tissue compartments and organ 
parenchyma. It is principally composed of two forms: basement membrane and 
the underlying interstitial stroma. The basement membrane separates epithelial 
and endothelial cells from mesenchymal tissue. Glycoproteins, such as laminin, 
collagens (mainly type IV), entactin, fibronectin, and proteoglycans such as 
heparan sulfate and chondroitin sulfate are the main constituents of basement 
membranes. These components interact with one another to create non-fibrillar 
continuous network. Underlying this layer is the interstitial stroma, which is 
composed of glycosaminoglycans, collagen (type I, II and III), glycoproteins and 
elastin. Composition of the ECM varies from one organ to the other to guide 
specialised functions for the normal physiology of the organ.
The ECM molecules form a continuous impermeable layer around tissues 
that becomes focally permeable to cell movement during selective physiological 
processes such as tissue remodelling and wound healing (Timpl and Dziadek, 
1986). The function of the ECM is not merely to provide strength and support for 
overlying tissue, but proteins of the ECM also can act as ligand for cellular 
receptors (integrins), creating specialised cell-matrix links called focal contacts 
(Burridge et al., 1988), which are critical for cellular motility. The ECM also 
sequesters and protects growth factors and cytokines through interactions with a 
variety of molecules such as collagen and heparan sulfate (Taipale and Keski-Oja, 
1997). For example, heparan sulphate interacts with both basic fibroblast growth
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factor FGF-2 and acidic fibroblast growth factor FGF-1, which are potent 
angiogenic factors. This interaction not only serves to provide a rich source of 
growth factors that are protected from degradation but also can be presented 
specifically to FGF receptors by heparan sulfate present on the cell surface (Miao 
et al., 1996).
The basement membrane is a critical barrier to tumour cell dissemination. 
However, tumour cells selectively reorganise and degrade their local basement 
membrane so that they can disseminate to other location. The interaction of 
tumour cells, growth factors and proteolytic enzymes with the ECM are critical 
during the invasion process. These concepts will be emphasised in the following 
sections.
2.3.2. Matrix Metalloproteases
Matrix metalloproteases are a family of transmembrane or secreted 
proteins that are capable of degrading ECM components. Currently, 16 family 
members have been identified (Table 2). They share a catalytic domain 
(VAAHEXGHXXGXXH) with the underlined motif responsible for zinc binding. 
MMPs are also characterised by possessing a distinctive PRCGVPD sequence in 
the amino-terminal prodomain that is responsible for maintaining latency of the 
enzymes (Birkedal-Hansen et al., 1993). The carboxy-terminal region of the 
MMPs possesses a haemopexin/vitronectin-like domain that is important in 
substrate and inhibitor bindings (Sanchez-Lopez et al., 1993). Matrilysin (MMP- 
7) is the only member that does not possess such a domain.
There are five major subclasses of MMPs based on their substrate 
preferences (Table 2): collagenases degrade fibrillar collagen, stromelysins
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degrade proteoglycans and glycoproteins, gelatinases are particularly potent in 
degrading non-fibrillar and denatured collagens or gelatin (Birkedal-Hansen et al., 
1993; Matrisian, 1992), metalloelastases are potent in elastin degradation and the 
membrane type MT-MMPs, which possess a transmembrane domain that localises 
their activity to the plasma membrane and are important activators of the pro­
form of MMP-2 or gelatinase A (Sato et al., 1994).
Table 2: Matrix metalloproteases nomenclature and substrate specificities
Enzyme Alternative names 
EC designation
Substrate
Matrilysin MMP-7, pump-1 
EC 3.4.24.23
Proteoglycans, Laminin, 
Fibronectin, Gelatin, Collagen IV, 
Elastin, Entactin, Tenascin
Stromelysin-1 Transin, MMP-3 
EC 3.44.24.17
Proteoglycans,Laminin, 
Fibronectin, Collagen III, IV, V, 
Gelatin
Stromelysin-2 Transin-2, MMP-10 EC 
3.4.24.22
Proteoglycans,Fibronectin, 
Collagen III, VI, V, Gelatins
Stromelysin-3 MMP-11 Laminin, Fibronectin (weak)
Metalloelastase MMP-12 
EC 3.4.24.65
Elastin
Interstitial Fibroblast Collagenase, Collagens I, II, III, VII, X,
collagenase MMP-1 EC 3.4.24.7 Gelatins
Neurophil
collagenase
MMP- 8  
EC 3.4.24.34
Collagens I, II, III,
Collagenase-3 MMP-13 Collagen I
MT1-MMP MMP-14 Activation of GelatinaseA
MT2-MMP MMP-15 Unknown
MT3-MMP MMP-16 Gelatinase A
MT4-MMP MMP-17 Unknown
Gelatinase A 72 kDa gelatinase, 
MMP-2 EC 3.4.24.24
Gelatins, Collagens IV, V, VII, X, 
Elastin, Fibronectin
Gelatinase B 92 kDa gelatinase, 
MMP-9 
EC 3.4.24.35
Gelatins, Collagens IV, V, Elastin
(Abstracted and modified from (MacDougall and Matrisian, 1995))
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The MMPs are regulated at a number of levels, including transcriptional 
regulation (induce the expression of MMPs) by growth factors and cytokines, 
post-transcriptional regulation at the level of mRNA stability, post-translational 
regulation by the activation of the secreted latent form, and inhibition by the 
general serum proteinase inhibitor a 2 -macroglobulin and specifically by a family 
of endogenous tissue inhibitors known as the tissue inhibitors of metalloproteases 
(TIMPS) (Stetler-Stevenson et al., 1993). The balance between the levels of 
activated MMPs and free TIMPs determines the net MMP activity, altering this 
equilibrium affects the process of invasion. To date, there are three well-defined 
members of the TIMP family. These are termed TIMP-1, TIMP-2 and TIMP-3. 
Recently, a murine TIMP-4 has been isolated, although a homologue of this new 
member is yet to be identified in humans (Leco et al., 1997).
It has been known for sometime that MMPs are associated with malignant 
tumours (Liotta et al., 1982). Since that time, extensive literature demonstrating a 
close association between MMPs family members and tumour progression has 
evolved (MacDougall and Matrisian, 1995)
There are two important observations made recently regarding the role of 
MMPs in the metastatic process. First, MMPs are not only expressed by tumours 
but are also expressed by stromal cells surrounding the tumours. For example, 
stromelysin-3 mRNA expression has been shown to be specifically localised to 
the stroma of colon, breast, and head and neck cancers (Powell and Matrisian, 
1996). Also, growth factors such as PDGF, secreted by tumours have been shown 
to stimulate collagenase expression by human fibroblasts (Circolo et al., 1991). In 
addition, several in vitro and in vivo tumour cells have been shown to possess a 
collagenase stimulatory factor termed EMMPRIN (a member of the
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immunoglobulin superfamily) on their cell surface. This factor has been shown to 
stimulate the production of interstitial collagenase, stromelysin-1 and MMP-2 in 
human fibroblast (Guo et al., 1997; Kataoka et al., 1993). Thus, MMP production 
in the surrounding stroma could enhance the ability of tumour cells to degrade the 
local ECM. Secondly, the ability of MMPs to enhance tumour invasion and 
metastasis has been "assumed" to be due to facilitating extravasation and 
increasing ECM degradation. However, recent evidence from IW M  has shown 
that not only do normal fibroblasts extravasate as well as malignant cells but that 
only malignant cells expressing high levels of MMPs could colonize distant 
organs (Koop et al., 1996; Morris et al., 1994). Also, B16F10 mouse melanoma 
cells engineered to overexpress TIMP-1 extravasated as well as cells expressing 
normal levels of TIMP-1. These results were surprising in that it was expected 
that cells overexpressing TIMP-1 would be defective in extravasation. However, 
the reduced metastatic ability of cells overexpressing TIMP-1 was due to failure 
to colonize distant organs i.e. post-extravasation growth (Koop et al., 1994; 
Soloway et al., 1996). In light of these results, the role of MMPs in the metastatic 
process should be re-evaluated. It is possible that MMPs enhance the growth of 
metastatic cells by increasing growth factor availability and by enhancing tumour 
angiogenesis. This is particularly important in early stages of colonization as will 
be discussed in section (2.5). In support of this, it has been shown that matrilysin 
is expressed in 88 % of adenomas arising in min-mice, which are transgenic mice 
bearing a nonsense mutation in the APC gene giving rise to multiple intestinal 
neoplasia. Matrilysin knockout in the min mouse demonstrated that matrilysin- 
deficient mice developed 60 % fewer intestinal adenomas (Wilson et al., 1997). 
Similarly, stromelysin-3 deficient mice demonstrated impaired tumour formation
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in response to chemical mutagenesis (Masson et al., 1998). These results argue for 
a role of MMPs in tumour initiation and growth beside their role in tumour 
metastasis.
2.3.3. Serine Proteases
Serine proteases are enzymes involved in activation of plasminogen and 
are therefore termed plasminogen activators. There are two types of plasminogen 
activators, the tissue-type (t-PA) and the urokinase-type (u-PA). Both convert the 
inactive plasminogen to the active proteases plasmin by cleavage of the arginine 
560-valine 561 bond. There is general agreement that t-PA generates plasmin for 
thrombolysis and that its activity is enhanced by the presence of fibrin, while u- 
PA generates plasmin for the degradation of the ECM and does not require fibrin 
for its function. u-PA can also activate the plasmin like HGF (Naldini et al.,
1992). For these reasons, u-PA has been widely studied in relation to tissue 
remodelling and tumour metastasis. u-PA binds a cell surface receptor termed u- 
PAR. The receptor was first described by Vassalli et al. (1985). Later, it has been 
shown that u-PAR is attached to the cell membrane by a glycosyl-phosphotidyl- 
inositol anchor (Ploug et al., 1991). u-PAR has been shown to bind a 
somatomedin B domain (an RGD integrin-binding sequence) on vitronectin 
(Deng et al., 1996). This binding not only stabilises the u-PA/-uPAR on the ECM 
for activation of the membrane bound plasminogen and subsequent degradation of 
the ECM but is important in juxtaposition of the u-PA/u-PAR system to integrins 
(avPi, a vP3 , a vPs, anbfb, agPi), which also bind the RGD sequences on vitronectin. 
Moreover, p2-integrin is frequently co-localised and purified along with u-PAR
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(Bohuslav et al., 1995) and binds to u-PAR in a purified system (Wei et'al., 1996). 
In addition, u-PAR can be co-immunoprecipitated with caveolin and Pi-integrins, 
and has been found to inhibit binding of pi-integrins to fibronectin (Wei et al., 
1996). It is therefore not surprising to find u-PA/u-PAR concentrated at focal 
adhesions. This localisation of the plasminogen activators to focal contacts is not 
only important for facilitating cellular motion through the ECM but could also 
alter the capacity of integrins to mediate intracellular signalling (Chapman, 1997).
There are two main inhibitors of the plasminogen activators, PAI-1 and 
PAI-2, while plasmin is inhibited by (X2-anti-plasmin. Binding of PAI-1 or PAI-2 
to u-PA/u-PAR complex (PAI can bind and compete with u-PAR for vitronectin 
binding) results in binding of the complex to the a 2-macroglobulin/lipoprotein- 
receptor related protein, which is an endocytic receptor, and rapid clearance of the 
complex from the cell surface (Conese et al., 1995).
There is now mounting evidence supporting the involvement of 
plasminogen activators in the process of cancer dissemination in vivo and 
enhanced cellular invasion in vitro. For example, experiments that involve 
manipulating the levels of the plasminogen activator system in cells in vitro have 
shown a strong correlation between expression of plasminogen activators and 
invasion of the ECM (Andreasen et al., 1997). In u-PA-deficient mice, the 
invasive potentials of carcinogen induced blue naevi and their progression to 
malignant melanomas were significantly reduced compared to mice carrying the 
wild-type gene (Shapiro et al., 1996). In human cancers, u-PA expression has 
been shown to associate with poor prognosis in a variety of cancers, including 
breast, lung, bladder and many others (Duffy, 1996). Similarly, u-PAR expression 
also appears to be a prognostic marker in many cancers, such as breast, stomach
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and squamous carcinoma of the lung. Interestingly, in colorectal cancer u-PA has 
been shown to be expressed by stromal cells around the tumours (Pyke et al., 
1991), while tumour cells have high concentrations of u-PAR (Pyke et al., 1994), 
which constitute an independent prognostic marker (Ganesh et al., 1994).
PAI-1 expression is also associated with aggressive cancers (Grondahl- 
Hansen et al., 1993). This is unexpected due to the inhibitory role of PAI-1 on the 
plasminogen activators system. However, it could be that PAI-1 has additional 
functions than merely inhibiting plasminogen activators (Stefansson and 
Lawrence, 1996). It is also possible that the associated of PAI-1 with aggressive 
tumours is due to its production by endothelial cell from angiogenic vessels within 
tumours.
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2.4. Cellular motility
Normal epithelial cells form continuous layer of cells that are polarised 
and non-motile. During malignant transformation, these highly differentiated 
epithelial cells convert to motile mesenchymal cells. Indeed, It has been known 
for a long time that these two cell type can interconvert (Hay, 1990). For example, 
epithelial cells can convert to fibroblast-like cells following disruption of cadherin 
function by v-src oncogene expression (Behrens et al., 1993) or by growth factor 
treatment (Weidner et al., 1991). Conversely, fibroblasts can be converted to 
epithelial-like following artificial expression of cadherins (Nagafuchi et al., 1987) 
or specific growth factors and their receptors (Tsarfaty et al., 1994). This 
interconversion illustrates the capability of malignant cells to switch on programs 
involved in cellular motility during embryogenesis, wound healing, 
morphogenesis and in immune surveillance.
Cellular motility is central to the process of tumour metastasis. Tumour 
cell invasion, intravasation, and extravasation as well as angiogenesis all require 
active cellular motility. The ability of tumour cells to migrate in response to ECM 
proteins has been found to correlate with in vivo invasion and metastatic capacity 
of tumour cell lines (Lester and McCarthy, 1992).
Cellular locomotion is a complex process that requires the co-ordinated 
interactions of growth factors, ECM and integrins. These co-ordinated interactions 
result in the formation of membrane ruffling and pseudopodia, formation of 
attachments to the ECM at the leading edge of the cell, and release of the cell 
attachment at the rear of the cell and forward motion of the cell body (Stossel,
1993). Tumour cells become motile in response to a variety of agents, including
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host-derived motility and growth factors, extracellular matrix components, and 
tumour-secreted factors (Kantor and Zetter, 1996).
Several forms of cell motility have been defined. Chemotaxis is a 
directional migration of cells towards a positive gradient of a soluble factor, such 
as fragments of ECM or growth factors. Chemokinesis is a randomly directed 
cellular motility, which occurs in the absence of a concentration gradient, while 
haptotaxis is a directed cellular motion towards a positive concentration gradient 
of an immobilised attractant. For example, growth factors immobilised within the 
ECM.
Scatter factor and hepatocyte growth factor are both autocrine and 
paracrine growth factors that stimulate scattering of epithelial cells and 
proliferation of hepatocytes respectively. However, they were later found to be the 
same molecule (Weidner et al., 1991). HGF is member of a family of soluble 
factors, which includes the macrophage stimulatory protein (MSP). Both 
molecules share sequence homologies with the serine-proteases of the blood- 
clotting cascade. These proteins are secreted as single chain precursors (92 kDa) 
that are subsequently activated in the ECM by serine- proteases to form a  and p 
subunits that are linked by disulfide bonds (Miyazawa et al., 1993). The a  
subunits of HGF and MSP have a molecular weight of 60 kDa and contain four 
kringle domains similar to those observed in coagulation factors. The p subunits 
have a molecular weight of approximately 30 kDa and are closely related to the 
catalytic domains of serine-proteases but they exhibit no known protease activity. 
The profound effects of HGF on cell growth, morphology and motility have been 
well-documented (Bhargava et al., 1993). A strong association between high 
levels of HGF in breast tumours and shorter relapse free and overall survival has
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been documented (Yamashita et al., 1994). However, the role of HGF in 
colorectal cancer is more controversial (Fukuura et al., 1998; Hiscox et al., 1997).
HGF binds to specific cell membrane receptor termed c-met. This proto­
oncogene is a 190 kDa protein and belongs to the tyrosine kinase receptor 
superfamily (Naldini et al., 1991). C-Met is synthesised as a large precursor that 
is made up of an extra-cellular a  chain and a (3 chain that spans the plasma 
membrane. Both chains are necessary for HGF activation and are connected by a 
disulfide bond. The intracellular domain includes a negative regulation 
juxtamembrane domain followed by a conserved tyrosine kinase catalytic domain 
and a C-terminal sequence which is responsible for receptor coupling to 
intracellular transducers (Bardelli et al., 1994). Upon HGF binding, 
autophosphorylation of the cytoplasmic domains activates a variety of 
intracellular molecules including the cytoplasmic tyrosine kinase C-Src, Ras 
(through Grb2/SoS binding), PI-3K, PLCy and the MAPK (Ponzetto et al., 1994).
C-met is overexpressed in a variety of sporadic tumours. In colorectal 
cancers, c-met is overexpressed up to 50-fold in about half of primary tumours, 
and in 70 % of liver metastases. Moreover, c-met overexpression in colorectal 
cancer has been shown to be associated with gene amplification (chromosome 
band 7q31) in a significant proportion of metastases (Di Renzo et al., 1995). 
Recently, the tyrosine kinase domain of c-met has been found mutated in 
hereditary and sporadic papillary renal carcinoma (Schmidt et al., 1997). Thus, 
establishing a direct role for c-met proto-oncogene in human cancers.
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2.5. Interplay between growth factors, adhesion receptors, extracellular 
matrix degrading enzymes in cellular motility
It is evident from the above description of the factors involved in cellular 
movement that this process is highly complicated and requires the interaction of 
many factors for its regulation. The way growth factors, integrins, MMPs and the 
plasminogen activators interact together to facilitate cellular movement will be 
discussed.
Growth factors such as EGF, PDGF, LPA and insulin induce the formation 
of stress fibers and focal adhesions that are necessary for cell movements (Ridley 
and Hall, 1992). This focal contact assembly can be ascribed to the action of the 
Rho family of GTPase. Rac has been shown to be directly responsible for the 
formation of membrane ruffling and lamellipodia, and Cdc42 can control the 
formation of filipodia (Hall, 1998). The Rho family can also be activated by 
clustering and ligation of integrins (Hotchin and Hall, 1995; Renshaw et al., 
1996). The convergence of growth factors and integrin-signalling pathways could 
have important consequences on enhancing cellular motion. For example, in 
human pancreatic carcinoma cells, integrin a vPs mediates adhesion but not 
migration on vitronectin (these cells readily migrate on collagen in an (X2P1- 
dependent manner). However, following stimulation with EGF, these cells 
migrate on vitronectin through an a vPs -mediated protein kinase C-dependent 
pathway without affecting constitutive migration on collagen (Klemke et al.,
1994). Similarly, IGF-1 stimulates motility and invasion of pancreatic and breast 
carcinoma cells on vitronectin by activating and co-operating with a vp5 integrin 
(Brooks et al., 1997; Doerr and Jones, 1996). Other growth factors, such as TGFp-
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1, are strong stimulators of integrin and u-PAR expression (Lund et al., 1991). In 
addition, bFGF can induce activation of latent TGF|3 by inducing u-PA synthesis 
in endothelial cells (Flaumenhaft et al., 1992). The plasminogen activators have 
also been shown to activate latent TGF|3 and HGF (ECM-bound) to their active 
forms (Odekon et al., 1994). Taken together, these two observations illustrate the 
possible existence of a positive regulatory cycle that could enhance cellular 
motility, invasion and metastasis.
The presence of certain ECM molecules also induces the expression of 
MMPs that degrade them. Indeed, it has been shown that integrins bound to 
specific matrix molecules induce the production of MMPs that specifically 
degrade that matrix. For example, integrin 012P1 has been shown to induced MMP- 
1 (interstitial collagenase) production when cells were grown on collagen gels 
(Riikonen et al., 1995; Sudbeck et al., 1994). Similarly, interaction of as|3i with 
the RGD-domain sequence in fibronectin stimulates the expression of MMP-1, 
stromelysin-1, and MMP-9 (Werb et al., 1989). Treatment of human keratinocytes 
with anti-a3 or anti-(3i monoclonal antibodies induces the expression of MMP-9 
(Larjava et al., 1993). Also, in human melanoma cells the expression of MMP-2 
has been shown to be regulated by a vP3 and asPi integrins during melanoma 
invasion (Seftor et al., 1992; Seftor et al., 1993). On the other hand, integrin (X4P1 
binding to the CS-l-domain in fibronectin suppresses production of MMP-1, 
stromelysin-1, and MMP-9 (Huhtala et al., 1995). Functional analysis, at least in 
the MMP-1 gene, has shown that integrin induction of the MMPs is the function 
of AP-l/PEA3-responsive DNA sequences (Tremble et al., 1995).
35
Recent significant findings implicating the co-ordinated action of integrins 
with the plasminogen activators in tumour cells migration and invasion have been 
reported. For example, integrins have been shown to induce production of 
urokinase plasminogen activators in a Ras dependent manner (Irigoyen et al., 
1997; Lengyel et al., 1996). Also, the induction of u-PA and its receptor u-PAR 
by TGFa has been shown to require the a vPs integrin (Brooks et al., 1997; Yebra 
et al., 1996). A significant step has been recently made illustrating a direct 
connection between the MMPs, integrins, and cellular invasion. Brooks et al. 
(1996) demonstrated that MMP-2 co-localises with integrin a vP3 on the surface of 
melanoma tumour cells in vivo and was shown to directly bind a vP3 (but not a vPs 
and (X5 P1 ) in vitro. That a vp3 promotes cell motility, while MMP-2 potentiates 
matrix degradation, suggests a close co-operative function between these proteins 
to favour melanoma dissemination. This observation is not unique to tumour cells, 
but has been also observed on angiogenic blood vessels endothelial cells during 
active angiogenesis (Brooks, 1996; Brooks et al., 1995).
It is, therefore, clear that close interaction between growth factors, 
integrins and the matrix degrading enzymes are important in facilitating and 
enhancing tumour cell invasion and metastasis. However, the remaining challenge 
is to dissect the precise role of each element in the transmission of biological 
signals leading to tumour cell migration.
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2.6. The role of angiogenesis in metastasis
Tumour angiogenesis is defined as the process by which new blood 
vessels sprout from the existing vasculature into developing solid tumours 
(Folkman, 1995). The main purposes of these vessels are to provide nutrients for 
the expanding tumour and a mean by which tumour cells can disseminate to 
distant sites.
The characteristics of the newly formed vessels are intriguing. In contrast 
to normal vessels, these form multiple branching points, they are spiralled and 
form extensively convoluted loops (Kus et al., 1981). In addition, the vessels are 
extensively leaky (fenestrated) due to the absence, in some parts, of a complete 
basement membrane which in turn may facilitate the migration of tumour cells 
and growth factors (Roberts and Palade, 1997).
Angiogenesis is a multi-step process that involves the dissolution of old 
basement membranes, migration, proliferation of endothelial cells, formation of 
vascular loops, and new basement membrane. This process is initiated when 
tumour cells start to produce diffusible angiogenesis promoting factors. Many 
factors are known for their ability to promote angiogenesis. The best-characterised 
factor is vascular endothelial growth factor (VEGF). It was initially identified as a 
high specific mitogen for vascular endothelial cells (Leung et al., 1989). It was 
simultaneously isolated by virtue of its blood vessel permeabilising activity, and is 
therefore also known by the name vascular permeability factor (VPF).
VEGF belongs to the platelet-derived growth factor (PDGF) family of 
growth factors because it contains the eight conserved cysteines that are the 
hallmark of this growth factor family.
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Five VEGF mRNA species encoding VEGF isoforms of 121,145, 165, 
189, and 206 amino-acids are produced by alternative splicing of VEGF mRNA 
(Tischer et al., 1991). All of these isoforms are synthesised with a hydrophobic 
leader peptide for secretion, which is then cleaved to yield the mature protein. 
However, only VEGF 121, 145, and 165 are actually secreted from producing 
cells (Poltorak et al., 1997). The two larger VEGF isoforms remain cell associated 
(Houck et al., 1992). The active forms of the various VEGF proteins were found 
to be homodimers linked via disulfide bonds (Leung et al., 1989). The existence 
of so many VEGF forms implies that they may differ in their biological 
properties, tissue processing, and distribution. Indeed, using rat organs, it has been 
found that VEGF 188 (in rodents all VEGF forms are one amino-acid shorter) is 
the predominant form in heart and lung tissues. VEGF 164 mRNA levels are 
relatively low in heart and lung, but predominant in brain and kidney. VEGF 120 
is present in equimolar amounts to VEGF 164 in spleen, and relatively large 
amounts of VEGF 120 are also found in kidneys and lungs, but only low levels of 
VEGF 120 have been observed in brain and heart tissue.
VEGF interacts with two known endothelial cell receptors. KDR/FLK1 a 
kinase insert domain containing receptor, which was first cloned from a human 
umbilical vein endothelial cell cDNA library (Terman et al., 1992), FLK1 (foetal 
liver kinase 1), which is the mouse homologue of KDR and was originally cloned 
from a foetal liver stem cell cDNA library and FLT1 a /ms-like tyrosin kinase 
initially cloned from a human placenta cDNA library (Shibuya et al., 1990). 
Other newly identified or as yet unidentified VEGF receptors also exist (Soker et 
al., 1996). KDR/FLK1 and FLT1 belong to the receptor tyrosine kinase family 
based upon similarity in structural features (Fantl et al., 1993). VEGF stimulation
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of KDR/FLK1 expressing Porcine aortic endothelial cells showed striking 
changes in cell morphology, actin reorganisation and membrane ruffling, 
chemotaxic and mitogenicity (Waltenberger et al., 1994). Although the specific 
signal pathways responsible for these changes are yet to be identified. On the 
other hand, VEGF binding to FLT1 leads to phosphorylation of PLC and GAP 
proteins as well as activation of MAPK (Seetharam et al., 1995). In FLT1- 
expressing PAE cells VEGF induces phosphorylation of Fyn and Yes onco­
proteins (Waltenberger et al., 1994). Cunningham et al. (1995) utilised a yeast 
two-hybrid system to demonstrate that FLT1 tyrosine kinase domain interacts 
with the p85 subunit of PI-3K.
Heparan sulfate proteoglycans are required for binding of VEGF to its 
receptors (Tessler et al., 1994). Interestingly, the large VEGF isoforms (VEGF 
165, 189, 206), which contain the 44 amino-acids derived from exon 7 contribute 
to the heparin binding ability of VEGF. For example, addition of heparin to 
heparinase-treated cells restores VEGF 165 binding but not VEGF 121 binding 
indicating that changes in the composition of cell-surface heparin-like molecules 
may differentially affect the interaction of various VEGF isoforms with VEGF 
receptors (Cohen et al., 1995).
Over-expression of the VEGF gene has been demonstrated in many types 
of developing solid tumours (Senger et al., 1993; Tokunaga et al., 1998). In 
addition, inhibiting the interaction of VEGF with endothelial cells slows the 
growth of tumours in vivo (Millauer et al., 1994).
Studies on tumour angiogenesis have shown that the expression of 
KDR/FLK1 and/or FLT1 in endothelial cells correlates with vascularity, 
metastasis, and proliferation of human colon cancer (Takahashi et al., 1995).
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Recently, melanoma-derived cell lines SK-MEL-2 which express normal, high 
and low levels of VEGF were injected into the subdermis of nude mice. These 
experiments revealed that VEGF over-expression dramatically improves tumour 
angiogenesis and growth. Also, high levels of VEGF expression demonstrated 50 
folds increase in lung tumour colonisation over control or antisense transfected 
SK-MEL-2 cell (Claffey et al., 1996). The requirement of VEGF for growth of 
metastatic deposits was also demonstrated by a model of liver metastasis from 
colorectal cancer cells in nude mice. Metastatic deposits can occur but do not 
grow beyond a minimal size of 1-3 mm when the animals were treated with anti 
VEGF antibodies (Warren et al., 1995). Taken together, these findings suggest 
that VGEF production by tumour cells is critical for tumour growth, 
extravasation, colonising distant tissues, and to overcome growth restraints in the 
extravascular space to produce metastatic nodules. The possibility of using VEGF 
and its receptors as prognostic indicators and for cancer irradication is intriguing. 
For example, the expression of VEGF and its receptor KDR in breast carcinoma 
was found to statistically correlate with the number of metastatic nodules (Toi et 
al., 1995).
Little is known about the mechanisms involved in VEGF induction during 
disease processes generally and cancer in particularly. The VEGF gene contains 
four potential AP-1 sites that are probably important in the transcriptional 
induction of VEGF by cytokines and growth factors (Finkenzeller et al., 1995; 
Kolch et al., 1995). In contrast, hypoxia, which is a strong inducer of VEGF, 
increases the stability of VEGF proteins through the activation of c-src gene 
(Mukhopadhyay et al., 1995; Stein et al., 1995).
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Puzzling clinical phenomena such as why does the removal of certain 
primary tumours lead to rapid growth of metastases (O'Reilly, 1997; Sckell et al., 
1998), have lead to the discovery of endogenous inhibitors of angiogenesis. The 
mechanisms by which angiostatin is produced by tumour cells is still unclear. 
However, angiostatin is a 38 KD protein believed to be an internal fragment of a 
larger protein plasminogen, which is cleaved by urokinase and free sulphhydryl 
donors produced by tumour cells (Gately et al., 1997). It is a paradigm of 
tumourigenesis that a tumour produces both angiogenic stimulators and inhibitors, 
but this discovery has lead to a concept that tumour angiogenesis depends on a net 
balance of positive and negative regulators of blood vessels growth (Folkman,
1995). This not only helps to explain the clinical puzzles stated above, but also 
considerably advanced our understanding of why certain tumours are aggressive, 
while others remain dormant for long-periods.
The role these molecules play in tumour irradication is intriguing. Indeed, 
angiostatin or endostatin administration to mice caused regression of their primary 
tumours. In addition, when both drugs were administered together tumours were 
irradicated to microscopic size lesions with no toxic effects noticed (O'Reilly, 
1997; O'Reilly et al., 1997).
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CHAPTER 3. RAS GTPase Superfamily
The p21 proteins encoded by N-, Ki- and H-ras are small quanine 
nucleotide-binding proteins that act as switches in several trunsduction pathways. 
The large superfamily of Ras-like GTPases is divided into several families. In 
humans, this superfamily consists of the Ras proteins, four Rap proteins; Rap la, 
Rap lb, Rap 2a, Rap 2b, two R-ras-like proteins; R-ras and TC21, two Ral 
proteins; Ral A and Ral B, and a recently identified Rheb protein. Less closely 
related to the Ras family, are other GTPase protein families. For example, the Rho 
family, which includes Rho-A, Rho-B, Rho-C, Rho-G, Rac-1 and -2, CDC42 and 
TC 10. An important concept that has emerged regarding the GTPase superfamily 
is the ability of some members to interact with one another. For example, 
microinjection experiments have revealed that CDC42 can activate Rac, which in 
turn activates Rho (Kozma et al., 1995; Nobes and Hall, 1995). Moreover, it has 
been shown that Ras, possibly acting via CDC42, requires both Rac-1 and Rho-A 
in order to establish a fully transformed state (Khosravi-Far et al., 1995).
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3.1. The ras genes
The ras genes family was first identified as the transforming oncogenes of 
the Harvey and Kirsten strains of rat sarcomas viruses. Subsequently, the ras 
oncogenes have been identified in a wide range of animal species including 
mammals, birds, insects, molluscs and yeast. Sequence analysis of ras genes and 
proteins in these species revealed a high degree of sequence homology and 
conservation, which suggests that they may play a fundamental role in cellular 
processes. Moreover, a remarkable property of the evolutionary conservation of 
the ras genes is their ability to function in heterologous systems. For instance, 
mammalian ras can complement non-viable rasl' ras2 yeast mutants. Similarly, 
yeast RAS gene can efficiently transform mouse NIH3T3 cells in vitro (DeFeo- 
Jones et al., 1985).
To date, three ras genes have been identified in mammalian cells. The 
genes have been designated H-ras-1 (Harvey-ras), Ki-ras-2 (Kirsten-ras) and N- 
ras (Neuroblastoma-ras). Pseudogenes, that is ras genes that lack introns, were 
also found in mammals. In humans and rats these were designated H-ras-2 and 
Ki-ras-1 (McGrath et al., 1983; Miyoshi et al., 1984). Chromosomal localisations 
of the ras genes in humans and rodents have also been determined. In humans, H- 
ras-1 has been assigned to chromosome 11 (Ilpl5.1-pl5.5), whereas, Ki-ras-2 
and N-ras has been assigned to chromosomes 12 (12pl2.1-pter) and 1 (Ip22-p32), 
respectively (Popescu et al., 1985). The coding sequences of each of these genes 
are found in four exons (I-IV). The exception is the Ki-ras-2 gene, which 
possesses two alternatively spliced fourth exons (IVA and IVB) that allow the 
synthesis of two isomorphic p21 proteins of 188 (Ki-Ras-2B) and 189 (Ki-Ras-
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2A) residues that differ in their carboxy terminal domains (Capon et al., 1983; 
McGrath et al., 1983). Although the spliced junctions of all mammalian ras genes 
correspond precisely, their intron sequences vary considerably. This results in ras 
genes ranging from 4.5 kbp size of H-ras-1 to 50 kbp of Ki-ras-2. In addition, 
mammalian ras genes contain an additional 5' noncoding exon downstream from 
their respective promoters (Jordano and Perucho, 1986). The ras genes promoters 
lack the characteristic TATA and CAT boxes of other eukaryotic genes and are 
instead rich in G/C boxes (Ishii et al., 1986).
At protein level, the ras genes code for highly conserved proteins known 
as p21 Ras (188 or 189 amino acid residues), which is present in all cells, with the 
highest levels found in proliferating cells. However, at the mRNA level H-ras is 
transcribed highest in skin and muscle, Ki-ras in gut and thymus, and N-ras in 
thymus and testes (Barbacid, 1987).
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3.2. The Ras proteins
Comparison of the mammalian H-, Ki-, and N-Ras protein sequences 
revealed the presence of three domains. The first domain (amino acids 1 to 85) is 
identical between the three Ras proteins even among different species. In the 
second domain (amino acids 8 6  to 165), the sequence and structure diverge 
slightly to reach up to 85% homology between any pairs of mammalian Ras 
proteins. The third domain (amino acids 166-185) is highly different in amino 
acid compositions not only between species but also between the three Ras 
proteins; hence, this region is termed the 'hypervariable region'. The last four 
carboxy terminal amino acids containing the sequence Cys -A-A-X-COOH (A 
is aliphatic amino acids and X is any amino acid) are present in all members of the 
Ras protein family (Barbacid, 1987). This conservation of the last four amino 
acids appears to be important in triggering post-translational modification and 
cellular localisation of the Ras proteins. The cytoplasmic pro-21 is farnesylated in 
the cytoplasm at the Cys 186 (Hancock et al., 1989) after which the three C- 
terminal amino acids are cleaved and a methyl group is transferred onto the 
exposed a- carboxyl group of Cys 186 (Gutierrez et al., 1989). The last two 
reactions seem to occur on the intracellular membrane and are important for 
efficient localisation of Ras to the intracellular membrane (Hancock et al., 1991; 
Stephenson and Clarke, 1990). However, farnesylation, cleavage and 
carboxymethylation are not alone sufficient to localise Ras to the intracellular 
membrane but efficient localisation requires the reversible palmitoylation of 
residues Cysl81 and Cysl84 (Hancock et al., 1989). Interestingly, Ki-Ras-2B 
lacks these cysteine residues but a stretch of extremely basic region comprising
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six lysine residues (177-182) seems to be essential for intracellular membrane 
localisation (Hancock et al., 1990). Thus, it is likely that the hypervariable region 
of all the Ras polypeptides confers different signals for intracellular membrane 
localisation that could potentially target different Ras proteins (H-Ras, Ki-Ras A 
or B and N-Ras) to specific sites in the membrane where they fulfil different 
requirements and functions for the cell. Indeed, it has only recently been shown 
that while oncogenic Ki-Ras blocked integrin |3i chain maturation and up- 
regulated CEA expression which disrupts basolateral polarity in colon epithelial 
cells, oncogenic H-Ras lacked such effects (Yan et al., 1997; Yan et al., 1997). 
Localisation of Ras proteins to the inner surface of the plasma membrane is 
important for their function since mutating Cys 186 (the farnesylated residue) or 
Cys 181 and 184 (the palmitoylated residues) or inhibiting farnesylation reduces 
the cell transformation capabilities of oncogenic Ras (Hancock et al., 1990).
The p21 proteins encoded by N-, Ki- and H-ras are small guanine 
nucleotide-binding proteins that act as switches in several signal transduction 
pathways (Figure 5). The GTP-bound protein activates the effector pathways 
while the GDP-bound form does not (Gibbs et al., 1984). The protein's GTPase 
activity returns it to the inactive state. The GTPase reaction is a hydrolytic one. 
In the wild-type Ras-GTP crystal structure a water molecule is seen in just the 
right position to catalyse the reaction (Pai et al., 1990). This water is correctly 
oriented by hydrogen bonding to the carboxy side chain of Gln-61. The 
oncogenic position 1 2  mutants may exert their major effect by the side chain 
sterically preventing correct access of this water molecule to the active site, or by 
the mutation causing a rearrangement of key P-loop residues (Maegley et al.,
1996). In either case, the oncogenic position 12 mutants have a lowered GTPase
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activity, and, perhaps more strikingly, a total absence of ability to be stimulated 
by GAP.
The three-dimensional structure of two GAP domain- G-protein - 
nucleoside diphosphate - aluminium fluoride complexes have been determined 
(Scheffzek et al., 1997). In both, the GAP domain binds directly on top of the 
nucleotide and also overlaps the effector site. The Switch II region becomes 
rigid. A conserved arginine protrudes into the nucleotide-binding site, its carbonyl 
group makes a hydrogen bond with the carboxylate group of glutamine-61 and its 
guanidino group is near to the y-phosphoryl group such that it has a key role in 
GTPase catalysis. The complex also reveals that Gly-12 contacts part of GAP 
closely so that there is little space for a side chain, and the authors argue this is the 
reason the GTPase activity of most Gly-12 mutants is insensitive to stimulation by 
GAP.
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Figure 5: Conform ational changes in key residues o f the Ras protein on GTP 
binding
The sw itch  I region bearing the Tyrosine-32 residue is coloured yellow. 
G lyc ine-12 (part o f the P-loop) is coloured green and the w ater m olecule is 
denoted by a green ball. G lutam ine-61 (part o f switch II) is shown in balls and 
sticks.
The thin arrow indicates the extent and the direction o f the conform ational 
change o f the sw itch I region o f Ras after its activation by GTP binding. On 
binding to G TP exchange factors (GEF) or Sons o f Sevens (SoS), G D P is 
exchanged for G TP and Ras is activated by the subsequent conform ational 
change. The G TPase activating protein (GAP) stim ulates the GTPase activity of 
Ras and the G TP is hydrolysed to GDP. This causes the switch I region to "flip" 
back to the inactive conform ation.
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SoS(GEF like)
Ras inactive Ras active
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3.3. Structure of Ras protein
Much is known about the tertiary structures of Ras protein molecules 
(Sprang, 1997). The nucleotide sits in a crevice at the surface and three regions 
closely surrounding the di- or tri-phosphate part can be distinguished: the P-loop, 
which binds the triphosphates and Switch I and Switch II, which are the regions 
that change conformation between the GTP- and GDP-bound forms (Figure 6 ). 
The P-loop (residues to 10-17) contains the GxxxxGKS/T sequence motif, which 
has the same 3D structure in a wide variety of proteins including GTPases, 
ATPases and kinases. Functionally it can be regarded as a triphosphate-binding 
site because several amide groups lie together in an anion hole (Dreusicke and 
Schulz, 1986) or nest (Sayle and Milner-White, 1995) that neatly accommodates 
the triphosphate by multiple hydrogen bonding to the oxygen atoms. In Ras the 
sequence is GxGxxGKS and it is the second glycine (residue 12) which is so 
oncogenic.
The effector region, also called Switch I, comprising residues 30 to 40 
which are mostly exposed at the surface, is found by genetic analysis to be the 
most important in determining the transducing effect of Ras. It shows differences 
in conformation between the GDP and GTP-bound forms of the protein (Figure 
5). The nature of the effector proteins for Ras was controversial, but it is now 
clear that Raf is a major effector protein (Moodie et al., 1993; Wittinghofer and 
Nassar, 1996). However, other proteins, including GAP (Trahey and McCormick, 
1987; Trahey et al., 1988), neurofibromin (Bollag and McCormick, 1991), 
RalGDS (White et al., 1996) and PI-3K (Rodriguez-Viciana et al., 1997) bind to 
this region of Ras and may also act as effectors (Katz
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Figure 6: 3-Dimensional-cartoon structure o f  the Ras protein in the active
conformation
The switch I effector region (residues 30-40) is coloured yellow. G lycine- 
12 and aspartate-13 (the frequently m utated  residues) are coloured green and the 
switch II region is coloured red (residues 61 and 59 w ithin switch II, w hich are 
also hot-spots for m utation) are coloured green. The GTP analogue is coloured 
m agenta and the water m olecule is coloured blue.
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and McCormick, 1997). Although the area to which they bind overlaps the Raf 
effector region, their binding sites on Ras are distinct (Winkler et al., 1997).
The switch II region (residues 60 to 70) contains the Gln-61 residue that is 
of interest because its amide side chain has been found to be necessary for the 
catalysis of GTP hydrolysis (Pai et al., 1990). The region exhibits relatively large 
conformational changes but, because its electron density has a high temperature 
factor, with the exception of that of Asp-12 Ras, it is found to be mobile and there 
can be little reliability about the apparent conformational changes that can be 
seen. The switch II region in Asp-12 mutants is different in that it displays a more 
fixed conformation than those in wild-type or other mutant Ras molecules 
(Franken et al., 1993). The switch II has also been shown to be important in 
binding of Raf-1 cysteine-rich domain (residues 139-184). Mutation in switch I 
(T35A and E37G) and switch II of Ras (G60A and Y64W) diminished binding of 
Ras to Ras binding domain of Raf-1 (residues 55-131) or the Raf-1 cysteine-rich 
domain (139-184) respectively (Drugan et al., 1996). Both of these interactions of 
Ras with the two domains of Raf-1 are necessary for transformation by Ras and 
for activation of Raf-1 (Drugan et al., 1996; Hu et al., 1995).
51
3.4. Ras the oncogenic protein
There is compelling evidence that mutations in codons 12, 13 or 61 of the 
ras genes render them oncogenic. These mutations are frequently found in human 
neoplasms, especially in adenocarcinomas of colon (30-50%), lung (30%) and 
pancreas (90%), with mutations in codon 12 being by far the most frequent (Bos, 
1989). This finding led to the discovery that Ras mediates a wide variety of signal 
transduction from the cell surface receptor tyrosine kinases. Upon receptor 
activation by ligand, receptor tyrosine kinases, such as EGFR, PDGFR, IGFR and 
heterotrimeric G proteins-coupled receptors, SoS (ubiquitous GEF) is recruited to 
the plasma membrane where it catalyse the exchange of GDP for GTP on Ras. 
The association of SoS with the receptor tyrosine kinases is mediated by (PH) a 
membrane attachment domain of SoS and the SH2- and SH3-domain-containing 
adaptor protein Grb2 (Byrne et al., 1996). In other types of receptors, such as 
NGFR, SoS and Grb2 are associated with these receptors via tyrosine 
phosphorylated She proteins. Serpentine receptors activate Ras by releasing the 
Py-subunit of the heterotrimeric apy-G protein complexes (van Biesen et al., 
1995). The Py-subunit activates PI-3 kinase y, which by ill-defined pathway 
involving Src or a Src-like tyrosine kinase, induces the tyrosine phosphorylation 
of She and subsequently SoS-mediated activation of Ras (Lopez-Ilasaca et al., 
1997).
Ras activation leads to activation of multiple signalling pathways (Figure 
7). However, the mechanisms of activation as well as the direct effects of 
activation of the downstream pathways are not understood in most cases. 
Nevertheless, Ras activation in immortalised cells results in proliferation (entry
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into S phase of the cell cycle) via the activation of cyclin D1 through 
Ras/Raf/MAPK pathway (Aktas et al., 1997; Mittnacht et al., 1997; Peeper et al.,
1997), differentiation and cellular transformation.
3.4.1. Role o f Ras in the cell cycle
It has been known for a long time that Ras alone is unable to 
transform normal primary cells but requires the presence of cooperating 
oncogenes such as C-myc, N-myc, cyclin D l, adenovirus E1A, polyoma large T or 
the loss of specific tumour suppressor genes such as p53, p l6  and p21 (Weinberg, 
1989). Interestingly, the reasons for requirement of cooperating oncogenes in Ras 
transformation has only recently been elucidated where it has been shown that in 
primary cells (cells with normal DNA), transfection of activated ras gene resulted 
in cellular growth arrest and senescence (Ridley et al., 1988; Serrano et al., 1997). 
Cellular senescence in valine-12 Ras transfected cells has been recently shown to 
be a consequence of increased intracellular H2O2 (Lee et al., 1999). The authors 
have demonstrated that the ability of Ras proteins to increase H2O2 levels was 
essential for Ras induced senescence because valine-12 Ras-expressing cells 
grown in the presence of either a peroxidase-scavenging antioxidant or low 
oxygen were rescued from senescence. On the other hand, inhibition of cell 
growth has been shown to be a consequence of activation of the Ras/Raf/MAPK 
pathway that leads to the induction of the universal cell cycle kinase inhibitor 
(CDKI) p2 iWAF1/ClP1 in a p53-dependent manner (Lloyd et al., 1997). Similarly, in 
another study, the inhibition of cell growth by Ras was shown to be associated
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Figure 7: A schematic presentation o f Ras protein signal transduction pathways
Ras activation of the MAPK pathway is denoted by red arrows and the 
activation of PI-3K/Rac/Rho pathway is illustrated by green arrows. See through­
out Chapter 3 for details.
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with induction of p2 i WAF1/QP1 and p l 6 INK4a, which binds and inhibits kinases 
associated with cyclin D1 (Serrano et al., 1997). Recently, oncogenic Ras was 
shown to induce the expression of p l9  ARF in MEF mouse cells (Palmero et al.,
1998). p l9ARF (the human homologue is p l4ARF) can activate p53 in a DNA- 
damage-independent manner (Kamijo et al., 1998; Kamijo et al., 1997; Pomerantz 
et al., 1998; Zhang et al., 1998). Taken together, these data indicate that 
oncogenic Ras elicits an anti-tumour response mediated by the upregulation of 
p ! 6 INK4A an(j p i 9 ^ ^  which in turn activate the tumour suppressors 
retinoblastoma and p53 respectively (Figure 8 ). Homozygous deletion of the 
INK4a-ARF, located on human chromosome 9p (Haber, 1997), is common in 
human tumours (Hall and Peters, 1996). The loss of these and other tumour 
suppressor genes could render tumour cells unprotected against the action of 
oncogenes. Thus, during the process of immortalisation, the presence of 
cooperating oncogenes or the deletions of suppressor genes render the overall 
signal from Ras proteins one that is associated with cell growth and proliferation. 
Indeed, NIH3T3 fibroblasts, a cell line in which many early transformation assays 
were performed are known to have deleted their p l6  gene (Quelle et al., 1995). 
Similarly, Rat-1 cells have reduced expression of p21 protein (Perez-Roger et al.,
1997). The Myc protein is a classical cooperating partner of Ras. Recently, the 
collaborative interaction between Myc and Ras has been spiked by the finding that 
Ras enhances the accumulation of Myc activity via the Ras/Raf/MAPK pathway 
by preventing its degradation (Sears et al., 1999). In transformation assays, Myc 
has been shown to be able to overcome a p53-dependent growth arrest by 
sequestering p21 (Hermeking et al., 1995), likewise, Myc is able to antagonise 
p l 6 -induced cell cycle arrest (Alevizopoulos et al., 1997; Serrano et al., 1995).
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Figure 8: Consequences o f Ras activation on the cell cycle
A ctivated Ras is thought to induce the production o f cyclin D1 via the 
M APK pathw ay (green arrows).
In normal cells, this induction is seen on release from GO and more strongly in 
mid G l.
Oncogenic Ras or R af may also produce such effects on cells. However, 
constitutively activated Ras or R af blocks cell cycle progression via the induction 
o f CD K  inhibitors (red pathw ays). This could represent a safety m echanism , 
which blocks inapropriately activated Ras. Deletions o f retinoblastom a (Rb) 
and/or the CDK inhibitors would favour a positive effect o f Ras on cell cycle 
progression. P, indicates phosphorylation.
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Human papilloma E6 , E1A and SV40LT viral oncogenes cooperate with Ras in 
transformation assays by virtue of their ability to block p53 function, or in the 
case of human papilloma E7, SV40LT and E1A block p l 6  by virtue of binding to 
Rb or block p21 function as seen with E7 viral oncoprotein (Funk et al., 1997; 
Vousden, 1995). Interestingly, other oncogenes such as Cyclin D1 and cdc25 A 
and B have been shown to cooperate positively with Ras on the cell cycle and it 
could be that the overexpression of these proteins may counteract CDKIs (Lovec 
et a l, 1994).
It is now becoming apparent that Ras activates at least two signal 
transduction pathways. The Ras/Raf/MAPK pathway that regulates gene 
expression (Thorburn et a l, 1994) and the other Ras/PI-3K/Rac/Rho pathway 
controls actin cytoskeleton organisation (Bar-Sagi and Feramisco, 1986; Ridley,
1994) (Figure 7). Clearly, these two pathway can be dissociated since H-Ras 
V12C40 mutants could induce membrane ruffling and JNK1 activity but failed to 
bind Raf-1 or induce MAPK activation, while H-Ras V12S35 mutants were able 
to bind Raf-1 and induce MAPK activation but failed to stimulate membrane 
ruffling. However, both mutants were defective in stimulating DNA synthesis but 
expression of both mutants resulted in stimulation of DNA synthesis that was 
comparable to Ras valine-12 mutants (Joneson et a l, 1996). Similarly, other 
studies have shown that while Ras V12S35 and V12G37 mutants were defective 
in transforming fibroblasts in culture, co-transfection of cells with both mutants 
resulted in an increase in focus formation approximating that obtained using Ras 
valine-12 mutants (White et a l, 1995). Moreover, V12G37 mutant Ras can 
cooperate with V12C40 Ras in transformation assays. Neither Ras mutant binds or 
activates Raf-1, indicating that Ras activated Raf-independent signalling pathway
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is important in cellular transformation (Khosravi-Far et al., 1996). These results 
argue strongly that different Ras effector pathways have to interact to produce full 
transformation.
3.4.2. Role o f Ras in apoptosis
Apoptosis is a morphologically distinct process of cell death (Kerr et al., 
1972). It is now well recognised that tumour growth is a consequence of disturbed 
balance between cellular proliferation and cellular death (Kerr et al., 1994).
As with the effects of Ras on the cell cycle, Ras has been shown to have 
similar double-effects on apoptosis. Several studies have shown that Ras can 
induce cellular apoptosis under stressful conditions (Kauffmann-Zeh et al., 1997; 
Vater et al., 1996).
The mechanism by which Ras promotes cellular apoptosis is not well 
defined. However, it has been found that the Raf/MAPK pathway is involved in 
this pro-apoptotic effect of Ras (Kauffmann-Zeh et al., 1997). As discussed in 
section 3.4.1, the ability of Ras to induce apoptosis is tied closely to its ability to 
induce the production of p l 6 INK and p21WAF1 via p53 that are important in cellular 
senescence. Loss of p53 has been shown by several reports to abrogate the 
induction of apoptosis in activated Ras-expressing fibroblasts (Fukasawa et al., 
1997; Nikiforov et al., 1996). On the other hand, Ras has also been shown to 
protect cells from apoptosis. In colorectal cancer, activated Ki-ras is associated 
with tumours that have lower apoptotic counts (Ward et al., 1997). It has recently 
been shown, by using the effector specific mutants of Ras, that activation of the 
PI-3K effector arm of Ras significantly reduces the apoptosis of Rat-1 cells 
(Kauffmann-Zeh et al., 1997). PI-3K is known to activate PKB/Akt and this
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pathway has been found to be activated by Ras in a variety of cell lines (Marte 
and Downward, 1997; Marte et al., 1997; Yao and Cooper, 1995). The way 
PKB/Akt inhibits apoptosis is not well understood but could involve the 
phosphorylation and the inhibition of BAD (a known inhibitor of Bcl-2) (Datta et 
al., 1997; Zha et al., 1996).
Ras has also been shown to activate the transcription factor NF-kB, which 
has anti apoptotic properties. Inhibition of NF-kB (by using a super-repressor 
form of the inhibitor of NF-kB (IkB), which cannot be phosphorylated or 
degraded) has been shown to induce significant apoptosis in Ras transformed 
fibroblasts in a p53-independent manner (Mayo et al., 1997). Thus, activated Ras 
can have both apoptotic and anti-apoptotic effects on cells. In general, the anti- 
apoptotic Ras/MAP kinase is dominant over the pro-apoptotic pathway 
(Kauffmann-Zeh et al., 1997). However, the final effects on cells depend on a fine 
balance between the two effectors of Ras (Raf and PI-3K). In tumour cells, 
activating Ras could shift the balance towards anti-apoptosis since p53 and p i 6  
are frequently altered. Similarly, different cell types will respond differently to 
activation of Ras depending on which arm of the Ras effector pathways is altered.
3.4.3. Role o f Ras in genomic instability
An emerging theme arising from studies comparing DNA content between 
adenomas and carcinomas is that carcinomas are frequently more aneuploid than 
adenomas. Although small adenomas are more likely to be deploid, large 
displastic adenomas and adenomas containing foci of carcinomas are frequently 
found to be polyploid (Suzuki et al., 1995). Since mutated Ki-ras gene has been 
associated with the transition of early adenomas to displastic adenomas
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(Vogelstein et al., 1988) and that activated ras genes are frequently found in 
aggressive and heteroploid tumours, it is tempting to speculate whether activated 
ras could be associated with genetic instability. Recent literature has indeed 
shown such an association to be possible. For example, expression of activated 
human H-ras oncogene in NIH3T3 cells induced rapid production of 
chromosomal aberrations ranging from multicentric, acentric, double minute 
chromosomes and gene amplifications to induction of heteroploidy. These effects 
have been shown to be induced by activated ras since they were repressed by a 
dominant negative effector of Ras, Raf 301 (Denko et al., 1995). Similarly, other 
studies, using a variety of cell lines, have shown a direct association between 
activated ras and genomic instability (de Vries et al., 1993; Giaretti, 1997; 
Ichikawa et al., 1990). Notably, the induction of chromosomal aberrations by 
activated ras has been shown to be rapid and occurred during a single cell cycle 
(Denko et al., 1994). It should be noted, however, that the cell line used to study 
the effects of activated ras on genomic instability contained other genetic defects 
such as mutated p53 that are important in permitting such ras-effects on the 
genome. Interestingly, it has been shown, although in a small number of 
adenomas, that codon-12 G-* C and G -> T tranversion mutations of Ki-ras 
oncogene were more significantly associated with DNA aneuploidy than the more 
common G -> A transition mutations (Giaretti et al., 1995).
Since metastasis is a multi-step process requiring the functions or de­
functions of many genes, it has been a scientific dogma that a single gene, such as 
activated ras, could activate such a complex process. Thus, the ability of 
activated ras to induce metastatic behaviour on cells could be ascribed partly to its 
ability to destabilise the genome in addition to its ability to activate many down­
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stream signals discussed below. However, it should be noted that fibroblasts 
transformed with activated H-ras oncogene, although were induced to 
metastasise, they remained diploid (Muschel et al., 1986). How do activated Ras 
proteins induce genomic instability is not well understood. However, the ability of 
Ras to induce reactive oxygen species production in cells lacking a functional 
senescence program or possessing a defective DNA repair machinery could result 
in oxidative DNA damage and genomic instability.
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3.5. The role o f Ras in the metastatic process
It has been known for a long time that introducing activated ras genes in 
immortalised cells render them more invasive in vitro and metastatic in nude mice 
(Chambers and Tuck, 1993). In this section, I will discuss some of the ways by 
which activated Ras proteins could induce cellular motility, invasion and 
metastasis.
3.5.1. Ras and cell adhesion molecules
As discussed in section 2.2, alterations of cellular adhesion can have 
profound effects on cellular behaviour. Transformation of cells with the small 
GTPase Ras results in increased tyrosine phosphorylation of p-catenin and 
decreased amount of P-catenin in the E-cadherin-p-catenin complex (Kinch et al.,
1995) that could explain the disruption of cadherin mediated cell adhesions in v- 
ras transfected cells. Also, Ras and APC proteins seem to act synergistically in 
transforming cultured murine colon epithelial cells (D'Abaco et al., 1996). 
Recently, phosphorylation of Akt by the Ras/PI-3K pathway has been shown to 
phosphorylate and inactivate glycogen synthase kinase 3, which may disrupt the 
degradation pathway of free P-catenin in cells (Sutherland et al., 1993). This is 
significant because excess p-catenin has been shown to play a role in 
tumorigenesis due to its activity in transcription of genes (Rubinfeld et al., 1997; 
Tetsu and McCormick 1999).
Activated Ras has been shown to disrupt the interaction of AF- 6  with ZO- 
1 by binding to AF- 6  (Han and Colicelli, 1995; Yamamoto et al., 1997). AF- 6  and
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ZO-1 proteins co-localize and accumulate at tight junctions in epithelial cells and 
at cell-cell junctions in non-epithelial cells and are important in cell-cell adhesions 
(Itoh et al., 1993; Yamamoto et al., 1997). In addition, activated Ki-Ras protein 
has been shown to increase CEA expression on epithelial cells in vitro resulting in 
disruption of epithelial cell polarity (Yan et al., 1997). Such disruption of cell-cell 
adhesions is necessary during mitosis. However, the disruption of epithelial cell­
cell junction by constitutively activated Ras could represent an important step in 
epithelial to mesenchymal cellular transformation.
Ras has been shown to affect integrins in at least two ways. Plantefarber 
and Hynes (1989) have shown that rat cells transformed with ras or Rous sarcoma 
virus expressed decreased amount of pi integrin. In addition, Yan et al. (1997) 
have shown that activated Ki-Ras reduced the maturation of Pi integrin in colon 
epithelial cells. Recently, H-Ras has been shown to inactivate integrin binding to 
the extracellular matrix (Hughes et al., 1997). The discovery that oncogenic H- 
Ras can reduce integrin affinity suggests a possible connection between reduced 
affinity and a more motile and invasive phenotype in cancer cells. Indeed, 
DeMilla et al. (1993) have shown using smooth muscle cell migration on 
fibronectin matrix that the optimal cellular migration occurred at an intermediate 
attachment strength. Both low and high levels of cell adhesion on fibronectin 
inhibited cell migration.
3.5.2. Ras in cellular motility and invasion
It has been known for some time that ras-transformed cells undergo 
significant morphological changes such as loss of stress fibers, decreased matrix 
adhesions, increased membrane ruffling and motility (Bar-Sagi and Feramisco,
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1986). Although the precise mechanisms of these changes are not well 
understood, they appear to involve the Rho family members of proteins. For 
example, activated valine-12 mutant of H-Ras induction of membrane ruffling 
was blocked by dominant negative Racl and bacterial C3-transferase, which 
inactivates Rho (Ridley and Hall, 1992). In addition, Racl, RhoA and Cdc42 have 
been shown to promote cellular motility and invasion. Notably, Rac has been 
shown to be directly responsible for forming membrane ruffling and lamellipodia 
and Cdc42 can control the formation of filipodia (Hall, 1998; Hall, 1994). These 
observations established that the ability of activated Ras to cause membrane 
ruffling and motility could be ascribed to its ability to stimulate the Rac-Rho 
cascade (Figure 7).
Genes of matrix degrading enzymes are induced by Ras. Several such 
genes contain regulatory sequences that are activated by Ras through binding of 
FOS/JUN (AP-1) family and the PEA3/Ets family of transcription factors. For 
example, Ras induce the expression of stromelysin-1 and collagenase via the AP-1 
elements (Matrisian et al., 1991; Schonthal et al., 1988), MMP-9 through NF-kB, 
SP-1, AP-1 and ETS (Gum et al., 1996; Himelstein et al., 1997), uPa via 
PEA3/AP-1 (ERK and JNK) and Cathepsin L through the ERK pathway 
activation (Silberman et al., 1997). The increased invasive and metastatic abilities 
of tumour cells harbouring activated Ras proteins could be in part be due to the 
increased expression of these matrix degrading enzymes, which have been shown 
to be expressed in aggressive tumours in vivo and in vitro.
Ras is also responsible for transmitting signals from growth and motility 
factors that induce invasion and metastasis. For example, recently, using 
signalling mutants of c-Met, it has been shown that coupling of the receptor to the
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Ras pathway is both essential and sufficient for proliferation, whereas, activation 
of PI-3K alone is sufficient to induce motility (Ponzetto et al., 1996). Notably, the 
activation of Ras and PI-3K by the receptor is both necessary and sufficient to 
induce invasion and metastasis (Giordano et al., 1997). In addition, migration of 
keratinocytes stimulated by HGF is inhibited by treatment of bacterial C3- 
transferase, which inactivates Rho (Takaishi et al., 1994). These results argue for 
an essential role of the GTPase super family in mediating the motility signals of 
HGF-Met to the cytoskeleton of cells (Hartmann et al., 1994). Also, murine NIH 
3T3 and C127 cells transformed by oncogenic Ras have been shown to over 
express the c-Met receptor and display increased invasive properties in response 
to HGF (Webb et al., 1998). Taken together, these results show that Ras can 
activates and induces many signals necessary for cellular invasion and metastasis.
3.5.3. Ras and angiogenesis
Angiogenesis, as discussed in section (2.6), is a critical biological process 
for tumour growth. It is now well established that activated Ras induces or 
upregulates the production of various pro-angiogenic factors such as VEGF 
(Bouck et al., 1996). Indeed, cells containing the activated Ras has been shown to 
induce significantly larger number and sized angiogenic vessels when grafted in 
mice compared to cells infected with other retroviral constructs (Thompson et al., 
1989). Moreover, Grunstein et al. (1999), by using VEGF null fibroblasts (in 
which VEGF can be conditionally deleted), have shown VEGF expression to be 
critical for ras-mediated tumourigenesis. Similarly, knocking-out ras in human 
colorectal cancer cell lines by homologous recombination (these cells contain a 
single mutated Kl-ras allele) suppressed VEGF production and reduced the ability
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of these cells to form tumours in nude mice (Rak et al., 1995). The authors argued 
that reduced VEGF production in these cells was partly to blame for their reduced 
tumuorigenicity since suppression of VEGF by antisense in the parental cells 
(containing activated Ras) reduced their tumourigenicity and also because the 
growth of ras knock out cells in vitro was unaffected (Okada et al., 1998). 
Although, subsequent work, by the same authors demonstrated a weak but 
detectable restoration of tumourigenicity when ras knock-out cells were 
transfected with one of the VEGF isoforms (VEGF 121). The inability to fully 
restore tumourigenicity by VEGF 121 made the authors conclude that VEGF up- 
regulation by activated Ras was necessary but not sufficient for tumourigenicity 
(Okada et al., 1998). This is not surprising because activated Ras is required for 
induction of other molecules necessary for tumourigenesis. Although it can also 
be argued that restoration of only one of the VEGF isoforms and not the others is 
a major flaw in this work since the other isoforms could be necessary in fully 
inducing angiogenesis by activated Ras.
The mechanisms by which activated Ras induces VEGF production are not 
fully understood. Although the VEGF gene is known to contain AP-1 sites for 
binding of FOS/JUN dimers (Tischer et al., 1991), Ras has been recently shown to 
induce VEGF production via the PI-3K pathway. For example, the inhibition of 
PI-3K by Wortmannin reduced VEGF production, angiogenesis and tumour 
volumes of SVR cells in nude mice (Arbiser et al., 1997). The authors also 
demonstrated that Ras induced angiogenesis by up-regulating the matrix 
metalloproteases and down regulating their inhibitors. As discussed in section 
(2.5), matrix metalloproteases are important in the process of angiogenesis and the 
ability of activated Ras to up-regulate MMP-2 and MMP-9 and down regulate
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TIMP could be an additional mechanism by which Ras induces angiogenesis 
(Arbiser et al., 1997).
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CHAPTER 4. Tumour heterogeneity
4.1. Genetic diversity in solid tumours
Tumours arise from single cells. This statement infers that tumours are 
monoclonal in origin. Numerous cancer biology researchers using a variety of 
experimental procedures demonstrated that tumour growth represents clonal 
expansion from a single aberrant cell (Fialkow, 1976; Nowell, 1976; Nowell, 
1986). One approach, utilised X-linked RFLP to examine the pattern of X 
chromosome inactivation in colorectal tumours of females and showed that in 
carcinomas and adenomas the same member of the X chromosome pair is 
functional in all cells of a given tumour thus demonstrating the monoclonal 
patterns of X chromosome inactivation (Fearon et al., 1987). It is of course 
possible that tumours may develop independently from a number of transformed 
cells but that only one of these will ultimately survive or overgrow to give rise to 
a clinically detectable tumour. Another obvious problem in correlating the pattern 
of X chromosome inactivation with tumour clonality is the fact that methylation 
pattern of DNA can be abnormal in malignancy. A fact that is frequently ignored 
in this field of study. Thus, the use of X chromosome inactivation by itself may 
not be a valid indicator of tumour clonality. For example, using tissue from a Y 
chromosome mosaic individual (XO/XY) and Y-chromosome probes in a in situ 
hybridisation experiment, Novelli et al. (1996) have shown that in this patient, 
while the crypts of the small and large intestine were clonal, at least 76 percent of 
the microadenomas were polyclonal in origin. Although this study is based on a 
single and a rare individual, it raises considerable doubt on the clonal origin of 
tumours. With this notion aside, it is now generally accepted that single-cell origin
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does not rule out subsequent variation in cellular composition as tumours progress 
(Dexter and Calabresi, 1982; Mitelman, 1971). Tumour heterogeneity is now a 
well-accepted phenomenon in cancer biology. Although it has been reported as far 
as the 1950’s.
The term heterogeneity requires a careful definition. Tumours are 
architecturally complex, differing regionally in differentiation status, growth 
potential, cell cycle phase, vasculature, immune-cells infiltrate, connective tissue 
compositions and other characteristics that can influence identical tumour cells to 
a different extent. However, the types of variability usually meant by the term 
heterogeneity are differences in the genetic composition of cells within a single 
neoplasm. This definition is intended to discriminate between variability that 
arises from genetic, as distinguished from non-genetic processes because this 
usage allows a more focused experimental analysis of at least one type of 
neoplastic variability.
The development of cellular heterogeneity is a prime manifestation of 
tumour progression. This in turn is a consequence of the stepwise emergence of 
subclones, a few of which possess selective growth advantage. This dynamic and 
Darwinian evolutionary process is driven by random or induced genetic or 
epigenetic factors and host selection pressures.
Another prediction of the tumour progression hypothesis is that metastatic 
cells arise stochastically during primary tumour growth (Nowell, 1976). Fidler et 
al. (1973) have shown earlier that re-injecting cells established from lung 
metastases enhanced their metastatic potential (Fidler, 1973). Also, by deriving 
single-cell clones from a parent culture of murine malignant melanoma cells 
Fidler and Kripke (1977) have shown that these clones varied in their ability to
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produce metastatic colonies in the lungs upon i.v. inoculation into syngeneic mice. 
Fidler's work, therefore, suggests that a malignant tumour is heterogenous and that 
highly metastatic cell populations preexist in parental tumours. However, it should 
be noted that other investigators were unable to confirm the pre-existence of 
subpopulations of metastatic cells in primary tumours (Milas et al., 1983; Weiss, 
1980).
There is numerous evidence in the literature supporting the existence of 
heterogeneity within tumours (Dexter and Calabresi, 1982; Dexter et al., 1978; 
Shapiro et al., 1981). However, most of the evidence is circumstantial and based 
on isolating different subclones from the same tumour in culture and thus could be 
artificially induced. If tumour heterogeneity exists, it should be directly evident in 
solid tumour in situ. Recently, microdissection techniques have shed more light 
on the extent of intratumour heterogeneity. For example, Nagel et al. (1995) 
studied 2 0  gastrointestinal cancers obtained from female patients and found that 
while these tumours were clonal in origin based in the patterns of X chromosome 
inactivation, a significant number of tumours had LOH in mini and microsatellite 
in restricted areas of single tumours and not others. Other researchers have shown 
similar evidence of intratumour heterogeneity using a variety of techniques 
(Dracopoli et al., 1985; Giaretti et al., 1996; Heim et al., 1997; Hiddemann et al., 
1986; Koha et al., 1992; Kuwabara et al., 1998; Simpson et al., 1996). On the 
other hand, recent work using LOH on 5q, 18q and 17p from colorectal tumours 
demonstrated pronounced allelic heterogeneity in high-grade dysplasia and in 
carcinomas within the high-grade dysplastic adenomas, while allelic losses in 
carcinomas were uniform (Boland et al., 1995). Similarly, in breast cancer and its 
precursor, ductal carcinoma in situ (DCIS), multiple microsatellite markers for
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allelic loss in multiple separate microdissected regions of more than 40 cases were 
evaluated (Fujii et al., 1996). Different microdissected foci of intraductal 
carcinoma in the same sample often differed from one another in their LOH 
pattern, while individual carcinomas exhibited much less intratumour diversity 
than their preinvasive stages. This clonal convergence seems in line with earlier 
reports form Kerbel et al. where it has been shown using a variety of genetic 
tagging methodologies that spontaneous metastases developed in a non-random 
fashion from genotypically distinct cell clones and that the progeny of a single 
metastatic clone could eventually overgrow the primary tumour (Bell et al., 1991; 
Kerbel, 1990; Korczak et al., 1988). Although many other researchers confirmed 
these findings (De Both et al., 1997; Price et al., 1990; Waghorne et al., 1988), 
work by Moffett et al. (1992) using identical techniques have shown that when a 
genetically tagged heterogenous cell population is injected in mice the resulting 
primary tumours and their metastases remained polyclonal and only in few cases 
there was evidence of clonal dominance of the primary tumours by a single 
metastatic clone. Nevertheless, comparing primary tumours and their metastases 
could shed more light on the clonal dominance theory put forwards by Kerbel et 
al. The work of Boland et al. (1995) and Fujii at al. (1996) give further support for 
the prediction made from the tumour progression hypothesis in that tumours may 
be subclonally highly heterogenous during early stages of tumour growth but 
relatively homogenous during advanced stages of growth as the progeny of one or 
few aggressive subclones dominate a tumour.
The presence of heterogeneity in tumours seems to be in conflict with the 
clonal dominance hypothesis. However, the concept of clonal dominance is not 
incompatible with the concept of cellular heterogeneity of tumours, since a
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dominant clone can be homogenous for one marker and heterogenous for other 
markers. For example, while a specific clonally dominant subclone of the mouse 
mammary carcinoma SP1/B5 was found to be homogenous for the plasmid-based 
genetic marker used in tagging the parent cell line, the subclone was in fact 
karyotipically heterogenous (Bell et al., 1991).
An important concept that emerges from the clonal dominance theory is 
that results of any comparison between the primary tumours and their metastases 
could be profoundly affected by the stage at which the primary tumour is removed 
and analysed. Thus, genetic analysis of early primary tumours (containing a very 
small proportion of metastatic cells) with their metachronous metastases (removed 
years after the primary tumour) could yield erroneous results on the clonal 
relationship between the two tumours. Indeed, recent work comparing the genetic 
progression of primary breast cancer with their metachronous metastases using 
CGH showed that primary tumours, in some significant number of cases, to share 
no genetic relationship to their metastases (Kuukasjarvi et al., 1997). On the other 
hand, genetic comparisons between advanced primary tumours and their 
synchronous metastases would, as expected, show closely related genetic changes 
between the two lesions. Similarly, orthotopic implantation of advanced colon 
cancer (Dukes' D) was shown to be capable of metastasis if injected 
subcutaneously in nude mice, whereas earlier staged (Dukes' B) cancer was 
comparatively deficient (Giavazzi et al., 1986; Morikawa et al., 1988; Morikawa 
et al., 1988; Naito et al., 1986). Taken together, the data suggest that the genetic 
composition of tumours could be different at different stages of their progression 
and that metastasis depends on the intrinsic metastatic capability of primary 
tumours. Therefore, results that compare primary tumours with their earlier or late
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metastatic lesions or with other seemingly similar staged tumours or even within 
each tumour should be interpreted with caution.
Thus, the need to develop comparable staging systems is crucial if we are 
to understand the role and extent of cellular heterogeneity in tumour progression. 
Indeed, recently a report from the Kananaskis, Alberta, Canada working group on 
quantitative methods in tumour heterogeneity, emphasised the need for 
quantifying heterogeneity and standardising methodologies used in assessing 
tumour heterogeneity (Chapman et al., 1998).
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4.2. Mechanisms for the generation o f genetic diversity
Colorectal cancer studies have brought to light the existence of at least two 
separate mechanisms for generating genetic instability (Ionov et al., 1993; 
Perucho et al., 1994). The first is found in about 15 % of colorectal cancers and 
involves mismatch repair deficiencies resulting in point mutations, 
microdeletions, and microinsertions (Marra and Boland, 1995). Tumours with 
microsatellites instability usually involves the proximal colon (Thibodeau et al.,
1993), have a distinctive undifferentiated mucinous appearance in which necrosis 
is a prominent feature (Kim et al., 1994) and usually remain diploid or near 
diploid even in advanced stages (Remvikos et al., 1995; Schlegel et al., 1995). 
Patients with this form of colorectal cancer usually have a better prognosis than 
the second form (Bubb et al., 1996).
One of the distinctive features of microsatellite instability is that it 
develops early in the course of the disease. It first becomes apparent in early 
adenomas and progresses with sufficient regularity that some have suggested its 
use as a molecular genetic evolutionary clock (Shibata et al., 1996). This form of 
colorectal cancer is clinically similar to HNPCC that commonly exhibit inherited 
defects in enzymatic repair of DNA. However, patients with sporadic colon cancer 
whose tumours exhibit microsatellite instability, the DNA mismatch repair 
enzymes are frequently normal (Konishi et al., 1996; Liu et al., 1995).
The second more common form is found in mismatch repair proficient 
cells and involves gains and losses of whole chromosomes (Lengauer et al., 
1997). Tumours with this form of instability are usually aneuploid, involve the 
distal colon (Delattre et al., 1989; Ionov et al., 1993; Lothe et al., 1993) and
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frequently exhibit loss and mutations of wild type p53 alleles (Boland et a l, 1995; 
Carder et al., 1993). Indeed, microdissection studies have indicated that p53 
mutations precedes the development of aneuploidy in colorectal cancer (Carder et 
al., 1995). Interestingly, introduction of specific mutant p53, termed class II 
mutants, that affects residues which contribute to the maintenance of the tertiary 
structure or conformation of the protein (Cho et al., 1994; Prives, 1994), rather 
than DNA binding capabilities, in human cells with null p53 or wild type p53, 
induced altered spindle checkpoint control and cells underwent repeated rounds of 
DNA synthesis without chromosomal segregation, generating polyploid cells. 
These specific p53 mutations were shown to act in a dominant fashion and 
represent gain rather than loss of p53 function (Gualberto et al., 1998).
By comparing colorectal cancer mismatch repair deficient cell lines with 
chromosomally unstable cell lines, it has been demonstrated that colorectal 
tumours with chromosomal instability exhibited a striking defect in chromosome 
segregation, resulting in gains or losses in excess of 1 0 ' 2 per chromosome per 
generation. In contrast, tumours with microsatellite instability maintained a 
diploid or near diploid genotype. Also, while mismatch repair deficiency was a 
recessive trait, chromosomal instability appeared to be a dominant one. The 
authors also demonstrated that chromosomal instability is the cause of the 
observed aneuploidy and not vice versa. Interestingly, only one of the eight cell 
lines studied had both genetic defects (MIN and CEN), suggesting that either type 
of instability may be sufficient for driving the neoplastic process, and that MIN 
does not preclude CEN and vice versa. Equally interesting, is the fact that p53 
mutation did not necessarily correlate with chromosomal instability. For example, 
p53 was found to be mutated in one of the chromosomally stable cell lines, but
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was wild type in one of the chromosomally unstable lines. Thus, gene(s) other 
than p53 could be responsible for generating chromosomal instability in these cell 
lines (Lengauer et al., 1997).
Recently, a striking difference in methylation ability between MMR- 
proficient (CIN) and MMR-deficient (MIN) cells has been suggested to play a 
role in chromosome segregation processes (Ahuja et al., 1997; Lengauer et al., 
1997). While mismatch repair deficient cells could methylate exogenously 
introduced retroviral genes, mismatch repair proficient cells were unable to do so. 
The authors hypothesised that methylation abnormalities are intrinsically and 
directly involved in the generation of chromosomal instability. This is supported 
by the observation that demethylation is associated with chromosomal aberrations 
(Schmid et al., 1983; Schmid et al., 1984) and is consistent with the hypothesis 
relating methylation and aneuploidy (Thomas, 1995). Moreover, hypomethylating 
agent, 5-azacytidine, has been shown to induce cell variants in several tumour cell 
lines (Kerbel et al., 1984).
Another mechanism by which significant genetic diversity is generated 
involves the generation of hydrogen peroxide species by tumours. This radical 
attack on primary tumour DNA is likely to result in additional mutagenic damage 
and genetic instability and further increase the number of structurally diverse 
DNA populations from which highly malignant clones could be selected 
(O’Donnell-Tormey et al., 1985; Malins et al., 1996).
76
4.3. Aims o f the PhJ). project
It is clear from the foregoing introduction that, although much is known 
about the metastatic process, much is still to be learned. A great emphasis has 
been previously placed on the progression of adenomas to carcinomas in 
colorectal cancer and much is still to be learned about the genetic aberrations 
associated with its progression to a metastatic phenotype, and about which ones 
are causative and which are the results of metastasis. So, the aims of this study 
were to find genetic aberrations associated with advanced colorectal cancer and 
relate them to cancer progression. Colorectal cancer was chosen for the following 
reasons:
(i) It has very well characterised stages of progression.
(ii) It progresses relatively rapidly.
(iii) Materials from primary and their synchronous metastases are 
readily available.
(iv) Metastases to either or both lymph nodes and liver are available, so 
there is an apportunity to compare two metastatic pathways.
Ultimately, if genetic aberrations are characteristic of tumour 
aggressiveness, then their prognostic value could be of immense importance 
clinically.
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MATERIALS AND METHODS
CHAPTERS. MATERIALS
5.1. ANTISERUM
Supplier: Affinity, Mamhead, Exeter, UK
-anti-|3i integrin monoclonal antibody 
-anti-E-cadherin monoclonal antibody
Supplier: Boehringer Mannheim UK, Lewes, East Sussex, England
-anti-digoxigenin-alkaline phosphatase conjugated antibodies 
-sheep anti-digoxigenin 
Supplier: Chemicon, Cardinal way, Harrow, UK
-anti-stromelysin- 1  polyclonal antibody
Supplier: Gibco Europe Life Technologies Ltd., Paisley, Scotland
-streptavidine-alkaline phosphatase conjugated antibodies
Supplier: Santa Cruz, Autogen Bioclear U.K Ltd, Wiltshire, England
-anti-Ras monoclonal antibody 
-anti-VEGF polyclonal antibody
Supplier: Serotec Ltd., Oxford, England
-anti-ct6 monoclonal antibody (Clone 4F10)
Supplier: Stratech, Luton, Beds., UK
-donkey anti-sheep Texas-red antibody
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Supplier: Vector Labs., Peterborough, UK
-FITC-avidin DCS 
-biotinylated anti-avidin D
5.2. CELL LINES, MEDIA AND TISSUE CULTURE
All cell lines used in this thesis were from The Beatson Institute 
Laboratory stocks.
Rat-1 cells were a kind gift from Professor B. Ozanne (Hennigan et al.,
1994).
Supplier: Beatson Institute Central Services
-sterile water 
-sterile PBS
-sterile glassware and glass pipettes 
Supplier: Becon Dickinson Labware, Plymouth, England
-60 mm and 1 0 0  mm diameter tissue culture dishes
Supplier: Becon Dickinson, Collaborative Research,Franklin Lakes, New Jersey, 
USA
-matrigel
Supplier: Costar Corporation, High Wycombe, Bucks, England 
-24 well cluster tissue culture dishes
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-sterile disposable cell scrapers 
-transwell chambers
Supplier: Fisons Scientific Equipment, Loughborough, Leics., England 
-DMSO
Supplier: Gibco Europe Life Technologies Ltd., Paisley, Scotland 
-BCIP
-chromosome medium 
-colcemid
-lOx DMEM concentrate 
-EGF
-foetal calf serum 
-200mM glutamine 
-NBT
-lOOmM sodium pyruvate 
-7.5% (w/v) sodium bicarbonate 
-1M HEPES 
-2.5% (w/v) trypsin 
-lOOx non-essential amino acids
5.3. CHEMICALS
Supplier: Alpha laboratories Ltd., Eastleigh, Hampshire 
-streck tissue fixative
Supplier: Amersham International pic., Amersham, Bucks., England
-[a-32P] dCTP ~ 3000Ci/mmol 
-[y-32P] ATP ~5000Ci/mmol
Supplier: BDH Chemicals Ltd., Poole, Dorset, England
Unless otherwise stated, all chemicals were obtained from BDH and were of 
AnalaR grade or better.
Supplier: Bethesda Research Laboratories, Life Technologies, Inc., USA
-agarose, ultrapure electrophoresis grade
Supplier: Boehringer Mannheim UK,Lewes, East Sussex, England
-BrdU 
-1 0 % block 
-DAPI
Supplier: James Burrough Ltd., Witham, Essex, England 
-ethanol
Supplier: Fluka Chemicals-Biochemica AG, Buchs, Switzerland 
-formamide
Supplier: Pharmacia Ltd., Milton Keynes, Bucks., England 
-dextran sulphate
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Supplier: Rathburn Chemicals Ltd., Walkerburn, Scotland
-phenol (water-saturated)
Supplier: Sigma Chemicals Co.Ltd., Poole, Dorset, England
-Bicinchoninic acid 
-bromophenol blue 
-BSA (fraction V)
-Copper (II) sulphate pentahydrate
-dithiotheitol
-ethidium bromide
-NP40
-pepsin
-Polyvinylpyrrolidone
-RNase
-salmon sperm DNA 
-TEMED
-tetramethyl ammonium chloride (TMAC)
-thymidine
-tRNA
Supplier: Victor Labs. Peterborough, UK 
-antifade
5.4. COLUMNS 
Supplier: Quiagen Ltd., Dorking, Surrey, England 
-QIAquick PCR purification columns
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5.5. ENZYMES AND INHIBITORS
Supplier: Bethesda Laboratories Research, Gibco Ltd., Paisley, Scotland
All DNA modifying enzymes were obtained from BRL and supplied with the 
appropriate buffers concentrates, with the following exceptions: -
Supplier: Boehringer Corporation (London) Ltd., Lewes, East Sussex, England
-Proteinase K
Supplier: Northumbria Biologicals Ltd., Cramlington, Northumbrerland, 
England
-RNase A
Supplier: Pharmacia Ltd., Milton Keynes, Bucks., England 
-T4 polynucleotide kinase
5.6. KITS
Supplier: Boehringer Mannheim UK,Lewes, East Sussex, England
-Biotin and digoxigenin DNA random priming labelling kit 
-Biotin and digoxidenin DNA nick-translation labelling kit
Supplier: Hybaid, Teddington, UK
-PCR purification kit
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Supplier: Perkin Elmer Cetus, Norwalk, CT 06859, USA 
-GeneAmp PCR reagent kit
-AmpliTaq DNA polymerase sequencing ready mix (part 402079)
5.7. MARKERS and DNA
Supplier: Amersham International pic., Amersham, Bucks., England
-Prestained protein standards: Rainbow markers, 
range 14 300-200 000 Da
Supplier: Bethesda Laboratories Research, Gibco Ltd., Paisley, Scotland
-Cot-1 DNA
-<t>X174 RF DNA/Hae III fragments 
-lOObp ladder check
5.8. MEMBRANES, PAPER AND X-RAY FILM S
Supplier: Amersham International pic., Amersham, Bucks., England 
-Hybond N+
Supplier: Eastman Kodak Co., Rochester, New York, USA 
-X-ray film (XAR)
Supplier: Millipore, Watford herts, England 
-immobilan P membrane
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Supplier: Whatman International Ltd., Maidstone, Kent, England 
-3MM paper
5.9. OLIGONUCLEOTIDES
Supplier: Beatson institute Technology Services, Bearsden, Glasgow, Scotland 
-PCR primers
Supplier: Chruachem LTD. West o f Scotland Science Park, Glasgow, Scotland 
-Allele specific oligonucleotides
5.10. SOFTWARE PROGRAMMES
Supplier: Digital Scientific, Cambridge, UK
-smart capture CGH software
Supplier: Micrografx, Arapaho Richardson, Texas, USA
-photomagic 
-micrografx draw
Supplier: SPSS Science, Chicago, Illinois 60611, USA 
-SPSS software for survival analysis
5.11. WATER
Distilled water for the preparation of buffer stocks was obtained from Millipore 
MilliRO 15 system, and for protein, RNA or DNA procedures was further purified 
on Millipore MilliQ system. Sterile distilled water for use in tissue culture media 
was supplied by the Beatson Institute for Cancer Research Technical Services.
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CHAPTER 6. METHODS
6.1. In  vivo Ki-ras study
6.1.1. Case selection
Two groups of colorectal carcinoma patients for whom archival paraffin- 
embedded tissue was available in Pathology Department files at Glasgow Royal 
Infirmary (Glasgow, Scotland) were studied. One had biopsy-proven hepatic 
metastasis of adenocarcinoma at presentation or subsequently while the other was 
free from hepatic or other distant metastases at presentation and remained so. 
Follow-up data were obtained from case sheets and augmented by cancer registry, 
primary care, and audit data as appropriate.
6.1.2. Tissue preparation and microdissection
6 pm sections of formalin-fixed paraffin-embedded tissue blocks of 
primary and secondary carcinomas and normal tissues were dried on plain glass 
slides, dewaxed, dehydrated and stained in 0.1% toluidine blue. They were 
dissected with microneedles (tip radius about 3pm) using a Leitz model M 
micromanipulater (Going and Lamb, 1996). The proportion of carcinoma cells in 
each neoplastic tissue sample was estimated and recorded. Tissue samples (0.1 to 
1mm2) were digested with proteinase K at 37 °C for 18h. After inactivation of the
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proteinase K at 90 °C for 10 min the material was used directly for amplification 
of Ki-ras sequence by PCR.
The median estimated percentage of carcinoma cells in 254 microdissected 
carcinoma samples from the complete series of 78 patients was 75%. Of these 
samples, 244 (96%) contained 60% or more of carcinoma cells, and all more than 
50%.
6.1.3. PCR
Part of Ki-ras first exon was amplified with the outer 5’ and 3’ primers 
(Table 3) using a commercial kit (Geneamp; Perkin Elmer/Cetus). PCR reactions 
consisted of 34 cycles of 92 °C for 30 s, 60 °C for 90 s, and 72 °C for 150 s 
followed by a final extension at 72 °C for 5 min.
To obtain consistent amplification lp l of the first PCR reaction was 
reamplified with the inner 5 ’ and 3’ primers (Table 3) in the following PCR 
reaction: 92 °C for 30 s, 60 °C for 1 min, 72 °C for 30 s for 34 cycles, with final 
extension for 5 min at 72 °C. In all reactions positive and negative controls were 
included. For the positive controls, an adenocarcinoma-derived cell line with GTT 
mutation in codon 12 of Ki-ras was used (Williams et al., 1993). For the other 
codon 12 and 13 mutations, patient specimens known to have these mutations in 
Ki-ras by direct sequencing were used as positive controls.
For negative controls, samples without DNA were included in the PCR 
reaction mixture and samples representing mock microdissections were also 
amplified to evaluate the possibility of DNA carry-over during microdissection.
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The PCR products were examined for amplification of the expected 121 bp 
fragment on 2% agarose gels (Figure 9).
Table 3: PCR primers and ASO probes
PCR primers used to amplify DNA from microdissected tissues for 
(a), allele-specific oligonucleotide hybridisation and (b), sequencing. Anti-sense 
probes used to detect various codon-12 and 13 mutations of the Ki-ras gene using 
allele-specific oligonucleotide hybridisation are listed in (c)
(a) 5’ outer 
3’ outer 
5’ inner 
3’ inner
5 ’ -AGGCCTGCTGAAAATGACTGAATA-3 ’
5’-CTGTATCAAAGAATGGTCCTGCAC-3 ’
5 ’ -CTCTATTGTTGGATCATATTCGTC-3:
5 ’-GCCTGCTGAAAATGACTGAATATAA-3 ’
(b) 5’ outer 
3’ outer 
5’ inner 
3’ inner
5 ’ -TAGTGTATTAACCTTATGTGTG AC-3 ’
5 ’-CTGTATCAAAGAATGGTCCTGCAC-35
5 ’ - AGGCCTGCTGAAAATGACTGAATA-3 ’
5 ’-CTCTATTGTTGGATCATATTCGTC-3 ’
(c) GGT-12 probe 
GAT-12 probe 
GTT-12 probe 
GCT-12 probe 
TGT-12 probe 
AGT-12 probe 
GAC-13 probe 
______ Mock control probe
5'-CCTACGCCACCAGCTCCAA-3'
5'-CCTACGCCATCAGCTCCAA-3'
5'-CCTACGCCAACAGCTCCAA-3'
5’-CCTACGCCAGCAGCTCCAA-3'
5'-CCTACGCCACAAGCTCCAA-3'
5'-CCTACGCCACTAGCTCCAA-3'
5'-CCTACGTCACCAGCTCCAA-3'
5’-CCTACGCGACCAGCTCCAA-3'
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Figure 9: Microdissection o f liver metastasis
a) An illustrative exam ple o f m icrodissection o f norm al liver (1) and 
adjacent areas o f adenocarcinom a (2 and 3).
b) 2% agarose gel o f nested PCR products generated from m icrodissected
tissue.
Lane 1: 100 bp ladder 
Lane 2-7: 121 bp K i-ras products 
Lane 8 and 9: M ock m icrodissection 
Lane 10 and 11: PCR negative controls
1 2 3  4 5 8 7 M  I Q 11
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6.1.4. Allele-specific oligonucleotide hybridisation
This was done as described previously (Verlaan-de Vries et al., 1986). 
Hybond Nylon N+ membranes (Amersham International) were soaked in distilled 
water then lOx SSC (20x SSC: 3M sodium chloride, 0.3M sodium citrate, pH 7.0) 
and air dried. Equal volumes of 20x SSC were added to the PCR reactions and the 
mixture boiled for 5 min and quenched on ice. 5pi of the denatured PCR product 
was then dotted on the membranes. The membranes were placed carefully in 
denaturing buffer (1.5M NaCl, 0.5M NaOH) for 5 min and then in neutralising 
buffer (1.5M NaCl, 0.5M Tris-HCl pH 7.2, O.lmM EDTA) for 1 min. The filters 
were allowed to air dry and the DNA fixed to the membranes by U.V. light 
crosslinking. The membranes were blocked in pre-hybridisation solution (3M 
TMAC, 50mM Tris pH 8 , 2mM EDTA, 100p,g/ml sonicated salmon sperm 
ssDNA boiled just before use, 0.1 % SDS, 5 x Dehardt's solution) at 56 °C for 16 h 
in a Hybaid rotating oven. 500 ng of codon-12 specific oligonucleotides (Table 3) 
were end labelled in a reaction volume of lOpi containing lx  T4 polynucleotide 
kinase buffer (lOx PNK buffer: 0.5M tris-HCl pH 7.6, 0.1M MgCl2, 50mM 
dithiothreitol DTT, ImM spermidine, ImM EDTA), 10 pCi [y-32P] ATP and 20 
units of T4 polynucleotide kinase enzyme. The mixture was incubated at 37 °C for 
1 h. The reaction was terminated with 2.5pl of 0.25M EDTA. Unincorporated 
nucleotides were removed from the oligonucleotide by addition of 10 pg t-RNA, 
7.5M ammonium acetate (v/v), 10 volumes 100 % ethanol, the mixture incubated 
at -70 °C for 1 h and centrifuged in a 4 °C bench top microfuge for 20 min at 14K 
rev/min. The supernatant was then removed and the pellet resuspended in distilled
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water. 32P incorporation was estimated using the scintillation counter. 2 x 107 
counts of each oligonucleotides were then added to each membrane in the pre­
hybridisation mix and left for 2 h at 56 °C in the hybaid rotating oven. After 
hybridisation, the membranes were washed at room temperature in 2x SSPE 
containing 0.1 % SDS for 5 min (20x SSPE: 3.6M sodium chloride, 0.2M sodium 
phosphate, 0.02M EDTA, pH 8.3). The filters were washed again for 5 min in 5x 
SSPE at 63 °C and for a further 1 h at 59 °C in hybridisation buffer without 
Denhardt's and ssDNA. Finally the membranes were dried and exposed to Kodak 
XAR films at -70 °C using intensifying screens for various times.
6.1.5. Sequencing
The DNA was amplified as before, using the primers in Table 3. PCR 
products were isolated using QLAquick system (QULAGEN GmbH) according to 
the maufacturer instructions, and were then cycle-sequenced using AmpliTaq 
DNA polymerase ready mix (part 402079) and 3’ primer 
5 ’ -CTCTATTGTTGGATCATATTCGTC-3 ’. The products were analyzed using 
the A B I373 system.
6.1.6. Statistical analysis
Categorical variables were analyzed by Chi-square and Fisher’s exact 
tests. Disease-free and overall survival were analyzed by constructing Kaplan- 
Meier survival curves, and the log rank test was used to test for difference in 
survival between groups.
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6.2. In vitro Ki-ras study
6.2.1. Ki-ras plasmid construct
The pCEXV-3 expression vectors containing wild-type or GTT mutated 
codon-12 of Ki-ras cDNA insert were a kind gift from professor Chris Marchall 
(Miller et al., 1993). The vectors and inserts were confirmed by sequencing. The 
GAT mutated codon-12 of Ki-ras cDNA was generated by PCR (Perkin Elmer) 
using the wild-type Ki-ras pCEXV-3 vector as template and 5' oligonucleotide 5'- 
TCAGTGAGCTCCACCATGACTGAATATAAACTTGTGGTAGTTGGAGCTGATGGCGTAG 
-3' and the 3' oligonucleotide 5'-TCAGTTCTAGATTCACAGGCATTGCTAGT-3' using 
the following PCR conditions: 95 °C for 1 min, 60 °C for 1 min, 72 °C for 2 min 
for 30 cycles and a final elongation step in 72 °C for 15 min. The PCR product 
was then purified from agarose using Hybaid recovery DNA purification kit 
(Hybaid). The purified product was then digested with sst/xbal and ligated into 
sst/xbal digested and phosphatased pCEXV vector. E.Coli (Novablue) was then 
transformed with the ligated vector and the recombinant plasmids were isolated 
and checked by sequencing using the forward primer 5 ’- 
TGTACGGAAGTGTTACT-3’ and the reverse primer 5 ’- 
CTTATCATGTCTGGATCG-3 ’.
6.2.2. Cell culture and transfection
Rat-1 cells were grown in DMEM containing 10% FCS. The cells were 
transfected by electroporation with either the plasmid (pUM-1) conferring
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resistance to G418 (neo) alone, or co-transfected with neomysin resistance 
plasmid together with pCEXV containing Ki-ras cDNA inserts (with different 
codon-12 i.e. GGT, GAT, GTT). The plasmids were mixed in a ratio of 20 
(pCEXV) : 1 (neo) (i.e. 10p,g pCEXV: 0.5pg neo) in a total volume of 50pl T.E. 
(Tris-EDTA).
After two days, G418 (600 ng/ml) was added to the cell culture medium 
and G418-resistant clones were picked (approximately after 10 days). Clones 
expressing the correct Ki-ras gene product were characterised by Western 
analysis and RT-PCR. The cDNA generated was subjected to allele specific 
oligonucleotide hybridisation using the procedure in section 6.1.4 and the probes 
specific for GAT-12, GTT-12 and GGT-12 mutations listed in Table 3.
The preparative work described in sections 6.2.1 and 6.2.2 was contributed 
by Mrs Elaine MacKenzie.
6.2.3. Western analysis
Cells were grown to sub-confluence in 10cm tissue culture dishes, washed 
twice with cold phosphate-buffered saline (PBS) and the excess PBS aspirated off. 
Cells were immediately transferred onto ice and 0.2 ml of stock lysis buffer (0.5% 
NP40, 250mM NaCl, 50mM HEPES pH 7, 5mM EDTA) containing fresh 
protease inhibitors (50mM NaF, 200pM sodium orthovanadate, 50mM 13- 
glycerophosphate, ImM phenylmethylsulphonyl fluoride (PMSF), 10p,g/ml 
leupeptin, 1 0 p,g/ml aprotinin) was added to cells, scraped immediately using a 
disposable cell scraper and transferred to pre-chilled screw cap eppendorf tubes.
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Samples were then centrifuged at 14K rev/min for 5 min at 4 °C. Supernatants 
were transferred in aliquots to fresh eppendorf tubes and stored at -70 °C until 
required. The protein concentrations were measured with a commercial reagent 
(Bio-Rad). 50p,g aliquots of proteins were resolved on SDS-polyacrylamide gels 
by electrophoresis according to the apparent molecular weights. Typically, the 
resolving gels were 7.5% or 10% with respect to the acrylamide concentration and 
stacking gels ranged between 4-5% acrylamide. Acrylamide solutions of the 
required concentration were mixed with the appropriate gel buffer to a final 
concentration of lx  with dt^O. ([4x resolving gel buffer: 1.5M tris pH 8.9, 0.4% 
(w/v) SDS][4x stacking gel buffer: 0.5M tris pH 6.7, 0.4% (w/v) SDS]). Prior to 
pouring of either resolving or stacking gels, lOOpl of a 10% (w/v) ammonium 
persulphate solution and lOpl of TEMED were added per lOmls of gel solution, 
mixed by gentle swirling and poured in ATTO mini-gel apparatus. Resolving gels 
were overlaid with butan-2 -ol and allowed to polymerize at room temperature for 
2 h. Excess butan-2-ol was then removed with a pipette, washed with dH2 0  and 
then lx  running buffer. The stacking gel was subsequently poured, appropriate 
comb inserted and the gel allowed to polymerize for 1 h. Both reservoirs were 
filled with lx  SDS-PAGE running buffer (lOx SDS-PAGE running buffer: 
522mM tris, 4% (w/v) glycine, 1% (w/v) SDS), the bubbles and comb carefully 
removed and the wells rinsed with running buffer before samples were loaded. 
50pg of proteins were denatured prior to loading by heating to 100 °C for 5 min in 
2 x SDS sample (62.5mM Tris pH 6 .8 , 2% SDS, 10% Glycerol, 0.1% 
Bromophenol blue, 4% p-mercaptoethanol) and quenched in ice. Equal amounts 
of proteins were added in each lane as calculated using the BCA/CUSO4 protein
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assay (BCA: Bicinchoninic acid solution [Sigma] 5mls, Q 1SO4 : Copper (II) 
sulphate pentahydrate lOOpl of 4% (w/v) solution [Sigma]). Protein extracts were 
resolved together with the appropriate molecular weight markers (Rainbow 
markers, Amersham UK).
Following electrophoresis, the gels were transferred to nitrocellulose 
membranes (Immobilon P; Millipore) using the dry blotting method. For this 
procedure, twelve pieces of Whatman 3MM paper and a single piece of 
nitrocellulose were cut to the size of the gel. The nitrocellulose membrane was 
wetted in methanol briefly then soaked in dH20  for 5 min before left in lx  
blotting buffer (lOx blotting buffer: 0.6M tris, 0.5M glycine, 16mM SDS) 
containing 20% (v/v) methanol with the Whatman papers. The gels were carefully 
rinsed in lx  blotting buffer and placed on top of six pieces of pre-soaked 
Whatman papers in a Transblot wet blotting apparatus (Bio-Rad), the 
nitrocellulose membrane was then laid on top of the gel and finally the remaining 
six pieces of Whatman papers were placed on top of the nitrocellulose membrane. 
Air bubbles were carefully removed and transfer effected towards the anode at 20 
volts and 200 mA for a maximum of 1 h. after transfer the membrane could be 
either used immediately for blotting or alternatively, air-dried and stored at 4 °C 
until required.
Immunoblots were blocked in PBS containing 0.1% Tween 20 and 5% 
skim milk (Marvel) for 1 h at room temperature and probed with anti-Ras MAbs 
(Santa Cruz), anti-pi Integrin MAbs (Affinity), anti-E-cadherin MAbs (Affinity), 
anti-Stromelysin-1 polyclonal antibody (Chemicon), and anti-VEGF polyclonal 
antibody (Santa Cruz) according to the manufacture's instructions. Membranes 
were subsequently washed 3 times with PBS containing 0.1% Tween 20 and
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incubated for 1  h with the appropriate peroxidase-conjugated secondary 
antibodies (1:5000). After 3 washes with PBS-0.1% Tween 20, band were 
detected with Enhanced Chemiluminescence Western Blotting system 
(Amersham) according to the manufacturer's instructions and visualized by 
exposure to Kodak X-Omat film for various times.
To check for efficiency of transfer and equal loading of proteins, 
nitrocellulose membranes were stripped with strip solution (0.2M glycine, 1% 
(w/v) SDS, pH 2.5) for 1 h with vigorous shaking at room temperature. 
Membranes were then washed 3 times for 10 min in PBS containing 0.1% Tween 
20 at room temperature and blocked for 1 h in PBS containing 0.1% Tween 20 
and 5% skim milk (Marvel) at room temperature and probed with anti-vinculin 
MAbs (Sigma) according to manufacturer instructions.
6.2.4. In vitro invasion assay
Inverse invasion assay in serum-free conditions was performed and 
quantitated as previously described (Hennigan et al., 1994). 2 x 105 cells were 
allowed to adhere to 8 -pm-pore-size filters in Transwell chambers (Costar) 
containing 100 pi of growth factor-depleted Matrigel (Collaborative Research) for 
4 to 6  h in a humidified 5% CO2 37 °C incubator. Filters were then washed in 
serum free DMEM to remove unattached cells and placed back in chambers filled 
with serum free DMEM. The top of the matrigels were filled with serum free 
DMEM with or without growth factor and the trays placed in a humidified 5% 
CO2 37 °C incubator for 3 days. In this assay, cells are first chemoattracted across 
the 8 -pm-pore-size filters, those that then migrate into Matrigel are visualized, 
and cell numbers are quantitated in 10-pm confocal optical sections. In assays
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containing Growth factor, human recombinant EGF (Life Technologies) at a 
concentration of 40 ng/ml was added above the Matrigel layer in serum-free 
DMEM as previously described (Hennigan et aL, 1994).
For inhibition of invasion by oligonucleotides, GTT-12 specific Ki-ras 
sense, 5'-TTGGAGCTGTTGGCGTAGG-3' or antisense, 5'-AACCTCGACAACCGCATCC- 
3' were used as described (Kawada et al., 1997). 20 pM/day of sense or antisense 
Ki-ras oligonucleotides were added above the Matrigel each day for 3 days. For 
anti-(X6 inhibition of invasion, the anti-(X6 antibody (Serotec) (a kind gift from Dr. 
Brunton; CRC Beatson laboratories) was applied above the Matrigel in serum-free 
DMEM at a final concentration of 20 pg/ml after the cells were allowed to attach 
to the filter. After 3 days, For assays of invasion, the Transwells were washed 
twice in PBS then fixed with ice-cold methanol. Cell nuclei were stained with 
Propidium-iodide and visualised by a Bio-Rad MRC 600 confocal illumination 
unit attached to Nikon Diaphot inverted microscope with various magnification. 
Cells at 20-pm and above in the Matrigel are considered to be invasive. To 
account for variations in cell numbers plated on the Transwell filters, results were 
quantitated by counting cell nuclei at 2 0 -pm and above as a percentage of cells in 
all optical sections. Assays were performed three-times in duplicates.
98
6.3. Comparative genomic hybridisation study
6.3.1. Patients
Paraffin-embedded, formalin-fixed tissue blocks were retrieved for 12 
patients who had been operated on for metastatic colorectal cancer at the 
department of surgery, Glasgow Royal Infirmary between 1984-1997. Patients 
had not been given chemotherapy or radiotherapy before surgery. Primary 
tumours were excised and their synchronous metastases were removed or biopsied 
at the time of initial surgery. Dukes' staging was assessed and sections were 
confirmed histologically to contain areas of adenocarcinoma by an experienced 
pathologist.
For the isolation of DNA, Four 7pm thick tissue sections from each 
sample were dewaxed and rehydrated and areas of high tumour content (more 
than 60%) were dissected and pooled into sterile Eppendorf tubes. The samples 
were then dried and resuspended in lysis buffer (0.1M EDTA, 0.01M Tris-HCL, 
0.02M NaCl, 0.4% Sarkosyl) containing proteinase K to a final concentration of 
lmg/ml and incubated at 37 °C for 3 days with gentle tumbeling. After extraction 
with phenol-chloroform and ethanol precipitation, the DNA was dissolved in 
lOmM Tris-HCl, ImM EDTA (pH 7.4) with RNAase at a final concentration of 
0.4mg/ml, and incubated at 37 °C for 1 hour. The DNA was purified by a second 
phenol-chloroform extraction.
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6.3.2. Comparative genomic hybridisation
Normal DNA was prepared from the peripheral blood of healthy female 
and male volunteers. Tumour DNA (500ng) was labelled with biotin-16-dUTP 
and normal DNA (500ng) was labelled with digoxigenin-dUTP using a nick- 
translation (1500ng of DNA) for 75 min at 16 °C or random primed labelling kit 
(less or equal to 500ng of DNA) (Boehringer Mannheim) at 37 °C for 10 h 
depending on the amounts of DNA extracted from samples. To ensure labelling of 
the DNA, 1 pi of the labelling mixture and serial 1 in 10 dilutions were dotted onto 
nylon membranes (separate membranes for Biotin and Digoxigenein labelled 
DNAs) and crosslinked with UV Stratalinker. The membranes were washed on a 
rocking table with buffer A (0.1M Tris pH 7.5, lx  SSC) for 5 min, the solution 
was poured out and the membranes were washed in buffer B (0.1M Tris pH 7.5, 
lx  SSC, 3% BSA) at 4 °C on a rocking table for 30 min. 5 ml of buffer B 
containing either 5\i\ Streptavidin Alkaline Phosphatase conjucated antibody for 
biotin labelled DNAs (Gibco-BRL) or Anti-Digoxigenin Alkaline Phosphatase for 
Digoxigenin labelled DNAs (Boehringer-Mannheim) (according to the 
manufacturers instructions) was added to the membranes in a plastic sealable bags 
and left for 30 min in the dark. The membranes were then washed 3 times, 5 min 
for each wash, in buffer A and a further 5 min in buffer C (0.1M Tris pH 7.5, lx  
SSC, 50mM MgCL). To detect successful labelling, 5 ml of buffer C containing 
developing solution (22pl NBT and 17pl BCIP, Gibco-BRL) according to 
manufacturer instructions, and the membranes were left in the dark overnight. The 
size of the biotin and digoxigenin labelled DNAs was in the range of 500 bp to 2 
Kb. To check for this, lp l of the labelled mixtures were run on 1% agarose gel.
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The labelling reaction was stopped by addition of 0.5M EDTA and heating at 100 
°C for 10 min. The labelled DNAs were ethanol precipitated in the presence of 
50p,g of Cot-1 human DNA (Gibco BRL, Gaithersburg, MD) and 3mM sodium 
acetate, dried and resuspended in 16pi of hybridization solution (50% formamide, 
500 pig/ml salmon sperm DNA, 10% dextran sulphate in 2x SSC) and left to 
dissolve at 4 °C for 20 min. The DNA was then denatured at 75 °C for 9 min and 
allowed to reanneal at 37 °C for 1 hour.
Target metaphase chromosomes were prepared from peripheral blood 
lymphocytes obtained from a healthy male using a standard protocol. 2 0 0 pl of 
whole venous blood was added to 5ml of chromosome medium (Gibco-BRL) and 
incubated at 37 °C in 5% CO2 for 72 h with gentle mixing every day. 294pl of 
6 mg/ml Thymidine (Sigma) was added to the medium and incubated for a further 
15-17 h in 5% CO2 at 37 °C. Samples were then washed three times in Hanks 
balanced salt solution, HBSS, after centrifuging at 1.5K rev/min for 7 min for 
each wash. The pellet was then resuspended in 5ml fresh chromosome medium 
containing 50pl of 3mg/ml Bromodeoxyuridine, BrdU (Boehringer) and incubated 
in the dark for a further 7-8 h at 37 °C in 5% CO2 . 50pl of 1 0 |ig/ml Colcemid 
(Gibco-BRL) was then added to each 5mls samples and incubated at 37 °C for a 
further 1-3 h. The samples were then centrifuged at 1.5K rev/min for 5 min and 
the supernatant carefully removed. The pellets were resuspended in 10ml of 
hypotonic solution (0.075M KC1) and incubated at 37 °C for 10 min. the cells 
were then fixed by the addition of 2-3ml freshly made methanol/acetic acid 
(3:lv/v). Samples were centrifuged at 1.5K rev/min for 5 min, resuspended in 
10ml of methanol/acetic acid and incubated at 37 °C for 10-15 min. This step was
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repeated at least 3 times. Finally, the samples were centrifuges at 1.5K rev/min for 
5 min, resuspended in a small volume of methanol/acetic acid, and stored at -20 
°C until used (maximum of 2 weeks).
To prepare the metaphase slides, a small volume of cells was dropped onto 
clean slides from a height and areas with usable metaphase spreads were marked 
with a diamond pen under phase contrast microscopy. The slides were fixed in 
methanol/acetic acid (3:lv/v) at room temperature for 1 h and left to air dry. After 
rinsing the slides in 2 x SSC they were incubated in 2 x SCC containing lOOpg/ml 
RNase (Sigma) at 37 °C. The slides were rinsed in 2x SSC twice and incubated in 
lOmM HC1 solution containing 0.01% pepsin (Sigma). Slides were rinsed in 2x 
SSC, fixed for 10 min in streck tissue fixative STF (Alpha labs.) and dehydrated 
for 2 min in 70 % ethanol then 2 min in 100 % ethanol and air dried. The 
metaphase slides were denatured in 70% formamide in a water bath at 73 °C for 3 
min and dehydrated in ice-cold 70%, 85% and 100% ethanol. The DNA solution 
(15 pi), containing equal amounts of tumour and normal DNA, was applied to 
each denatured metaphase slides under a coverslip, sealed with rubber cement and 
left to hybridise in a humidified chamber at 37 °C for 72 hours.
After the slides were washed in denaturing solution (50% formamide in 2x 
SSC) for 20 min at 42 °C, then 2 x SSC for a further 20 min, the slides were 
blocked with 4x SSCTB (4x SSC containing 0.4% Tween 20 (v/v) and 10% block 
(v/v)) (Boehringer Mannheim, UK) for 10 min under parafilm coverslips. lOOpl 
of 1:200 dilution of FITC-Avidin DCS (Vector Labs. Peterborough, UK) in 4x 
SSCTB was added to each slide for 45 min at room temperature. Slides were then 
washed in 4x SSCT (4x SSC containing 0.4% Tween 20 (v/v)) for 10 min at room
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temperature. lOOpl of the second layer of antibodies containing 1:200 dilution of 
biotinylated anti-avidin D (Vector Labs. Peterborough, UK) and 1:200 dilution of 
sheep anti-digoxigenin (Boehringer Mannheim, UK) in 4x SSCTB was applied 
onto slides for 45 min at room temperature. Slides were then washed in 4x SSCT 
for 10 min at room temperature. Finally, 100pl of the third layer of antibodies 
containing 1:200 dilution of FITC-Avidin DCS and 1:300 dilution of donkey anti­
sheep Texas-red in 4x SSCTB was added to slides for 45 min at room 
temperature. Slides were then washed in 4x SSCT for 20 min at room 
temperature, dehydrated in 70% then 100% ethanol, air dried and mounted in 
antifade (Vector Labs. Peterborough, UK) containing 0.1pg/ml DAPI (Boehringer 
Mannheim, UK) to identify the chromosomes.
In all experiments green-labelled normal versus red-labelled normal DNA 
hybridizations were included as controls. Hybridisation of green-labelled normal 
male DNA versus red-labelled normal female DNA (Karhu et al., 1997) and of 
DNA from a characterised colorectal cancer cell line (Colo-320) against normal 
female DNA was also done for quality control. Chromosome 19 was excluded 
from the study because of the reduced hybridization of normal DNA to 
chromosome 19, a problem which has been reported previously (Kallioniemi et 
al., 1994). The sex chromosomes were excluded because hybridisation of DNAs 
from different genders (e.g. female normal DNA and male tumour DNA) could 
give false signals reflecting the differences in the number of the X chromosomes 
in the samples (Karhu et al., 1997).
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6.3.3. Image collection and analysis
Images were collected using a cooled charge-coupled-device (CCD) 
camera mounted on an epifluorescence microscope (Zeiss) equipped with filters to 
detect DAPI, fluorescein, and Texas Red. Uniformly labelled metaphases with 
minimal overlaps were chosen in each case. Five metaphases were collected from 
each sample and analysed using CGH computer program (SmartCapture, Digital 
Scientific, Cambridge, UK).
Stringent criteria were used to identify gains and losses. Amplifications 
were scored if the median ratio was above or equal to the 1.25 threshold and 
deletions were below or equal to the 0.75 threshold. Secondly, the genetic 
aberration was scored if the standard errors representing 99% confidence intervals 
of the tumour versus normal profiles were outwith the 99% confidence intervals 
of the normal versus normal control profiles. Three-colour images were processed 
using image processing software (Photomagic, Micrografx, Arapaho Richardson, 
Texas, USA), annotated in Micrografx Draw (Micrografx) and printed using a dye 
sublimation printer (Colour Ease, Kodak, Harrow, UK) to be used as a visual 
support and to reinforce fluorescence analysis. All original unedited images were 
stored on optical disks and have been retained.
6.3.4. Statistical analysis
Statistical differences in the prevalence of the most commen gains and 
deletions between the primary tumours and their metastases and between Dukes' 
stages C and D were performed using Fisher's exact test.
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To calculate the probability of clonal relationship between primary 
tumours and their metastases a model developed previously was used 
(Kuukasjarvi et al., 1997). This model evaluates the probability that a set of gains 
and losses shared by a pair of tumours might occur by chance alone. If ai, 0 ,2,
ci3 t etc are specific gains or losses, the probability of a particular gain or loss in
an individual tumour is estimated from its frequency in the group, as
p(an)= n(a„)/N
where n(an) is the number of occurrences of an in the N tumours analysed. If P = 
the set of aberrations present in a particular primary tumour, and M = the set of 
aberrations in an associated metastasis, then events in common are P (T M = 
Ci,C2,C3,...cn, the probability that shared events occurred independently in the two 
tumours being compared is
P(C]) X p(c2) X . .  . X  p(cn) = X 
If X is small, we reject chance as a plausible explanation of the shared events, and 
accept the non-random explanation, ie that the shared abnormalities are a 
consequence of a clonal relationship. The model assumes that the paired 
specimens must be both losses or both gains and that the breakpoint along the 
chromosome arm is the same.
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RESULTS AND DISCUSSION
SECTION 1
CHAPTER 7. The Role of Mutant codons-12 and 13 of Ki­
ras gene in in vivo Colorectal Cancer Progression
Ras proteins play a fundamental role in signal transduction pathways in 
cells. Mutations at codons 12 and 13 of the Ki-ras gene appear to be a relatively 
frequent and early event in colorectal cancer. During the last decade, a large 
number of publications have tried to address the role and dissect the precise signal 
transduction pathways activated by Ras proteins in cells. These studies have 
immensely clarified our understanding of the role activated Ras proteins play in 
human tumours in general and colorectal cancer in particular. However, the 
importance of activated Ras proteins in tumour progression in vivo is still largely 
controversial. Moreover, the role different codon 12 mutations play in colorectal 
cancer progression and aggressiveness is even more controversial. For example, 
as will be discussed later, some authors have suggested that certain codon 1 2  
mutations are associated with more aggressive colorectal cancer than others. If 
this is correct, could specific codon 12 mutations in the Ki-ras gene be used 
clinically as prognostic indicators or as markers of aggressive cancers? In 
addition, since Ki-ras mutations appear early in the adenoma-carcinoma 
sequence, are these mutations also present in metastases? Thus, are these 
mutations important in colorectal progression into a metastatic phenotype or are 
they a consequence of tumour progression?
This study was designed to shed some light on the role of Ki-ras codons 12 
and 13 mutations in colorectal cancer and to attempt to address these questions.
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7.1. Patients and sample characteristics
DNAs from 8 6  patients with colorectal adenocarcinoma were analyzed for 
codon 12 and 13 mutations in the first exon of Ki-ras by ASO hybridisation and 
direct sequencing (see for example, Figures 10 and 11). Data from 8  patients 
were not interpretable, and they were excluded from the study. Six patients were 
classed as Dukes’ A, 25 as Dukes’ B, 21 as Dukes’ C, and 26 as Dukes’ D. The 
patients were 40-96 years old (mean + SD, 68.7 + 11.3). A total of 145 specimens 
from primary carcinomas were analysed (duplicate samples of the same primary 
were analysed where available), 57 from 32 lymph node metastases and 52 from 
26 liver metastases from Dukes’ D patients. Twenty-three adenoma specimens 
from 11 of these patients were analysed. As controls, 158 specimens of 
morphologically normal mucosa from the 78 patients were microdissected from 
the same primary carcinoma histological block or an adjacent block, and analysed 
for Ki-ras mutation. A total of 435 tissue samples were analysed.
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Figure 10
Figure 10: Detection o f Ki-ras mutations by allele-specific oligonucleotide hybridisation
Detection of Ki-ras mutations by allele-specific oligonucleotide hybridisation to 
PCR-amplified DNA from multiple microdissected liver metastases and adjacent normal
32liver (nlv) from 29 Dukes' D patients. Hybridisations were with p-labelled probes 
specific for codon-12 and 13 mutations as indicated beside each membrane.
The coloured panel illustrates the nature of the dotted DNAs. Multiple samples 
from each patient are given identical colour shade. Control DNAs with known sequences 
and mock dissections are illustrated in rows H and F respectively. A mock codon 13 
probe (CAC) was also included to exclude non-specific hybridisation.
The GGT (wild-type) probe shows DNA present in dots since the mutations occur 
in one allele only. In certain samples the GGT probe shows no hybridisation. In these 
cases, either the DNAs were not amplified or, in the presence of a mutation, the mutation 
is homozygous or one allele is mutated and the other is deleted.
Normal liver sample B4 has a codon 12 AGT mutation. All Samples were 
subjected to at least three separate ASO hybridisations.
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Figure 11: Selected examples o f sequence data around codons-12 and 13 o f the 
Ki-ras exon-1
Part of the Ki-ras exon-1 was amplified by PCR as described in section 
6.1.5 and sequenced using the antisense primer 5’- 
CTCTATTGTTGGATCATATTCGTC-3’. The products were analysed using the ABI 
373 system.
The figure shows sequences obtained from tumours of five different patients and a 
cell line with a homozygous GTT-12 mutation. A) GGT-12 to GCT mutation, B) GGT-12 
to GTT mutation, C) GGT-12 to GAT mutation, D) GGT-12 to TGT mutation, E) GGT- 
12 to AGT mutation and F) GGC-13 to GAC mutation. Codon-12 is underlined and 
codon-13 is double underlined.
Samples A, C and D have either a homozygous mutation in codon-12 or the wild- 
type allele is deleted. Sample B has a homozygous codon-12 mutation. Samples E and F 
are heterozygous for codon-1 2 .

7.2. Frequencies ofKi-ras mutations
The overall incidence of mutations (34-38%) was the same in primary 
carcinomas, lymph node metastases, liver metastases and adenomas (Table 4). Of 
the 158 histologically normal mucosa specimens analysed, one was found to have 
a GGT to GTT transversion in codon 12. Also, 1 of 23 apparently normal 
microdissected areas of lymph nodes was found to have a GAT mutation in codon 
12 of Ki-ras. In all but two of the DNAs analysed, the normal allele of Ki-ras had
Table 4: Frequency of Ki-ras codon 12 and 13 mutations in adenomas, 
primary carcinomas, lymph node and liver metastases from 78 patients with 
colorectal adenocarcinoma
Tissue
No. with 
mutation (%)
No. without 
mutation (%) Total
Primary adenocarcinoma 26 (34) 52 (6 6 ) 78
Lymph node metastasis 10 (32) 2 1 (6 8 ) 31
Liver metastasis 10 (38) 16 (61) 26
Peritoneal metastasis 1 (1 0 0 ) 0 (0 ) 1
Colon adenoma 4(36) 7(64) 1 1
been retained. The data were analysed with respect to specific type of Ki-ras 
mutation (Table 5). Little difference in the incidence of the various mutations 
between this and other similar studies (Bos et al., 1987; Boughdady et al., 1992; 
Finkelstein et al., 1993; Moerkerk et al., 1994; Span et al., 1996) were noted 
except that transversions to GTT tended to be less prevalent than in Yugoslavia 
(Urosevic et al., 1993). Mutation at codon 13 was limited to the GAC
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transversion. Also, no codon 12 GGT to CGT transversion was found though this 
is a common mutation of Ki-ras in pancreatic adenocarcinoma (Bos, 1989).
Table 5: Type and frequency of specific Ki-ras codon 12 and 13 mutations in 
primary and secondary carcinomas (lymph node and liver metastases) in 
patients with colorectal adenocarcinoma
Mutation Primary carcinoma (%) Secondary carcinoma (%)
Codon-12
AGT 2  (8 ) 0
GAT 10 (38) 8(38)
CGT 0 0
GCT 3 (11) 1(5)
GTT 4 (15) 7(33)
TGT 1 (4) 2 (1 0 )
Total 20 (77) 18 (8 6 )
Codon 13
GAC 6  (23) 3(14)
Codons 12 + 13 26 (1 0 0 ) 2 1  (1 0 0 )
Metastatic deposits showed a similar trend. There were no statistically 
significant differences in the incidence of particular mutations between primary 
carcinomas and metastatic lesions. However, when the data were viewed with 
respect to Dukes’ stage (Table 6 ), the codon 12 GGT to GTT transversion was 
exclusively found in primary carcinomas and metastatic deposits of Dukes’ C and 
D patients. The incidence of all other types of mutation was not significantly 
different in terms of Dukes’ classification.
Of possible significance, five of the Dukes’ D patients, of whom two had 
been staged as Dukes’ A, and three as Dukes’ B on presentation, had later 
relapsed with liver metastases; in three of these patients (one Dukes’ A and two 
Dukes’ B) the primary carcinoma harboured a GTT mutation also found in the
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subsequent metastatic deposits. In another, the primary carcinoma had a GAC 
mutation in codon 13, while in the remaining patient the primary and the 
metastatic carcinoma harboured wild-type Ki-ras.
Table 6: Type and frequency of specific Ki-ras codon 12 and 13 mutations in 
relation to Dukes’ classification
Mutation
Dukes’ A and B 
(n = 31)
Dukes’ C 
(n = 21)
Dukes’ D 
(n = 26)
Codon 12
AGT 2 0 0
GAT 6 1 4
CGT 0 0 0
GCT 2 1 0
GTT 0 2* 5*
TGT 0 0 1
Total (%) 10 (32) 4(19) 10 (38)
Codon 13
GAC 3(10) 1(5) 4 (15)
Codons 12 + 13 (%) 13 (42) 5(24) 14 (54)
*Frequency of codon 12 GGT to GTT transversions in primary and 
secondary carcinomas of Dukes’ C/D patients is highly significant (P = 0.01) 
as measured by Fisher’s exact test. No statistical differences were observed 
between the other types of Ki-ras mutations in relation to Dukes’ 
classification (P>0.05).
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7.3. Ki-ras mutations and survival
The relationship between Ki-ras mutations and aggressiveness was 
investigated further by examining disease-free and overall survival using Kaplan- 
Meier survival curves. No significant difference in disease-free and overall 
survival was observed between carcinomas with Ki-ras codon 12 and 13 
mutations and carcinomas carrying wild type Ki-ras (Figure 12). However, 
overall survival was significantly (P=0.001) decreased in patients with GGT to 
GTT transversions compared to patients with no Ki-ras mutation (Figure 13). 
Moreover, a comparison between Dukes’ D patients with wild type Ki-ras and 
Dukes’ D patients with GGT to GTT transversions in codon 12 of Ki-ras showed 
that overall survival of the latter was significantly shorter (P=0.012) (Figure 14). 
No other statistically significant effects of Ki-ras mutations on overall or disease- 
free survival were found.
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Figure 12: Survival curves o f patients with colorectal cancer
A) Disease-free survival curves from 43 patients with wild type Ki-ras  
(black line) compared to 28 patients with mutated codons-12 and 13 Ki-ras  (red 
line). No statistical differences in survival were observed between the two groups 
(P>0.05).
B) Overall survival curves from 43 patients with wild type Ki-ras  (black 
line) compared to 28 patients with mutated codons-12 and 13 K i-ras (red line). No 
statistical differences in survival were observed between the two groups (P>0.05).
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Figure 13: Kaplan-Meier survival analysis o f patients with colorectal cancer
Survival curves from 43 patients with wild type Ki-ra.v (black line) 
compared to 8 patients (A) with codon -13 mutated Ki-ras (blue line) and 11 
patients (B) with GAT mutated c odon -12 (green line).
No statistical differences in survival were observed between the three groups 
(P>0.05).
C) Seven patients with GGT to GTT transversion in codon 12 o f  Ki-ras  
(red line) and 43 patients with wild type K i-ras  (black line). Overall survival was 
significantly reduced in patients with the GTT mutation (P=0.001; log-rank test).
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Figure 14: Kaplan-Meier survival analysis o f  D ukes’ D patients
Kaplan-Meier survival analysis of (A) 3 D ukes’ D patients with GGC to 
GAC mutation in codon 13 o f  K i-ras (blue line), (B) 4 Dukes’ D patients with 
G G T to GAT transition in c odon -12 o f  Ki-ras (green line), and (C) 5 D ukes’ D 
patients with GGT to GTT transversion in codon 12 of K i-ras (red line) compared 
to 12 Dukes’ D patients with wild type Ki-ras (black line). Patients with only a 
G TT mutation have a significantly shorter survival than patients with the same 
D ukes’ stage but harbouring the wild type Ki-ras (P=0.012; log-rank test).
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7.4. Heterogeneity o f tumours
In the majority of patients with Ki-ras mutations the same mutation was 
found in adenomas, primary carcinomas and their metastases, but there were 
exceptions. For example (Figure 15), both specimens of primary carcinoma from 
one patient had a GAT mutation (A9, A10), as had the corresponding liver 
metastasis (Bl), but three adenomas from the same patient had three different 
mutations, one to GAT (A5), one to GTT (A8) and one to TGT (not shown). As 
these were probably independent neoplasms, this result is not surprising. In a 
second patient, three specimens of primary carcinoma (B4-6) and two of a lymph 
node metastasis (B7, B8) had a codon 12 GTT mutation, but only one of two liver 
metastasis specimens (Cl) carried this mutation (Figure 15).
No instances of multiple mutations in a single carcinoma, as described by 
Span et al., (1996), were found even when multiple sections of carcinomas were 
analysed. However, heterogeneity in the presence of a Ki-ras mutation within and 
between primary and secondary carcinomas was frequent, both between different 
sections of the same carcinoma, and between closely adjacent regions of 
carcinoma cells from a single section (Table 1): Moreover, in 2 of 26 Dukes’ D 
patients (numbers 3 and 10) a mutation was found in the primary carcinoma but 
none in liver metastases and, conversely, in 6 of 47 Dukes’ C and D patients 
(numbers 4, 5, 6, 7, 11 and 15) there was a Ki-ras mutation in a liver or lymph 
node metastasis, but none was found in the primary carcinomas (Table 7).
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Figure 15
Figure 15: Detection of Ki-ras heterogeneity by allele-specific oligonucleotide
hybridisation
Detection of Ki-ras mutations by allele-specific oligonucleotide hybridisation to 
PCR-amplified DNA from microdissected normal mucosa, adenoma, primary and 
secondary tumours from three patients, two showing heterogeneities.
Hybridisations were with 32P-labelled oligomers specific for (a), GGT (gly); (b), GTT 
(val); (c) GAT (asp) at codon 12.
A5 to B3-DNAs from one patient: A5, A8, A12, from 3 adenomas; A9, A10, 
adenocarcinoma from two parts of the same section of primary tumour; A6, A ll, 
adjacent normal mucosa; B l, B2, liver metastasis; B3, adjacent normal liver.
B4 to Cl - DNAs from a second patient: B4, B5, B6, adenocarcinoma from three parts of 
the same section of primary tumour; B7, B8, B12, lymph node metastases; B9, Cl, two 
parts of the same section of a liver metastasis; BIO, B ll, adjacent normal liver and 
mucosa, respectively.
Controls: C12, negative control (no DNA); CIO, GTT-positive mutant DNA; D l, GGT- 
positive wild-type DNA
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Table 7: Heterogeneity of Ki-ras mutations within and between primary and 
secondary carcinomas
Primary Lymph node Liver
Patient Adenoma carcinoma metastasis metastasis
1 GCC/GGV/N1 GN GN
2 GGNN
3 GG GGGN GG
4 GG N NN
5 GG GV
6 GG W
7 G GV
8 GCC CCC C
9 GV GG
10 GN GGGG
11 GGG G N N
12 GS
13 GN
14 GN
15 GGG GN
Results for replicate samples from the same section shown by individual 
symbols; G, wild-type codon 12 and 13; codon 12 mutations: N, GAT; V, 
GTT; C, TGT, S, AGT; codon 13 mutation: N, GAC. Each sample was 
assayed at least 3 times by ASO hybridization by two independent observers; 
most were also confirmed by direct sequencing.
Sections from three separate adenomas.
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CHAPTER 8. Characterisation of two different Ki-ras 
codon-12 mutations in vitro
An important concept that emerged from the analysis of Ki-ras mutation 
in vivo is that transversion mutation GGT-12 to GTT appears to be associated 
with aggressive colorectal tumours compared to the more common GAT-12 
transition mutation. The reasons behind such difference in the biological 
behaviour of the two mutants can be ascribed to many factors including 
differences in tumourigenicity, invasion, growth and VEGF production to mention 
a few. It was decided to compare some of the characteristics of the two mutants in 
vitro to see whether the difference in the behaviour found in vivo could also be 
reflected in vitro.
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8.1. Ki-ras expression
As described in section 6.2.1, Rat-1 cells were transfected with wild-type 
or GTT-12 (valine) or GAT-12 (aspartate) mutant human Ki-ras expression 
constructs along with the plasmid (Pum-1) conferring resistance to G418. Of six 
Rat-1 clones transfected with each type of Ki-ras, two clones of each Ki-ras type 
expressing the appropriately transfected Ki-ras were selected for subsequent 
analysis. Allele-specific oligonucleotide hybridisation of RT-PCR products and 
Western blotting were used to demonstrate the expression of the appropriate type 
of Ki-ras in these cells (Figure 16). Of the two Rat-1 clones expressing mutant 
GAT-12 mutant Ki-Ras, GAT clone 6 expressed lower levels of Ras as assessed 
by Westen blotting. However, Ras mRNA expression of the transfected GAT-12 
Ki-ras could be detected by RT-PCR from this clone (Figure 16). Due to this 
inconsistency, it is advisable to treat the results obtained from this clone 
cautiously.
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8.2. Invasion assay
Invasion by tumour cells of the extracellular matrix and the basement 
membrane is a crucial event in tumour metastasis. Therefore, the ability of the 
various codon-12 Ki-Ras clones to invade matrigel in vitro was tested. All cells, 
including controls were able to invade matrigel in the presence of EGF (Figure 
18a). Consistently, valine-12 (GTT-12) mutants Ki-Ras clones demonstrated 3 to 
5 folds increased invasion in vitro compared to the aspartate-12 mutant clones in 
the absence of growth factors (Figure 17 and 18b). The invasive capability of 
valine-12 clone 6 in the absence of growth factor was particularly as efficient as in 
the presence of growth factor. Remarkably, clone 4, which expressed high levels 
of aspartate-12 mutant Ki-Ras demonstrated significantly lower invasive 
capability compared to valine-12 mutant clones (Figure 18b and c). To 
demonstrate that mutant valine-12 Ras (GTT-12) and not random genetic events 
was directly responsible for the enhanced in vitro invasion, antisense 
oligonucleotide against valine-12 was used. Antisense oligonucleotides centred 
along the GTT codon-12 mutation reduced invasion back to control levels. On the 
other hand, sense oligonucleotides had no effect on invasion (Figure 18d).
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Figure 16: Western analysis and allele-specific oligonucleotide hybridisation  
showing relative abundance o fR as proteins and mRNA expressed by control and 
K i-ras transfected Rat-1 cells
A) 10 % polyacrylamide immunoblot detecting the relative abundance of 
Ki-Ras protein. B) Detection o f  the appropriate Ki-ras mutations by allele- 
specific oligonucleotide hybridisation to amplified cDNA as described in section 
6.2.2. Membrane probes with a) GGT-12 specific probe (Wild type), b) GTT-12 
specific probe and c) G A T -12 specific probe as described in section 6.1.4.
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Figure 17: In vitro invasion assay
Confocal microscopy images of propedium iodide-stained cell nuclei (red 
dots) at 0, 10, 20, 30 pm  in Matrigel of Rat-1 cells transfected with va line-12 
(GTT clone 6), aspartate-12 (GAT clone 4), wild-type Ki-Ras (WT clone 5) and 
control neo transfected cells. A) represents a cartoon of the invasion well.
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Figure 18: Quantitative analysis o f invasion.
Invasion assay results were quantitated as described in the material and 
methods with a Bio-Rad program (Comos) and represent the average of two 
separate assays from three experiments, a) Invasions of GAT, WT, GTT or neo 
clones in the presence of epidermal growth factor, b) Invasions of GAT, WT, or 
neo clones are expressed as percentages of GTT clone 6 (100 %). c) The 
differences in invasion between GTT clone 6 and GAT clones 4 and 6 is 
statistically significant p =0.02 using student’s /-test. (If GTT clone 4 is included 
in the analysis, the statistical difference in invasion becomes insignificant), d) 
Invasion of Rat-1 cells transfected with valine-12 mutant Ki-Ras (GTT 6 clone) 
with no treatment (GTT), Ki-ras antisense (GTT+AS), sense (GTT+S) or anti-0C6 
integrin antibody (GTT+Ab).
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The difference in Matrigel invasion capabilities of the two mutants could 
partly be due to differences in matrix metalloproteases production. Stromelysin-1 
was chosen for three reasons. Firstly, Ras has been previously shown to increase 
stromelysin-1 production (Matrisian et al., 1991). Secondly, Matrigel is primarily 
made up of laminin, collagen VI, and proteoglycans, which are prime substrates 
of stromelysin-1 (it is devoid of fibronectin and vitronectin) (Coussens and Werb, 
1996; Kleinman et al., 1986) and thirdly, Matrigel invasion has been shown to 
depend primarily on the expression of stromelysin-1, rather than on other protease 
families (Lochter et al., 1997).
Stromelysin-1 (57 and 59 KDa) was surprisingly upregulated in cells 
expressing wild type Ki-ras. Notably, cells containing valine-12 (clones 4 and 6) 
activated Ras expressed 2-fold more stromelysin-1 than clone 4 expressing GAT- 
12 Ras. Although clone 6 containing GAT-12 Ras still expresses high levels of 
stromelysin-1. However, it should be noted that results from GAT-12 clone 6 
should be interpreted cautiously. The reduced expression of stromelysin-1 
demonstrated by GAT-12 clone 4 cells is consistent with their decreased ability to 
invade Matrigel (Figure 19).
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Figure 19: Western analysis showing relative abundance o f  stromelysin-1  
expressed by control and various Ki-ras transfected Rat-1 cells
7.5 % immunoblot for Stromelysin-1 (Transin), arrows showing pro- 
stromelysin (59 KD) and stromelysin-1 (57 KD). The blot was re-probed with 
antivinculin MAb to control for loading variations and transfer. The Table shows 
relative abundance o f  the 59 and 57 KDa stromelysin-1 normalised against the 
loading control. This was repeated twice using different protein preparations with 
consistent findings.
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57 KDa 0.71 0.6 0.68 0.5 1 1 0.5 0.86 0.64
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8.3. Transformation o f Rat-1 cells in vitro
The increased in vitro invasiveness of Rat-1 cells containing the mutant 
GTT-12 Ki-ras could be ascribed to many factors including increased 
tumourigenicity, transformation and changes in adhesion molecules. Although, 
neither tumourigenicity nor anchorage independent growth were studied, the 
ability of mutant Ras to induce cellular transformation in vitro was assessed. Both 
valine-12 and aspartate-12 mutant Ki-Ras were able to equally disrupt the 
quiescent monolayer (this was more pronounced in GAT-12 clone 4 than GAT-12 
clone 6) and form disordered network of spindled refractile Rat-1 cells compared 
to the flat morphology of Rat-1, neo and wild type Ki-Ras transfected cells. Wild 
type Ki-Ras transfected cells demonstrate close cell to cell contacts, whereas, both 
mutant Ki-Ras transfected cells demonstrated significant loss of cell-cell 
adhesions (Figure 20).
The effects of mutant and wild type Ki-Ras on adhesion molecules were 
also investigated, since the dramatic cell shape, cell to cell contacts and cellular 
invasion could be due to perturbation of adhesion molecules involved in cell to 
cell and cell to matrix adhesions. Both mutant Ki-Ras transfected cells 
demonstrated complete loss of E-cadherin, whereas cells containing wild-type Ki- 
Ras maintained E-cadherin expression (Figure 21). Similarly, both mutants Ki- 
Ras containing cells showed a dramatic loss of Pi integrin (Figure 21). The effects 
of mutant Ki-Ras on these adhesion molecules could explain the dramatic cell 
shape changes seen in mutant Ki-Ras transformed cells. It can also explain the 
reduced ability of wild-type Ki-ras expressing cells to invade the Matrigel 
compared to cells expressing the mutant GTT-12 Ki-ras. Although the former,
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expressed higher levels of stromelysin-1. Thus, the maintained expression of E- 
cadherin and Pi integrin could have played a major part in reducing in vitro 
invasiveness of Rat-1 cells expressing the wild-type Ki-ras. However, the loss of 
E-cadherin and Pi integrin expression was comparable between the two mutant 
Ki-ras expressing cells, which could indicate that the reduced expression of 
stromelysin-1 by clone 4 GAT-12 expressing cells was probably partly 
responsible for their reduced invasiveness in vitro. Notably, the loss of E-cadherin 
and Pi was not as pronounced in GAT-12 clone 6  as GAT-12 clone 4 or GTT-12 
clone 6 .
Integrin has been shown to be associated with tumour aggressiveness in 
vivo and to stimulate chemotactic migration of cells in vitro (O’Connor et al., 
1998). Therefore, anti-integrin a 6 antibody was used to test its effect on invasion. 
The antibody was able to reduce in vitro invasion of the valine-12 mutant clones 
demonstrating the importance of this integrin monomer in the invasive process 
(Figure 18d). Integrin a 6 monomer can dimerise with Pi and P4 . Since pi is 
significantly reduced in these cells, it was of interest to investigate the levels of p4 
integrin in the cells. Unfortunately, during the time of analysis, there were no 
suitable antibodies against P4 monomer available for Westen analysis.
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Figure 20: Phase-contrast m icroscopy images o f  Rat-1 cells growing in DM  EM  
containing 10% FCS
A) Rat-1 cells expressing valine-12 mutated Ki-Ras protein (GTT clone 
6). B) Rat-1 cells expressing A spartate-12 mutated Ki-Ras protein (GAT clone 4). 
C) Rat-1 cells expressing wild-type Ki-Ras protein (W T clone 5). D) Control Rat- 
1 cells transfected with plasmids carrying neomycin resistance only (neo). 
Magnification lOOx
130
Figure 21: Western analysis showing relative abundance o f  E-cadherin and p i  
integrin proteins expressed by control and Ki-ras transfected Rat-1 cells
A) 7.5 % immunoblot for E-Cadherin. B) 7.5 % immunoblot shows pi 
integrin. Blots were probed with anti-vinculin MAb to control for loading 
variations and transfer.
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8.4. VEGF production
It is now well established that VEGF production by tumour cells improves 
not only their growth but also their subsequent dissemination. Thus, genetic or 
epigenetic events that induce VEGF production could play an important role in 
inducing tumour growth and metastasis.
As discussed in section 3.5.3, activated Ras has been shown to induce 
VEGF production. However, most, if not all, work done in this area has used 
valine-12 activated Ras to establish such association. It was, therefore, of interest 
to examine the extent to which the two mutants differ in stimulating VEGF 
production. Therefore, valine-12 (GTT), aspartate-12 (GAT) and wild-type (GGT) 
Ki-ras transfected cells were analysed with respect to their ability to induce 
VEGF production. Western analysis against VEGF demonstrated the ability of the 
two mutant Ki-Ras bearing cells to increase production of various isoforms of 
VEGF. On the other hand, Rat-1 cells transfected with wild type Ki-ras or control 
plasmids had no effect on VEGF production (Figure 22).
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Figure 22: Western analysis showing relative abundance o f  VEGF protein  
expressed by control and K i-ras transfected Rat-1 cells
10 % immunoblot for VEGF. The arrowheads indicate the major isoforms. 
Equal loading was confirmed by staining the membrane with Giemsa. Mrs Elaine 
MacKenzie kindly contributed this result.
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CHAPTER 9. Structural characterisation of Valine-12 and 
Aspartate-12 Ki-ras mutants
The data described above linking valine-12, but not aspartate-12, 
mutations with more aggressive disease in vivo and more invasive phenotype in 
vitro raise the important question of how differences in the amino acid residue 
substituted for glycine at codon 12 cause differences in the biological activity of 
Ras. One idea is that it is due simply to differential GTPase inhibition. However, 
the difference in this respect between G12D and G12V is relatively small (Table 
8) and it is necessary to consider other possible ways in which these mutants 
could affect downstream events to different extents. Although the structures of 
various Ras mutants have been analysed in detail, there has as yet been no attempt 
to correlate conformational differences between Ras mutants with their 
differences in signal transduction activity and tumour aggressiveness. To address 
this question, comparison of the molecular structures and other biochemical 
characteristics of the more aggressive G12V mutant Ras with the more common, 
but less aggressive, G12D mutant, was made.
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9.1. Review o f published biochemical properties o f mutant Ras protein
The known biochemical differences between glycine-12 (wild type), 
valine-12 and aspartate-12 mutant Ras are summarised and compared to other 
codon-12 mutant Ras proteins in Table 8.
The GTPase activity of the valine-12 mutant, which is one-fourth of that 
of the aspartate-12 mutant (Goody et al., 1992) and one-tenth of that of the wild- 
type Ras (John et al., 1988; John et al., 1989). The importance of this is 
outweighed by the fact that GAP stimulates the GTPase activity of wild type Ras 
whereas both the valine-12 and aspartate-12 mutants are unaffected by GAP. 
These mutants do, however, still bind GAP. The G12D mutant binds as well as 
the wild type while G12V has a three-fold lower affinity for GAP.
Table 8: Biological and biochemical characteristics of codon 12 mutant Ras 
proteins relative to wild type
Codon
12
Transformation GTPase GTP
dissociation
GAP
affinity
GAP
activation
Raf-1
binding
WT ....'■ " I'l) ...................... 1 1 1 +++ .....' ^ 5  ""
G12 V ++++« 0.1(3’4) X (3 ,4 ) 0.3(5) _ (5 ) 2.25(2)
G12D + + ( d 0.2(7) -0.4(6) 8(7) j(8 ) _(7) ND
G12P .0) 2.7(7) f l ) 0.3(7) + C0 f ? )
G12R + + + + “ ) 0.05(3,4) ^ 3 , 4 ) 0.2(5) _(5) f t ? )
The GTPase, GTP dissociation, GAP affinity, and Raf binding in wild-type Ras 
(WT) were arbitrary chosen as 1. ND is not determined. Numbers in brackets are references.
1. (Seeburg et al., 1984) 2. (Herrmann et al., 1995) 3. (John et al., 1988) 4. (John et 
al., 1989) 5. (Krengel et al., 1990) 6. (Goody et al., 1992) 7. (Franken et al., 1993) 8. (Bollag 
and McCormick, 1991).
One notable difference in Table 8 is that the rate at which the GTP 
analogue GppNp dissociates from its complex with Ras is 8-fold greater with the
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Asp-12 mutant Ras (Franken et al., 1993) than with either wild type or Val-12 
mutant Ras (John et al., 1988; John et al., 1989).
The X-ray structure of the complex between GppNp and G12D shows that 
the Asp-12 side chain is hydrogen bonded to the side chains of both Gln-61 and 
Tyr-32. The Asp-12 side chain oxygen hydrogen-bonded to Tyr-12 is also very 
close to the y-phosphate of the GppNp (the 0 ...0  distance is 2.65A, lA=10-1 nm). 
Under physiological conditions, both are negatively charged so it is likely one or 
other is protonated, in which case there is a hydrogen bond between them. P 
NMR evidence with the Ras-GppNp complex indicates that it is the y-phosphate 
that is protonated (Franken et al., 1993).
The y-phosphate of GTP is less able to become protonated as its pKa is 
about 2.0 pH units (100-fold) lower than that of GppNp (Yount, 1975), so binding 
of GTP by Aspl2 Ras is likely to be even weaker than that of its analogue. 
Taken together, with the observation that the GppNp dissociation rate from G12D 
is 8-fold faster than that from Ras (Table 8) the binding of GTP to the aspartate 
mutant could be as much as 800-fold weaker than for the wild type. However, 
dissociation is not the same as hydrolysis to GTP, since after dissociation of GTP, 
a likely next stage is reassociation of GTP (Feuerstein et al., 1987). It also has 
been observed that Ras in the absence of the nucleotide is unstable, so the weaker 
GTP binding may make the G12D Ras more susceptible to breakdown by 
proteolysis (John et al., 1990). Nevertheless, together the kinetics of the Ras- 
GTP dissociation and the GTPase measurements indicate that Val-12 Ras forms a 
more stable complex with GTP than Asp-12 Ras does. Thus, probably providing a 
more constant positive signal to the pathways it stimulates.
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9.2. Structural properties o f the valine-12 and aspartate-12 mutants
The comparisons of the three-dimensional structures of GppNp-bound G12V and 
G12D show there to be significant differences between the mutants that may 
provide reasons for the biochemical and biological differences between them 
(Figure 23). The hydrogen bond network of the carboxylate side-chain of the 
G12D mutant involving Asp-12, Gln-61 and Tyr-32 has already been mentioned 
(Figure 23 b). In contrast, in Gly-12 and Val-12 Ras (Figure 23 a and c), Tyr-32 
takes up a distinctive orientation in which it is pointing more away from the 
surface. (At this point, it should be noted that in the crystal lattice the tyrosine is 
hydrogen bonded to the y-phosphoryl group of the nucleotide of an adjacent Ras 
molecule; however in the molecule in the living cell it is probably mobile.) The 
hydrogen bonding between, and subsequent orientations of, Asp-12, Tyr-32 and 
Gln-61 cause the Asp-12 mutant to differ from Gly-12 and Val-12 Ras in at least 
three ways that could affect the recognition site for an effector protein 
approaching Ras from the exterior. First, in the Asp-12 mutant, Tyr-32 is pulled 
towards the interior of the molecule to occupy the b and g crevice for the 
phosphates of GTP. Second, Gln-61 is pulled towards the y-phosphate covering 
Gly-60 which is an important residue for the binding the Cysteine rich domain of 
Raf-1 (Quilliam et al., 1996). Third, Pro-34 is fully exposed at the surface, 
presumably because Tyr-32 is hydrogen bonded to Asp-12 (Figure 23 c). In G12V 
Ras, Tyr-32 is not displaced and sits above Pro-34 (Figure 23 d).
It is, thus, deduced that the arrangements of Gln-61, Tyr-32 and Pro-34 
differ markedly between the G12D mutant and both wild type and G12V Ras. A 
protein such as Raf-1 recognising the surface including Tyr-32 and Pro-34 (switch
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Figure 23
Figure 23: Crystal structures o f H-Ras protein
The wild type and codon-12 mutant Ras proteins were extracted 
from the Brookhaven Protein Data Bank (Bernstein et al., 1977). The Ras 
PDB files give the coordinates of the crystal structures of the truncated 
versions (residues 1-166), expressed in E. coli, of the human protein 
Harvey-P21ras complexed to either MgGppNp or MgGDP. (GppNp is an 
analogue of GTP in which the oxygen atom linking the b,g phosphates is 
replaced by an NH group.) The molecular graphics package Rasmol 
(Sayle & Milner-White, 1995) was used to manipulate the Ras PDB 
images.
Wild type (a,d), G12D (b,e) and G12V (c,f) Ras proteins: a, b and 
c show views of the surface at the ligand of p21 Ras; all protein and ligand 
atoms are shown in spacefill. The GppNp atoms are dark blue. The side 
chain atoms of Tyrosine-32 are coloured violet and its phenolic oxygen is 
purple. The main-chain atoms of residues 30-33 (part of the effector site) 
are coloured yellow. Residue 12 is coloured green. In (b) the carboxylate 
side chain of aspartate-12 is hydrogen bonded (as an acceptor) both to 
phenol of Tyr-32 and the amide of Gln-61, which are both acting as 
hydrogen bond donors. The dotted lines represents these hydrogen bonds. 
Slice sections through the surface of wild-type and mutant Ras molecules, 
using the Rasmol slab command, are shown in d, e and f. They are 
designed to highlight the arrangement of Tyrosine-32 and Proline-34 at the 
surface. Atoms that are sliced appear flat.

Figure 23
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Figure 23: Crystal structures o f H-Ras protein
The wild type and codon-12 mutant Ras proteins were extracted 
from the Brookhaven Protein Data Bank (Bernstein et al., 1977). The Ras 
PDB files give the coordinates of the crystal structures of the truncated 
versions (residues 1-166), expressed in E. coli, of the human protein 
Harvey-P21ras complexed to either MgGppNp or MgGDP. (GppNp is an 
analogue of GTP in which the oxygen atom linking the b,g phosphates is 
replaced by an NH group.) The molecular graphics package Rasmol 
(Sayle & Milner-White, 1995) was used to manipulate the Ras PDB 
images.
Wild type (a,d), G12D (b,e) and G12V (c,l) Ras proteins: a, b and 
c show views of the surface at the ligand of p21 Ras; all protein and ligand 
atoms are shown in spacefill. The GppNp atoms are dark blue. The side 
chain atoms of Tyrosine-32 are coloured violet and its phenolic oxygen is 
purple. The main-chain atoms of residues 30-33 (part of the effector site) 
are coloured yellow. Residue 12 is coloured green. In (b) the carboxylate 
side chain of aspartate-12 is hydrogen bonded (as an acceptor) both to 
phenol of Tyr-32 and the amide of Gln-61, which are both acting as 
hydrogen bond donors. The dotted lines represents these hydrogen bonds. 
Slice sections through the surface of wild-type and mutant Ras molecules, 
using the Rasmol slab command, are shown in d, e and f. They are 
designed to highlight the arrangement of Tyrosine-32 and Proline-34 at the 
surface. Atoms that are sliced appear flat.

I) and Gly-60 (switch II) would find the G12D mutant presenting a different 
shape and partial charge distibution from both wild type and G12V proteins 
(Figure 24). In particular the |3, y-phosphates of the nucleotide sit at the bottom of 
a trough in the wild type and G12V, whereas in G12D protein the trough is filled 
by the aspartate and Tyr-32, to which it is hydrogen bonded. Since Tyr-32 is not 
securely fixed on the surface of Gly-12 and Val-12 Ras it is to be expected that 
residues from a protein recognising GTP-Ras could protrude into the b, g- 
phosphate crevice of these proteins, but are less likely to do so for G12D. 
Three-dimensional structures of GAP-G12D and GAP-G12V have not been 
determined but when they are it may be possible to test these expectations. The 
same principles would also apply to other proteins recognising the nucleotide 
phosphates and the residues surrounding its trough at the surface of Ras. Another
possibility that ought to be considered is that the three-dimensional structure 
adopted by GppNp-Ras, with the trough filled in by Asp-12 and Tyr-32, is not 
favoured when the true substrate GTP binds, at least in its complex with GAP, 
because of its lower affinity for protons. In addition, since Raf is one of the down 
stream effector of Ras and that GAP and Raf use overlapping binding domains on 
Ras (residues 30-38 for GAP (Bollag and McCormick, 1991; Gideon et al., 1992) 
and 32-40 for Raf (Stang et al., 1997) then it can be postulated that increased 
affinity of GAP to aspartate-12 compared to valine-12 might interfere with Raf 
binding in aspartate-12 but not with valine-12 mutant, which has low affinity for 
GAP. This interference in binding between Raf and GAP has been documented 
recently. The authors show that binding of Raf protein to Ras prevented 
productive interaction between Ras and GAP as measured by competitive 
inhibition of GAP-stimulated Ras-GTP hydrolysis (Chuang et al., 1994).
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Figure 24: Comparison o f the 3-Dimensional-cartoon structures o f the valine-12 and
aspartate-12 Ras proteins in the active conformation
The switch 1 effector region (residues 30-40) is coloured yellow. Switch II is 
shown in red with residues 64 and 60, which are important for Raf binding are shown in 
blue, a) This is valine-12 mutant H-Ras. Notice the absence of hydrogen bonds, b) This is 
aspartate-12 mutant H-Ras. There are hydrogen bonds formed between the triad of Tyr- 
32, asp-12 and Gin 61, but also there is an additional hydrogen bond between Tyr-64 and 
Gln-61 backbone, which increases the rigidity of switch II region. Notice also how 
residue 61 blocks access to residue 60.

Some of these features are summarised in Scheme 1. The different 
physiological effects of G12D and G12V cannot simply be explained on the basis 
of different GTPase activity and are, we argue, likely to be due either to weak 
binding of GTP specifically to G12D and/or to the significantly different 
conformation of G12D in the region of the g-phosphate of GTP. G12V is 
continuously activated giving rise to a persistent downstream signal in tumours 
harbouring this mutation while, in G12D, the downstream signal, though still 
oncogenic, is less persistent, giving rise to less aggressive tumours. There have 
to be molecular explanations for the different effects of these two mutations and 
this analysis represents a start in addressing them.
Scheme 1: Comparison of WT, G12V, and G12D Ras
Wild-type G12V G12D
GTP binds strongly GTP binds strongly GTP binds weakly
y-Phosphate of 
GTP exposed at 
bottom of trough.
y-Phosphate of 
GTP exposed at 
bottom of trough.
y-Phosphate of 
GTP covered 
in its trough by 
aspartate side chain.
Switch II is mobile Switch II is mobile Switch II is rigid and 
residue 60, which is 
important for Raf
binding, is obstructed 
by Gln-61
GAP binds strongly. GAP binds weakly. GAP binds strongly.
Ground-state formed. Ground-state not formed Ground-state formed.
so well.
Transition state formed Also transition-state 
not formed because 
R789 of GAP cannot 
fit in trough.
Transition-state not 
formed because 
R789 of GAP
by R789 of GAP 
binding in trough.
(Val-12 obstructs both.)
Cannot fit in trough. 
(Asp-12 obstructs it.)
GTPase hydrolysis rate GTPase hydrolysis rate GTPase hydrolysis
rate increased by GAP. not increased by GAP. not increased by GAP.
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CHAPTER 10. Summary and discussion
In this study, primary adenocarcinomas and their metastatic deposits from 
78 patients were examined for Ki-ras mutation in codons 12 and 13. In 
agreement with most other published data using similar techniques (Bos et al., 
1987) Ki-ras was found mutated in 35% of all carcinomas.
Finkelstein et al. (1993) reported that a G to A transition in the second 
base of codon 12 is associated with aggressive carcinomas, and Moerkerk et al. 
(1994) found G to A transitions in either first or second base exclusively in less 
aggressive (Dukes’ B) carcinomas. Here, G to A transitions in carcinomas have 
been found in all Dukes’ stages, with no difference in frequency of G to A 
transition between metastatic and non-metastatic primary carcinomas. Both 
Finkelstein et al. (1993) and Moerkerk et al. (1994) found G to T transversions in 
the second base in Dukes’ C carcinomas, though the latter group subsequently 
reported a preponderance of GTT mutations in Dukes’ A and B carcinomas (Span 
et al., 1996). G to T transversions were observed only in Dukes’ C and D 
carcinomas. It may be significant that the three carcinomas in this study with 
codon 12 GTT mutations which were originally staged as Dukes’ A or B were 
later re-staged as Dukes’ D. These patients with apparently early carcinomas 
must already have had covert metastatic deposits since they relapsed with liver 
metastases.
The majority (65%) of carcinomas in this study and in others (Bos, 1989; 
Bos et al., 1987; Boughdady et al., 1992; Moerkerk et al., 1994; Urosevic et al., 
1993) contained only wild-type Ki-ras. This and the absence of any difference in 
Ki-ras mutation frequency between primary carcinomas and their metastatic
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deposits, and between metastatic and non-metastatic primary carcinomas, indicate 
that Ki-ras mutations are not essential for the attainment of metastatic capacity. 
Kato et al., (1996) reported that mutations of Ki-ras codon 12 in patients with 
colorectal cancer are less frequent in patients with liver metastases than in patients 
with no liver metastases (Kato et al., 1996). Together, these observations point to 
the involvement of genetic factors other than Ki-ras mutations in the metastatic 
process.
As observed by others (Bos et al., 1987; Oudejans et al., 1991; Suchy et 
al., 1992), this study shows that, if there was a mutation in Ki-ras, it was the same 
mutation in the primary carcinoma and its metastases. On the other hand, 
populations of carcinoma cells heterogeneous with respect to wild-type versus 
mutant Ki-ras were found both within and between primary and secondary 
carcinomas, implying that even when a Ki-ras mutation occurs in a colon 
carcinoma it cannot always have been necessary for emergence of the malignant 
(invasive) phenotype. In 13% of Dukes’ C and D patients, Ki-ras point 
mutations were detected in metastases but not in the primary carcinomas. 
Provided the mutation was not in cells of the primary carcinoma other than those 
analysed, these findings are consistent, in some cases at least, with a point 
mutation in Ki-ras occurring at one of the later stages of carcinoma progression.
Substantiation of the adverse prognosis associated with the codon 12 
GGT-^GTT (Gly-*Val) Ki-ras mutation in colorectal cancer by larger studies 
might help to identify, for instance, Dukes’ A and B patients at greater risk of 
systemic relapse and hence likely to benefit from adjuvant systemic therapy. 
Such studies may be compromised if they do not address the issue of ras 
mutational heterogeneity. If ras-mutant malignant cells in ras-heterogeneous
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carcinomas emerge subsequent to malignant transformation, then the ras mutation 
is a progression event, and might be expected to confer a more aggressive 
phenotype, being additional to genetic changes already conferring the malignant 
phenotype.
A logical hypotheses can be proposed. It is possible that some colorectal 
carcinomas are, in fact, polyclonal with respect to the transforming mutations they 
have acquired. Or, transformed cells are capable of inducing the transformed 
phenotype in adjacent adenoma cells, even if those cells do not themselves have a 
full complement of transforming mutations, via paracrine mechanisms or by gap- 
junctional communication of dominant signals. That neoplastic cells may confer 
new behaviours on adjacent cells has been shown by experiments in nude mice in 
which co-injection of metastasis-incompetent cells admixed with metastasis- 
capable cells leads to the formation of chimeric metastases in which both cell 
types are represented (Moffett et al., 1992).
Another important implication of ras mutational heterogeneity relates to 
therapies directed against ras function, such as inhibitors of farnesyltransferase. 
Transgenic mice expressing v-H-ras under mouse mammary tumour virus LTR 
control develop spontaneous salivary and mammary carcinomas. 
Farnesyltransferase inhibition can effect complete regression of these tumours 
without detectable toxicity, but resistance has also been observed (Kohl et al., 
1995). Work on farnesyltransferase inhibitors continues but, clearly, the potential 
of these agents in human cancer will be critically influenced by the phenomena 
described.
While a strong correlation of mutation of codon 12 to GTT with the more 
aggressive/advanced (Dukes’ C and D) carcinomas was observed, analyses of Ki­
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ras in colorectal carcinomas did not reveal the same strong relationships between 
some other codon 12 mutations and the aggressiveness of the disease described by 
others (Finkelstein et al., 1993; Moerkerk et al., 1994; Span et al., 1996). It seems 
unlikely that differences between studies are due to differences (genetic, dietary, 
etc) between the American (Finkelstein et al., 1993), Dutch (Moerkerk et al., 
1994; Span et al., 1996), and Scottish populations of patients since none of these 
factors would be expected to influence the phenotypic effects of particular Ki-ras 
mutations, although they might cause differences in the frequencies of the various 
mutations, as has already been noted (Urosevic et al., 1993). The variations 
between studies may either reflect differences in the mutation rates of other genes 
encoding proteins that interact, directly or indirectly, with p21 Ras, or the use of 
different methodologies. ASO hybridization, for example, detects 1 mutant cell in 
100 normal cells (Slebos et al., 1992) whereas sequencing and analysis of single­
strand conformation polymorphisms are at least 10-fold less sensitive. 
Publication bias may also be significant.
Survival data on colorectal cancer patients with Ki-ras mutations are also 
controversial. Laurent-Puig et al. (1992) and Kern et al. (1989) found no relation 
between the occurrence of Ki-ras mutations and overall survival. In contrast, 
Span et al. (1996) found decreased 10-year survival of patients with colon 
carcinomas harbouring Ki-ras mutations, in particular the codon 12 GAT 
mutation, whereas Benhatter et al. (1993) and I found this mutation to have no 
significant association with survival. The association found here was between 
transversions of GGT to GTT in codon 12 and decreased survival. The 
controversial results between studies are not surprising, most studies including 
this, contained a relatively small number of patient to reach a conclusive result.
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However, a recent more elaborate study of the RASCAL project, which has 
collected data from 2721 colorectal cancer patients from 22 groups in 13 countries 
(including data from Finkelstein et al. (1993), Span et al. (1996), but not mine), 
also came to the conclusion that the codon 12 GTT mutation in Ki-ras but not 
GAT mutation is associated with increased risk of relapse and death (Andreyev et 
al., 1998). In addition, a similar association between this mutation and poor 
prognosis has been found for patients with lung cancer (Keohavong et al., 1996).
The role of valine-12 mutant Ras protein in metastasis in animal models is 
well-established (Bondy et al., 1985; Radinsky et al., 1987; Thorgeirsson et al., 
1985). As detailed in Chapter 3, Ras proteins activate a number of intracellular 
signalling pathways. For example, valine-mutant Ha-Ras stimulates surface 
membrane ruffling in colon cancer cells (Li et al., 1997) and the expression of 
matrilysin (a matrix metalloproteinase) (Yamamoto et al., 1995) and angiogenic 
factors (Rak et al., 1995). Consequently, there are plausible mechanisms by 
which different ras mutants might influence both local carcinoma aggressiveness 
and the growth of metastatic deposits. However, most, if not all, studies 
addressing the role of mutant Ras proteins in metastasis in vitro and in animal 
models concentrated on valine-12 mutant Ras and no attempt as yet was made to 
compare the effects of valine-12 and aspartate-12 mutant Ras on invasion and 
metastasis in these studies.
The mechanisms whereby different ras mutations might influence the 
aggressiveness of carcinomas are still little understood, although it has long been 
known that the transforming capacity of Ha-ras genes varies with particular codon 
12 mutations (Seeburg et al., 1984). Rat fibroblasts transformed with H-ras 
encoding valine in place of glycine display a more fully transformed phenotype
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than those transformed with Ha-ras encoding aspartate at this position (Seeburg et 
al., 1984).
In vitro comparison of Rat-1 cells expressing wild type or two different 
codon 12 activating mutations was undertaken. One of the main conclusions 
suggested by this study is that Rat-1 cells containing valine-12 mutant Ki-Ras 
were significantly more invasive in vitro than clones expressing aspartate-12 or 
wild type Ki-Ras. This is consistent with valine-12 Ki-Ras being more aggressive 
in vivo. Increased invasion has been shown to be a direct consequence of valine- 
12 mutant Ki-Ras because antisense against this particular mutation significantly 
diminished cell invasion. Although it has to be admitted that to attain more 
reliable and significant results 10 or more clones of each mutant Ki-Ras should 
have been compared (in contrast to the 2 clones of each mutation type used here 
or in the case of GAT-12 clones only one clone has been shown to express GAT- 
12 Ki-Ras). Unfortunately, this was not practical due to time and funding 
limitations.
Both valine-12 and aspartate-12 mutant Ki-Ras transform Rat-1 cells 
equally well. These cells also demonstrate reduced expression of E-cadherin. E- 
cadherin has been shown to suppress metastasis in animal models (Vleminckx et 
al., 1991). Moreover, induction of the invasive phenotype by the activated H-ras 
oncogene has been shown to correlate with weak expression of E-cadherin 
(Chastre et al., 1993). With carcinoma cells, changes in cellular adhesion often 
reflect a more invasive phenotype. For example, human breast epithelial cells 
transformed by oncogenic ras generally display reduced cell-cell adhesion and 
increased cell migration (Basolo et al., 1991; Ochieng et al., 1991). However, it is 
currently unclear how activated Ras proteins alter adhesion junctions but could
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involve elevated tyrosine phosphorylation of proteins such as p-catenin and pl20 
Cas (Kinch M., 1995).
Both mutant Ki-Ras transformed Rat-1 cells demonstrated a reduced 
expression of Pi integrin. This is in line with published data showing that Rat cells 
transformed with ras or Rous sarcoma virus were found to have decreased 
expression of Pi integrins (Plantefaber and Hynes, 1989). Recently, valine-12 
mutant H-Ras was found to negatively affect the integrin activation state (Hughes 
et al., 1997). The discovery of such a negative feedback loop due to inactivation 
or reduced expression represents an important connection between decreased 
matrix adhesion and malignant transformation. Therefore, while anchorage- 
dependent cells are susceptible to apoptosis when induces to detach from matrix 
substrate by disruption of integrin mediated cell adhesion (Meredith et al., 1993), 
transformed cells may overcome the apoptotic pathway by alleviating the 
requirement for cell adhesion to substratum, thus conferring anchorage 
independence and initiating the malignant transformation of cells (Ruoslahti and 
Reed, 1994).
The role of integrin in invasion and metastasis is well established 
(Robinovitz 1996). Indeed, the use of functional anti-a6 integrin antibody was 
also able to reduce invasion of valine-12 mutant Ki-Ras cells showing an 
important role of this integrin monomer in in vitro invasion.
The difference in invasion capability between the two mutants was also 
shown to correlate, at least in some clones, with stromelysin-1 production. 
Increased stromelysin-1 production has been shown to correlate with aggressive 
tumours in vivo, and recently has been shown to play a direct role in facilitating 
invasion through Matrigel in vitro (Lochter et al., 1997). Valine-12 mutated Ki-
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Ras has also been shown to increase stromelysin production (LoSardo et al., 1995; 
Matrisian et al., 1991). It is worth noting, however, that in colorectal cancer 
stromelysin-1 has been shown to be expressed indirectly by stomal rather than 
tumour cells (Heppner et al., 1996; Matrisian et al., 1994). Interestingly, 
stromelysin-1 production was shown to be a consequence of MAPK pathway 
activation (LoSardo et al., 1995; McDonnell et al., 1994). The reduced ability of 
aspartate-12 to induce stromelysin-1 production could be due to its reduced ability 
to bind Raf-1 and stimulate MAPK pathway. Indeed, molecular modelling 
demonstrates a clear difference in structure between the two mutants where 
important residues for Raf binding have substantially different conformation or 
are inaccessible.
Since it is speculative that the MAPK pathway is not activated by the 
aspartate-12 mutation, how then could aspartate-12 transform cells? And why is 
aspartate-12 mutant Ki-Ras selected for in colorectal cancers? Are intriguing 
questions. The ability of both Ki-Ras mutants to stimulate VEGF production as 
shown here and by others (Arbiser et al., 1997; Okada et al., 1998; Rak et al., 
1995) could partially shed some light on these questions. VEGF production was 
shown to require PI-3K arm of the Ras pathway (see section 3.5.3). This particular 
Ras pathway (Ras-PI3K-PKB/Akt) was also shown to be responsible for 
transformation of cells by R-Ras. Activated R-Ras is unable to stimulate the Raf- 
MAPK pathway but synergizes strongly with Raf in the transformation of NIH 
3T3 cells (Downward, 1996; Saez et al., 1994). It is arguable, based on the ability 
of activated Ras to induce VEGF production, that in aspartate-12 Ki-Ras, the Ras- 
PI-3K pathway is fully functional and could give selective advantage for cells 
harbouring this mutation. However, in valine-12 Ras both the Ras-PI-3K and Ras-
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MAPK pathways are fully functional making this particular mutation more 
oncogenic and associated with more aggressive tumours in vivo (Figure 25). This 
hypothesis is supported by recent work of Webb et al. (1998). The effector 
domain mutants of oncogenic H-Ras, V12S35 Ras, V12G37 Ras, and V12C40 
Ras were tested for their abilities to mediate tumourigenic and metastatic 
phenotypes in athymic nude mice when expressed in NIH3T3 fibroblasts. The 
authors show that all mutants displayed comparable tumourigenic properties, but 
only the mutant that activatess the Raf-mitogen-activated protein kinase kinase 
(MEK)-extracellular regulated kinase (ERK) 1/2 pathway, namely the V12S35 
Ras, induced tumours in the experimental metastasis assay. The authors also show 
that R-Ras which fails to activate the ERK 1/2 pathway, is tumourigenic but non­
metastatic. These results suggest that Ras-mediated tumourigenicity can arise 
independently of ERK 1/2 activation and that experimental metastasis appears to 
require constitutive activation of ERK 1/2 pathway. The authors argue that the 
Ras effector pathways mediating the tumourigenic and metastatic activities can be 
segregated. Similarly, I argue that aspartate-12 Ki-ras mutants are not associated 
with metastatic phenotype but are still tumourigenic because, on one hand, they 
fail to sufficiently activate the Raf-mitogen-activated protein kinase kinase 
(MEK)-extracellular regulated kinase (ERK) 1/2 pathway but on the other hand 
they activate the PI-3K arm sufficiently. That GAT-12 Ki-ras mutants are unable 
to activate the MAPK pathway, which is associated with cellular senescence and 
apoptosis in primary cells, probably gives early tumour cells harbouring this 
particular mutation a selective advantage. This can help to explain why GAT-12 
mutation is the most common ras mutation in colorectal cancer.
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In summary, there is now mounting evidence supporting the notion that 
some mutations in ras are more aggressive than others. In vivo, the RASCAL 
study demonstrated this with a high degree of certainity. In vitro, Seeburg et al. 
(1984) have shown that valine-12 is more transforming than aspartate-12. 
Recently, Giaretti et al. (1998) have shown that DNA aneuploidy in colorectal 
adenomas was strongly associated with the presence of GTT-12 transversional 
mutations in Ki-ras, whereas adenomas harbouring GAT-12 transition mutations 
were associated with low S-phase values. Here, the results not only suggest that 
different mutations in Ki-ras have different biological effects on cells, but a 
preliminary model illustrating possible reasons for such differences has been 
introduced. What remains is to verify this mode proposed in Figure 25. This will 
be discussed in section 12.1.
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Figure 25: A model illustrating probable differences between valine-12 and 
aspartate-12 mutant Ras proteins in activation o f  downstream effectors o f  Ras 
and their biological consequences
V aline-12 Ras is thought to activate both the M APK and the PI-3 kinase 
pathway with full biological advantages shown in boxes. On the other hand, 
aspartate-12 is thought to be unable to activate the M APK pathway (or activates it 
to a small extent), which is important for invasion and metastasis. However, it can 
probably still activate the PI-3 kinase pathway giving cells survival advantages 
such as inhibition of apoptosis, tumourigenicity and the ability to induce 
angiogenesis
The arrow thickness is proportional to the strength of Ras effectors activation.
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SECTION 2
CHAPTER 11. Genetic comparison of advanced primary 
colorectal tumours and their metastases using 
Comparative Genomic hybridisation
An important concept that emerged from analysis of Ki-ras mutations in 
vivo, is tumour heterogeneity. Equally important is the fact that Ki-ras mutations 
occurred in only 34-38 % of colorectal tumours and in some instances metastases 
contained only wild type Ki-ras. This argues that activated Ki-ras is not 
necessary, in many instances, for metastasis and that there are possibly other 
mechanisms through which a metastatic phenotype is attained. It was, therefore, 
rational to use a wide scanning genomic methodology such as CGH in order to 
answer two main questions. Firstly, what is the extent of the genetic diversity 
(heterogeneity) between primary colorectal tumours and their synchronous 
metastases? And secondly, what genetic aberrations, other than Ki-ras mutations, 
are frequent in advanced colorectal cancers?
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11.1. Optimisation o f comparative genomic hybridisation
CGH is a relatively recent technique developed by Kallioniemi et al. 
(1992) for analysing whole genomic DNA (Figure 26). The benefits of using such 
a robust technique is that a single experiment provides an overview of DNA 
sequence copy number changes, which include deletions, gains, and 
amplifications. This method is particularly suited to study metastatic colorectal 
cancer because the "gross" genetic alterations associated with the metastatic 
process are still poorly defined.
Increased attention to quality control of CGH is essential since 
experimental variability remains a significant problem (Karhu et al., 1997). 
Therefore, CGH was carefully optimised by including two controls in every 
experiment. Firstly, a colorectal cancer derived cell line (Colo320) which has a 
known amplification of the Myc oncogene in the form of double minute 
chromosomes was used (Schwab et al., 1983) (Figure 27). Secondly, hybridisation 
of green-labelled normal male DNA versus red-labelled normal female DNA and 
its reverse, red-labelled normal male DNA versus green-labelled normal female 
DNA were used to show consistent difference in copy number of the X 
chromosomes between the two genders (Figure 28). In both cases, CGH clearly 
detected these changes. Moreover, these controls were used in every experiment 
and unless these controls showed the expected differences the experiment was not 
considered for analysis.
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Figure 26: Schematic representation o f  CGH
Tum our genomic DNA is labeled with biotin (green) and normal genomic 
DNA is labeled with digoxigenin (red) in a nick-translation reaction or by using 
random priming. An equimolar amount o f  both reactions are hybridised to normal 
male metaphase chromosome spreads and quantitated as described in the methods 
section. The chromosomes are counter-stained with DAPI and identified by Q- 
banding patterns.
Normal DNA
Digoxigenin
Labelled
Tumour DNA 
Biotin
labelled
Metaphase Spread
Amplification No differences Deletion
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Figure 27: Detection o f c-myc amplification by CGH
Green labeled DNA from Colo 320 cell line hybridised against normal 
DNA to normal metaphase chromosomes, a) shows green, red and blue colour 
intensities along one chromosome 8. The centromeric region is indicated by the 
arrow.b) Visual representation of two normalised chromosome 8. Arrows indicate 
the amplified loci on 8q24. c) Average green:red fluorescent intensity profile of 
chrom osome 8 collected from 5 metaphase spreads. Mean ratio is shown as a red 
line, and the 99% confidence intervals of the mean are shown as black lines. The 
baseline value that represents the mean ratio of 1.0 is shown as dashed line and 
the ratio profiles of 0.75 and 1.25 are shown as solid horizontal lines.
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Figure 28
Figure 28: CGH detection o f X-chromosome copy number difference by hybridising 
normal DNAs from different genders
A) Normal female DNA labeled green hybridised against normal male DNA 
labeled red to normal male metaphase chromosomes.
a) Average greenrred fluorescent intensity profile of X-chromosome collected from 5 
metaphase spreads. Mean ratio is shown as red line, and the 99% confidence intervals of 
the mean are shown as black lines. The baseline value that represents the mean ratio of
1.0 is shown as dashed line and the ratio profiles of 0.5 and 1.5 are shown as solid 
horizontal lines.
b) shows green, red and blue colour intensities along one X-chromosome.
c) Visual representation of the normalised X-chromosome.
B) The reverse of (A), Normal male DNA labeled green hybridised against 
normal female DNA labeled red to normal male metaphase chromosomes.
a’) Average green:red fluorescent intensity profile of X-chromosome collected from 5 
metaphase spreads. Mean ratio is shown as red line, and the 99% confidence intervals of 
the mean are shown as black lines. The baseline value that represents the mean ratio of
1.0 is shown as dashed line and the ratio profiles of 0.5 and 1.5 are shown as solid 
horizontal lines.
b’) shows green, red and blue colour intensities along one X-chromosome. 
c’) Visual representation of the normalised X-chromosome.
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Figure 29: CGH optimisation by hybridising normal D N A ’s from  different genders
A) Male DNA labeled green (arrowhead showing the X chromosome and 
arrow indicates the Y chromosome) hybridised with female DNA labeled red 
(arrowhead indicating the X chromosome) to normal male metaphase 
chromosomes.
B) Female DNA labeled green (arrowhead showing the X chromosome) 
hybridised with male DNA labeled red (arrowhead indicating the X chromosome 
and arrow showing the Y chromosome) to normal male metaphase chromosomes. 
See appendix for chromosomal green: red ratio profiles.
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11.2. Comparative genomic hybridisation analysis of primary
colorectal cancer tumours and their synchronous metastases
11.2.1. Genetic changes in primary and secondary tumours detected by 
CGH
The extent of the genetic alterations in 12 primary colorectal cancers and 
their corresponding 14 metastases was assessed. Five patients were classified as 
Dukes' stage C with only synchronous lymph node metastases, and seven patients 
were classified as Dukes' stage D with synchronous liver metastases. In two of 
the patients with liver metastases, lymph node metastases were also available for 
analysis.
CGH detected extensive genetic alterations in all 12 primary colorectal 
carcinomas and their metastases (Table 9 and Figure 30). The mean number of 
genetic aberrations per sample detected by CGH was 9.7 ± 4.6 in primary tumours 
(range, 1-16) and 11.6 ± 2.9 in metastases (range, 7-18). In nine patients the 
metastases had more genetic aberrations than their primary tumours, while in 
three patients the primary tumours had accumulated more genetic aberrations than 
their metastases. In none of the patients studied were the primary tumours and 
their metastases either genetically identical or totally different.
Particular chromosomal aberrations were frequent in these advanced 
colorectal cancers, including increases in copy number of chromosome arms 6p, 
7p, 8q, 13q, 16q, 17q and 20q and losses of chromosome 4, 18 and chromosome 
arm 8p (Table 10).
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Table 9: Summary of clinical data and chromosomal copy number changes of
26 tumours from 12 patients with metastatic colorectal carcinoma
Patient Tninour" Copy number gains* ; X*Copy number losses
1 D P
LNM
LVM
2 D P
LNM
LVM
3 D P
D
D
6 D
D
10 C
11 c
12 C
LVM
P
LVM
P
LVM
P
LVM
P
LVM
P
LNM
P
LNM
P
LNM
P
LNM
P
LNM
21q21, 18, 15q21, 14q21-ter, 
12pl2, llq23, 10q21-25, 8p.
18, 15q21, 14q21-ter, 12pl2, 
10q21-25, 8p.
22ql3-ter, 18,15q21,14q21-ter, 
10q21-25, 8p.
18, 8p, 3q28-ter.
21q22, 18q, llq23, 8p, 4, 3q28.
22ql2.3-ter, 18q, 8p, 4, 3q28.
21q21, 18q, 15q21.3, 8p23.2, 
6q, 5q21, 4, 2q36.
18,15, 12p, llq21-23, 9p, 8p, 
6q, 4, lpll-31.
21q, 18, 14q, 8p, 4, lpll-31.
18,14q23, 8p, 4.
21q21-22.2, 18, 14q23, 12q21, 
llq23, 9p21, 5q23, 4, lpll-31. 
18, 9p, 4, lpll-31.
10pl4, 8p, 4q.
18, 4.
21q21-22, 18.
22, 21, 18, llq21-23.
22, 18q, 17pl2,15q, lOq, 8p, 
4q26-28.
22ql3.2, 22pll, 18q, 15q25, 
12q23, lOq, 8p23.2-22, 4, 3q24, 
lq.
22, 21q22.2, 18q, 17p, 15, 
12pl2, 4q32-34.
22, 18q, 17pl2, llq , 8p, 5ql4- 
34, 4.
22q, 18q, 17pl2, 16pl3.2, 
15q25, llq , 5ql4-34, 4.
18q22, 17pl2.
22ql3.2-ter, 18, 17pl2, 4q32- 
ter, 3p24.
18q, 4pl5.3-ter, 3p21-ter, lp31- 
ter.
22, 18, 17, 15q26.2, 14q31-32, 
4pl5.3-ter, 4q32-28, lp31-ter.
22ql3-ter, 20q, 17ql2-22, 
llq l4 , 9q31, 8q, 7pl2.
22ql3-ter, 20q, 17ql2-22, 16, 
llq l4 , 9q31-ter, 8q24.2-ter, 7p. 
20ql3-ter, 17ql2-22, 8q, 7p.
20q, 16qll.2, 6p. ^
20ql3.2,17q, 16, llq l4 , 9p21, 
8qter, 6p22,
P< 0.001
20ql2-ter, 17ql2-22,16qll.2, 
llq l4 , 9p21, 8q, 7pl2, 6p.
>T>< 0.01
>^P< 0.001
22ql3.2-ter, 20, 17q, 13ql3,
8q24.2, 7p21-14, 6p21.2, 3pl4,
3q24
20, 17q23, 16, 13ql3, llq l4 - 
14.3, 8q, 7p, 6p, 3q.
20ql2-ter, 17q, 13q, 8q23-ter,"j 
7p. [ P< 0.001
20ql2-ter, 17q21-24, 16q21- 
ter,13q,8q23-24.2,7p,6p21,lqU 
22ql3.2, 20q, 16,13q, 6p21.
>P< 0.01
20q, 13q, lOq, 3q24.
20q, 13ql3, 12q24.32, 8q, 7p, ^  
6p21.2-ll, 2ql2, lq. I
20q, 17q22-24, 16, 13ql3, f P< 0.01
12q24, llq , 8q, 7p, 6p. ^
20q, 16qll.2, 7pl2, 6p21, lql2.
20q, 8q23-ter, 7pl2, 6p21. 
20q, 16ql 1.2-21, 13q, 7p.
20q, 16qll.2 ,13q, 9p, 
9q34.2, 7p21.
13ql3-21.1.
20ql2,13q.
13q, 12, 7q35, 5pl4,
3q, lp21, lq31.
13q31, 12pl2, 7q35, 3, lq31.
20ql2-13.2, 8q.
20ql2-13.2, 13q, 8q, 7.
13q, 2q34-36.
13q, 2q34-36, lq31.
>- P< 0.01
>- P< 0.001
P=0.4
P< 0.001
-P< 0.05
>?<  0.01
D, Dukes’ stage D; C, Dukes’ stage C. P, Primary tumour; LNM, Lymph node metastases; 
LVM, Liver metastases. High-level copy numbers are in boldface; *X, the probability that 
shared genetic aberrations in paired specimens are clonally unrelated.
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Figure 30
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Figure 30: Ideogram summary o f copy number aberrations involving chromosomes 1 to
22 in 12 patients with metastatic colorectal cancer
Gains are represented on the right side of the chromosome ideogram and losses on 
the left. Primary tumours from Dukes’ D patients are coloured black and their metastases 
are shown in green. Primary tumours from Dukes’ C patients are coloured red and their 
lymph nodes metastases are shown in blue. Patient numbers (Table 9) are shown above 
each line.
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Some, at least, of these genetic changes could be involved in the metastatic 
process, especially as they were also frequently found in metastases. Many other 
genetic aberrations were present in the tumours analysed at low frequencies. 
These, perhaps, represent random events neither necessary nor sufficient to 
advance the tumour's evolutionary process.
Table 10: Number of patients with the most frequent genetic aberrations 
occurring either in the primary, or secondary tumours only, or in both
Genetic
aberration*
Total number 
of patients 
with aberration 
(n=12)
Primary
tumour
only
(n=12)
Metastases
only
(n=12)
Primary 
and metastases
(n=12)
4 ' 10 0 3 7
6p+ 6 1 1 4
V 8 0 2 6
8p 7 2 0 5
8q+ 7 0 1 6
llq21-23" 6 2 3 1
llq l4 -te r+ 4 0 3 1
13q+ 9 0 1 8
15 ' 6 0 3 3
16q+ 8 2 4 2
17q+ 5 0 2 3
17p 5 1 2 2
1 8 ’ 12 0 2 10
20q+ 10 0 1 9
22- 8 0 6 2
* -, Indicates decrease in copy number; +, increase in copy number; losses and 
gains could involve all of the chromosome or its arms or parts of its arms.
11.2.2. Comparison o f two Dukes' stages by CGH
A comparison of two different stages of aggressive colorectal cancer could 
delineate interesting common and different genetic aberrations that explain their 
different behaviour in vivo. Thus, primary tumours and their liver metastases from
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seven Dukes’ D staged patients and primary tumours and their corresponding 
lymph node metastases from five Dukes’ C staged patients were analysed by 
CGH.
Some chromosomal aberrations were frequently found in both stages of 
the disease, including increases in copy number of chromosome arms 7p (8/12), 
13q (9/12), 20q (10/12) and losses of chromosomes or chromosome arms 4 
(10/12), 8p (7/12), 18 (12/12) and 22 (8/12) (Table 11). These particular changes 
could have occurred early in the evolution of the disease since they are common 
to both stages. However, other genetic aberrations seem to be non-randomly 
distributed between Dukes' C and Dukes' D carcinomas. For example, increased 
copy number of chromosome arms 6p (6/7 versus 0/5) and 17q (5/7 versus 0/5) 
were significantly associated with Dukes’ stage D and liver metastases (p<0.05) 
(Table 11), whereas loss of chromosome arm 17p (5/5) was only found in primary 
tumours and lymph node metastases of Dukes’ stage C (p=0.001) (Table 11).
Table 11: Frequencies of genetic aberrations in Dukes' C and D patients
Genetic Dukes’ C Dukes’ P Fisher’s exact
aberration21 (n=5) (n=7) testb
4 - 5 5 -
8 p - 2 5 -
15- 4 2 -
17p- 5 0 p=0.001
1 8 - 5 7 -
2 2 - 5 3 -
6p+ 0 6 p=0.007
7p+ 2 6 -
8q+ 1 6 -
13q+ 5 4 -
17q+ 0 5 p=0.027
20q+ 3 7 ”
a-, Indicates decrease in copy number; +, increase in copy number; losses and 
gains could involve all of the chromosome or its arms or parts of its arms. 
b-, Fisher’s exact statistical test is not significant (p>0.05).
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11.2.3. Comparison o f primary tumours and their metastases
Primary tumours and their synchronous metastases in individual patients 
frequently revealed the same chromosomal changes at both sites. Such changes 
included increases in copy number of chromosome arms 6p, 7p, 8q, 13q, 17q and 
20q and loss of chromosomes 4,18 and chromosome arm 8p (Table 12), indicating
Table 12: Frequencies of the most common genetic alterations in primary 
colorectal cancers and their metastases
Genetic
aberration*
Primary tumour 
(n=12) p " : '
Secondary tumour 
(n=14)
4 ' 7 11
6p+ 5 6
7p+ 6 9
8p 7 7
8q+ 5 9
llq21-23" 3 4
llq l4 -ter+ 1 5
13q+ 8 9
15 “ 3 7
16q+ 4 7
17q+ 3 7
17p 3 4
18 ' 10 14
20q+ 9 12
22- 2 8*
9|C
Indicates decrease in copy number; +, increase in copy number; losses and 
gains could involve all of the chromosome or its arms or parts of its arms. * 
indicates p=0.051
close clonal relationships between primary and secondary lesions. In an attempt to 
quantitate the degree of clonal relationship, a mathematical model, described 
previously (Kuukasjarvi et al., 1997) was used. This model, estimates the 
probability that shared genetic aberrations in paired specimens are not shared by 
chance alone. Eleven of 12 patients had a high probability of a close clonal
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relationship between primary and secondary carcinomas (Table 9). In patient 9, 
the clonal relationship probability by this model was low, so that the shared 
genetic gain was likely to be attributable to chance alone. In no case analysed 
were the metastases genetically identical to their primary tumours. In all patients, 
the metastases seem to have acquired new genetic aberrations not found in their 
primary tumours. For example, in patients 1, 2, 7, 9, 11 and 12, all chromosome 
22 or part of its q arm was underrepresented only in the metastases (Table 9). 
Similarly, in patients 2 and 11, increased copy number of chromosome arm 7p 
and in patient 4 increased copy number of chromosome arm 6p was detected only 
in the metastases (Table 9, Figure 31 and 32). Furthermore, some of these genetic 
changes found only in the metastases seem to be frequent and not just random 
genetic events (Table 10), suggesting their importance in the metastatic process. 
Interestingly, reduced copy number of chromosome 22 was mainly found in 
metastases (p=0.051) (Table 12)
The presence of different genetic lesions between the primary tumours and 
their metastases not only indicates genetic heterogeneity between the two lesions, 
but may also point to the presence of genetic heterogeneity within primary 
tumours. This is best illustrated by patients 1 and 2 (Table 9), where both the 
primary tumours and two different metastatic lesions (lymph node and liver) were 
available from the same patients for CGH analysis. In patient 1 the genetic 
aberrations found in lymph node and liver metastases differed to such an extent 
that they are likely to have evolved separately from the original 'founder' clone 
(Figure 32). In patient 2, the lymph node and liver metastases were similar 
genetically to each other and so may have evolved from the same clone in the 
primary tumour. However, they differed from the primary clone analysed, thus
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again suggesting the existence of more than one clone of cells within the primary 
tumour (Figure 32).
The same conclusion, that the primary tumours used in this study are 
heterogeneous, can be deduced from the comparisons of the genetic similarities 
and differences between each primary tumour and its metastasis. Interestingly, 
lymph nodes metastases seem to have accumulated substantially more 
chromosomal aberrations than hepatic metastases. On average, lymph nodes 
metastases have a median of six more changes than the corresponding primary 
tumours, while liver metastases have a median of only one more change. Indeed, 
two patients (1 and 5) have hepatic metastases with many fewer chromosomal 
changes than their corresponding primary tumours (Table 11).
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Figure 31
Figure 31: Examples o f genetic gains and losses from patient 4 primary tumour and its 
liver metastasis detected by CGH
Average green:red fluorescent intensity profiles collected from at least 5 
metaphase spreads and corresponding chromosome ideograms are shown. The primary 
tumour profiles are shown on the left, and its liver metastasis profiles are shown on the 
right. Mean ratios are shown as thick lines, and the 99% confidence intervals of the mean 
are shown as thin lines. The baseline value that represents the mean ratio of 1.0 is shown 
as dashed lines and the ratio profiles of 0.75 and 1.25 are shown as solid horizontal lines.
The normalised three-colour image of the primary tumour from the same patient 
is illustrated in Figure 32 for visual support. Chromosome numbers are given on the left.
The primary tumour shows losses of chromosomes or chromosome arms 4, 8p, 
18, 21q and gains of chromosome arms 7p, 8q23-ter, 13q, 17q, 20ql2-ter. The liver 
metastasis shows losses of chromosomes or chromosome arm 4, 8p, 18 and gains of 
chromosome arms 7p, 6p, 8q23-24.2, 13q, 17q21-24, 20ql2-ter. * Chromosome arm 6p 
copy number is increased in the liver metastasis only, while 21q is only lost in the 
primary tumour.
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Figure 32: Representative CGH images from  patient 4 (Table 9) primary tumour 
DNA
A) Normal DNA labelled with digoxigenin. B) Tum our DNA labelled 
with biotin. C) DAPI stain of the chromosome spread. D) Normalised image.
Deletions or decreased chromosomal copy number are stained red. and 
amplifications or increased chromosomal copy number are intensely stained 
yellow/green. Arrowheads represent specific genetic aberrations with + indicating 
amplifications or increased copy number and - indicate deletions or decreased 
chromosomal copy number. The profiles for the normalised image is shown in 
Figure 31.
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Figure 33: Clonal relationships between primary and metastatic carcinoma in 
lymph node and liver for two patients with metastatic colorectal cancer
Common genetic aberrations between all tumour lesions are shown in 
bold. The order in which the genetic aberrations are shown to occur between 
branch points is arbitrary. - indicates deletion or loss, while + indicates 
amplification or gain.
Pa t i en t  1
21 q 21 - Pr imary  t umo u r
___  1 1 q 2 3 -
2 2 q 13- t e r +
7p+ 1 2  p  1 2  - ___  1 6+  L y m p h  n o d e  m e t a s t a s e s
8p- __  1 l q 1 4  +
8q+ 9 q  +
10q21-25-
14q21-ter-
15 q 2 1 -
17ql2-22+ -------2 2 q - Hepa t i c  m e t a s t a s es
18-
20q+
Pa t i ent  2
3q- ------  1 8 p - Pr i mary  t umour
6p+
8p* _
16q+
lSq- 4-
21 q 22-  L y mp h  n o d e  m e t a s t a s e s
20q+ 8q + 1 6 p  +
9 p 2 1 + -----  1 1 q 23 -
1 1 q 14+
1 7 q +  —
—  7 p  1 2  +
2 2 q  1 2 . 3- t e r -  Hepat i c  m e t a s t a s e s
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11.3. Summary and discussion
The progression of adenoma to colorectal carcinoma is accompanied by 
accumulation of many genetic changes (Fearon and Vogelstein, 1990). Recently, 
Mertens et al. (1997) assessed the distribution of chromosomal gains and losses in 
published karyotypes from 11 tumour types including 333 cases of colorectal 
carcinomas. Frequent gain of chromosomes 7, 8q, 13 and 20 and losses of lp, 5q, 
8p, 14p, 17p, 18 and 22 were found. In another study, Ried et al. (1996) used 
comparative genomic hybridisation to identify chromosomal imbalances in 
adenomas and carcinomas of patients with colorectal cancer. Carcinomas were 
found to have multiple chromosomal aberrations involving gain of chromosomes 
1, 13 and 20 and chromosome arms 7p and 8q, whereas chromosome 4 and 
chromosome arms 8p and lOq were frequently underrepresented. This study 
showed that the transition of adenoma to carcinoma is characterized by the 
emergence of multiple chromosomal aberrations. Such studies, clearly, define the 
genetic imbalances found in colorectal carcinoma and point to the accumulation of 
non-random genetic aberration patterns that lead to progression of adenomas to 
carcinomas. However, the relevance of these and other genetic alterations to 
evolution of a metastatic phenotype has not yet been defined. The progression of 
colorectal carcinoma to metastatic disease remains poorly studied, and has been 
restricted to genes thought to be involved in the metastatic process, despite the 
fact that metastasis, particularly to the liver, is one of the major causes of death
from colorectal cancer.
The study of metastasis in colorectal cancer would be informative, since
clinically the disease is subdivided into stages with different clinical and 
pathological behaviours in vivo. Comparing genetic changes in the primary 
tumours and their corresponding metastases from the same patients could reveal 
subtle genetic differences between the lesions, thereby pinpointing important
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genetic events that could predispose to metastatic dissemination. Also, the 
analysis of paired samples from the same patient make it possible to assess the 
degree of clonal divergence and genetic heterogeneity, which could have immense 
importance not only in understanding the biology of metastasis, but also in its 
treatment.
This study was designed to assess the extent of genetic similarities and 
differences between primary colorectal carcinomas and their corresponding 
metastases, and to investigate whether additional genetic aberrations are 
associated with progression of colorectal carcinoma beyond the primary tumour.
The use of CGH, a broadly scanning genome method, combined with 
analysis of paired tumour samples from the same patients, have facilitated our 
search for molecular cytogenetic markers that may indicate regions of the genome 
involved in progression and metastasis of colorectal cancer in vivo. Previous 
studies relied on animal models and LOH techniques to study tumour progression 
(Dove et al., 1995). Although these studies were very valuable in advancing our 
understanding of the metastatic process, they gave a restricted view of genomic 
changes involved in human colorectal cancer progression.
This CGH analysis shows that certain genetic alterations are especially 
common in metastatic colorectal carcinoma. These changes include gains of 
chromosome arms 7p, 8q, 13q and 20q and underepresentation of chromosome 4, 
18, chromosome arms 8p, and 22q. Thus, a chromosome profile for metastatic 
colorectal cancer that can be used to identify and set priorities in selecting genes 
for further study has been constructed.
Previous analysis using karyotyping (Mertens et al., 1997) or CGH (Ried 
et al., 1996) have also shown that most of these genetic aberrations are frequent in
171
colorectal cancer. The results, therefore, are concordant with the published data 
regarding genetic alterations in colorectal cancer. However, the previous studies 
did not focus on a particular stage of the disease, which could underestimate the 
importance of some aberrations to particular Dukes’ stages. This study shows that 
both Dukes' C and D stages of the disease share many genetic changes (Table 11 
and Figure 34), some of which are probably involved in invasion, since invasion 
is probably an essential step in metastasis to both lymph nodes and liver. For 
example, chromosome arm 20q was frequently gained in both lymph node and 
liver metastases. Interestingly, chromosome arm 20q is the location of the gene 
for the enzyme matrix metalloprotease-9 (MMP-9 or gelatinase B) (Linn et al., 
1996), which degrades collagen type IV, a major component of basement 
membranes. Increased MMP-9 levels have been shown to be associated with 
metastatic colorectal cancer (Zeng et al., 1996). Also, chromosome arm 7p gain 
was frequently found (8/12) in primary tumours and/or their metastases. 
Chromosome arm 7p is known to harbour epidermal growth factor receptor 
(EGFR) and T-cell tumour invasion and metastasis-1 (TTIM1) genes (Kondo and 
Shimizu, 1983). Increased EGFR expression has also been found in advanced 
colorectal tumours (Dukes’ C and D) and those exhibiting vascular and lymphatic 
invasion (Kluftinger et al., 1992). Somatic cell fusion studies have shown that the 
invasive capabilities of hybrid cells depended on the presence of chromosome 
fragment 7pl2-cen (Collard et al., 1987; Habets et al., 1994).
Decreased copy number of chromosomes 4, 18 and 22 was also very 
frequent in both Dukes' stages. Putative tumour suppressor genes have been 
localized to 18q21: DCC, deletions of which have been correlated with colon 
cancer progression (Cho and Fearon, 1995), and two members of the SMAD gene
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family, SMAD2 and SMAD4, which are mutated in a proportion of human colon 
cancers (Riggins et al., 1997). Interestingly, it has recently been shown that over­
expression of SMAD4 is associated with p21 induction and growth inhibition of 
carcinoma cells (Hunt et al., 1998).
To date, no convincing tumour suppressor genes or oncogenes have been 
mapped to chromosome 4. Though it has been shown that chromosome 4 is 
involved in cellular senescence in vitro (Ning and Pereira-Smith, 1991). Deletions 
or decreased copy number of this chromosome could therefore be an advantage in 
the selection of immortal cells. Also, in agreement with the data presented, LOH 
involving 22q has been shown to be frequent in colorectal cancer, and correlates 
with metastatic colorectal carcinoma (Yana et al., 1995).
Increased copy number of chromosome arms 6p and 17q were only found 
in Dukes' stage D tumours and liver metastases. This has not been previously 
shown to be frequent in colorectal cancer, perhaps due to the fact that very few 
studies have analysed the most advanced colorectal cancer and even fewer have 
analysed the most advanced colorectal cancer. To date, most cytogenetic studies 
concentrated on either earlier stages of colorectal cancer progression or made no 
attempt to correlate genetic aberrations with progression markers such as Dukes' 
staging. Chromosome 6p harbours the gene encoding vascular endothelial growth 
factor (Wei et al., 1996), a promoter of tumour angiogenesis. Over-production of 
VEGF has been associated with distant metastatic recurrence in lymph-node- 
negative patients with colorectal cancer (Ishigami et al., 1998; Kang et al., 1997). 
Chromosome arm 17q contains the ERBB2 gene (Popescu et al., 1989), which is 
highly expressed in bone metastases from breast and gastrointestinal cancers, and 
its expression to be correlated with advanced cancers (Pantel et al., 1993).
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Notably, Yang et al. (1997) have shown that liver metastasising primary 
colorectal tumours and their liver metastases expressed significantly higher levels 
of c-erbB-2 mRNA than non-metastasising primary tumours. Moreover, c-erbB-2 
mRNA expression significantly predicted the development of liver metastases in 
tumours that had not metastasised to lymph nodes. The authors argue that ERBB2 
gene may play an important role in the development of metastasis in colorectal 
cancer and its mRNA expression may have important implications for deciding 
which patients with lymph node negative disease require chemotherapy. In 
addition, by using an amplotype-PCR approach on 12 primary colorectal tumours 
and their metastases, a recent study has shown that loss of chromosme 4 and gain 
of chromosome 6 were significantly more frequent in metastases (Malkhosyan et 
al., 1998).
The data presented here show that advanced colorectal cancer is clonally 
diverse. Indeed, this CGH analysis suggests that heterogeneity is not only present 
between the primary tumours and their metastases but could also be present within 
primary tumours themselves. The results also suggest that metastases accumulate 
genetic aberrations additional to those found in the primary tumours. Whether 
these additional changes are underepresented in the primary tumours but are 
manifestations of the clonal evolution of metastatic cells (Korczak et al., 1988) or 
have evolved in the metastases themselves, is not clear. Nevertheless, the data 
indicate that additional common genetic aberrations could be important in the 
acquisition of a metastatic phenotype (Fearon and Vogelstein, 1990).
The genetic heterogeneity between primary tumours and their metastases 
demonstrated here not only supports the previous observation regarding Ki-ras 
heterogeneity, but also reveals its extent in advanced colorectal cancer. Similarly,
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LOH studies demonstrated significant heterogeneity within early carcinomas 
arising within colorectal adenomas (Boland et al., 1995). Previous CGH studies 
involving primary breast carcinomas and their corresponding metastases 
(Kuukasjarvi et al., 1997; Nishizaki et al., 1997) have demonstrated extensive 
heterogeneity within the primary tumours and between the primary tumours and 
their metastases, to the extent that, in some patients, the metastases genetically 
differ almost completely from their paired primary tumours. In my case, 
however, the primary tumours and their metastases often shared many common 
genetic aberrations. This indicates that clonal divergence and genetic instability in 
colorectal cancer are not as extensive as those seen in some breast cancers.
The finding that lymph node and liver metastases, even those from the 
same patients, do not always show similar genetic aberrations indicates that the 
mechanisms involved in haematogenous dissemination to distant organs differ 
from those required for spread to regional lymph nodes. The marked genetic 
differences between Dukes' C (lymph node metastasis) and Dukes' D (liver 
metastasis) tumours suggest that the former are not always simply an earlier stage 
of the latter and, thus, in some instances at least, they are distinct forms of the 
disease (Figure 34). Indeed, it is not uncommon in clinical practice to find patients 
with haematogenous metastases without the involvement of their lymph nodes 
(Dworkin et al., 1995).
Through the use of a wide-scanning genome methodology, I have 
described a number of genetic aberrations associated with metastatic colorectal 
cancer, albeit in large chromosomal regions which must contain many possible 
target genes, both known as well as those yet to be discovered. The generation of 
such aberrant chromosome profiles is valuable for guiding future research. The
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data suggest that chromosomes 4, 6, 7, 8, 13, 17, 18, 20, and 22 are all worthy of 
further analysis with more focused techniques. They also stress the importance of 
correlating genetic aberrations with progression markers such as Dukes' staging to 
avoid missing critical events in the metastatic process. In addition, the analysis of 
primary tumours and corresponding metastases has proved valuable in delineating 
genetic mechanisms that might underlie cancer progression through clonal 
evolution.
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Figure 34: A model representing genetic aberrations involved in the metastatic
process in colorectal cancer
Common genetic aberrations between Dukes' C and D (4-, 8p-, 15-, 18-, 
7p+, 8q+, llq l4 + , 13q+, 16+ and 20q+) could represent early genetic events 
important in the acquisition of invasive phenotypes since invasion is required for 
successful metastasis in both stages. Further genetic aberrations such as loss of 
chromosome 22 seen mainly in metastases of Dukes' C and Dukes' D patients and 
chromosome arm 17p found only in lymph nodes metastases could give cells the 
capability to colonize regional sites.
The addition of further genetic aberrations such as the increase copy 
numbers of chromosome ams 6p, 17q representing gain of function, could give 
cells survival advantages in colonizing distant sites such as the liver.
4 -  7p +
8p - 8q +
15- I lq l4  + 
18- 13q +
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Invasive 
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2 2 -
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GENERAL DISCUSSION
CHAPTER 12. GENERAL DISCUSSION
Functionally, it is useful to divide the results in this thesis into two parts. 
The first part deals with genetic aberrations associated with colorectal cancer 
progression, while the second part gives an insight into genetic heterogeneity in 
colorectal cancer.
To assess the genetic aberrations associated with progression of colorectal 
cancer, mutation analysis of the Ki-ras gene and CGH were used. Mutation 
analysis of codons 12 and 13 of the Ki-ras gene in 78 patients with colorectal 
cancer has shown that valine-12 (GTT) mutation in codon 12 to be associated 
with aggressive colorectal tumours and with early mortality of patients harbouring 
this particular mutation. None of the other codon 12 and 13 mutations showed 
such correlation. Interestingly, the dramatic effect of valine-12 mutation on 
survival was masked when the analysis of survival included all the other possible 
codon 12 and 13 mutations. This result was not surprising since YA-ras mutations, 
other than valine-12, were not particularly associated with aggressive tumours. 
However, these results stress the importance of separately correlating or 
stratifying each type of Ki-ras mutations with survival data to avoid 
misinterpreting the “real” role of Ki-ras mutations in colorectal cancer 
progression.
It is worth noting that this study, as with the majority of other studies, 
included a relatively small number of patients and when the results were stratified 
further each class of YA-ras mutations contained too small a number of patients to 
be of any significant reliability. However, the recent study of Andreyev et al.
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(1998) compiled from the work of many investigators, which included a total 
number of 2721 patients, gives the results obtained in this thesis significant 
support in that when specific mutations were evaluated, only valine-12 mutations 
were associated with increased risk of recurrence and death. However, contrary to 
my findings, it has shown that the Ki-ras mutations are not associated with any 
Dukes’ stage and that the presence of Ki-ras mutation increased the risk of 
recurrence and death. Nevertheless, it is evident that mutations of Ki-ras by 
themselves are neither necessary nor sufficient for tumour formation or metastatic 
progression since only 30-50 % of colorectal tumours contain mutated Ki-ras 
gene and as I have shown, in some cases at least, the metastases could form 
without the need for mutationally activated Ki-ras.
It was therefore of some importance to search for genetic aberrations, 
other than Ki-ras mutations, that could be associated with metastatic colorectal 
cancer. The choice of a wide-scanning methodology such as CGH was essential 
for two reasons. First, very little is known to date about the “gross” or overall 
chromosomal aberrations in advanced colorectal cancer and secondly, metastasis 
is a complex process involving multiple genetic and epigenetic events. The use of 
a wide-scanning methodology could shed more light on the significance of the 
interactions of multiple genetic aberrations present within each tumour sample 
and their combined importance in the metastatic process.
CGH analysis of 12 patients with colorectal cancer pinpointed genetic 
aberrations, albeit large areas of chromosomal aberrations, frequently associated 
with advanced colorectal cancer. The results obtained from CGH analysis of these 
tumours have been summarised previously. To date, this represents the first study 
to directly compare advanced primary colorectal tumours with their synchronous
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metastases. Other studies using CGH concentrated on genetic events associated 
with the progression of adenomas to carcinomas (Ried et al., 1996; Meijer et al., 
1998) or CGH and Karyotypic analysis of primary colorectal tumours without any 
attempt to stratify primary tumours into different stages (Nakao et al., 1998; 
Mertens et al., 1997). Although the results presented here are remarkably similar 
to the results presented in the above studies, direct comparisons of the results is 
unfair since the comparison would be between tumours of different Dukes’ stages. 
To date, there is only one other study that restricted the analysis to Dukes’ D 
colorectal tumours and compared the genetic composition of primary tumours to 
their synchronous metastases, albeit using a different approach known as 
amplotyping (Malkhosyan et al., 1998). The agreement in chromosomal 
aberration between the results presented here and Malkhosyan et al. (1998) study 
indeed is striking. Nevertheless, the data presented here are based on a small 
number of patients and further larger studies should shed more light on the nature 
and extent of genetic aberrations in advanced colorectal cancer.
It should be mentioned that the results I present do not necessarily prove 
that the chromosomal aberrations found in advanced colorectal cancer are 
associated with poor prognosis or that early colorectal tumours do not possess 
these aberrations; they merely state the reportoire of genetic aberrations found in 
advanced colorectal cancer. The stratification of tumours into different Dukes’ 
stages has important implications on the study of genes involved in tumour 
progression since currently the majority of studies either make no attempt to 
classify primary tumours into different stages before analysis and are clumped 
together as "primary tumours" or patients with occult metastasis are erroneously 
included in studies as "early tumours". This in turn can partly explain the wide
180
variation in results obtained from different studies on the genetics of tumour 
progression and stresses the importance of choosing the appropriate tumour 
material to avoid masking genetic events that are essential for the metastatic 
process.
Regarding the other part of the thesis, namely tumour heterogeneity, the 
evidence for and causes of tumour heterogeneity were dicussed in Chapter 4. In 
this section, I will discuss the relevance of my findings to tumour heterogeneity in 
general.
The data obtained from mutational analysis of codons 12 and 13 of the 
Ki-ras gene show that the presence of a Ki-ras heterogeneity within primary 
carcinomas from single sections was not infrequent. For example, some primary 
tumours contained areas of cells with mutated Ki-ras gene, while adjacent areas 
from the same section contained cells with wild-type Ki-ras. There are at least 
two mechanisms by which such heterogeneity could have arisen. One mechanism 
involves the evolution of the two clones from separate stem cells (polyclonality). 
The other mechanism could simply reflect genetic instability in cancer where Ki­
ras mutant clones have arisen from previously established cancerous clone(s) 
containing wild type Ki-ras gene. Thus, the presence of genetic heterogeneity in a 
tumour by itself does not necessarily indicate a polyclonal origin but it merely 
indicates that a developed cancer can be composed of more than one clone. 
Giaretti et al. (1996), using FACS analysis, has confirmed the presence of Ki-ras 
heterogeneity in colorectal cancer. However, while Shibata et al. (1993) found 
evidence of Ki-ras heterogeneity in adenomas, different areas within colorectal 
carcinomas were found to be homogenous for Ki-ras mutations. These 
discrepencies in results between different investigators are not uncommon in
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cancer research since they usually reflect the effects of different methodologies, 
tumour materials used and personal interpretations of the presented data. For 
example, Shibata et al. (1993) have used a small number of patients (seven 
carcinomas) whose tumours have been pre-selected to contain Ki-ras mutations. 
This pre-selection step can be misleading because it excludes from the analysis 
tumours containing a small proportion of Ki-ras mutants. Also, in these “special” 
cases, mutant Ki-ras gene might have been a necessary genetic aberration for 
progression into carcinomas. Thus, finding Ki-ras homogenously mutated in 
different parts of a tumour does not necessary indicate that the tumour is not 
heterogenous for other markers, but rather could suggest a role for Ki-ras 
mutations in progression in some tumours. Indeed, the authors found loss of the 
normal p53 allele to be variable within the single cancer analysed and detected 
evidence, albeit in a small number of cases, of tumour heterogeneity with respect 
to the Ki-ras locus.
These observations were unfortunately attributed to contamination by 
normal cells or dismissed from the argument. In my case, the majority of primary 
tumours and their synchronous metastases contained the same mutation indicating 
the importance of Ki-ras mutations in tumour progression in some patients. A 
similar argument would also apply to the study of Boland et al. (1995). The 
authors findings that deletions involving 5q, 17p and 18q were homogeneously 
found in carcinomas could indicate the importance of these genetic aberrations in 
tumour progression and so can not be used as markers for tumour heterogeneity. 
This argument raises an important point about tumour progression in that there 
appear to be different mechanisms by which tumours progress. For example, those 
that require mutated Ki-ras gene for their progression, which appear
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homogeneous for that particular aberration (but can give the false impression of 
monoclonality or homogeneity in tumours), and tumours that require genetic 
aberrations other than mutated Ki-ras for their progression (the use of Ki-ras 
mutations in these tumours is a better indicator for the presence of tumour 
heterogeniety since they are not required for tumour progression).
Another caveat of particular relevance to the study of genetic 
heterogeneity in tumours is the stage at which the tumour is analysed. The 
analysis of advanced tumours could be misleading in term of the extent of genetic 
heterogeneity, since early heterogeneous tumours may become apparently 
homogeneous because of domination of tumours by a growing clone under strong 
selective pressures, to a point where the minor clones become undetectable. 
Although the use of tissue microdissection could alleviate this problem, the 
numbers of sites sampled and the size of patches used remain poorly standardised 
and potential sources of experimental errors.
The comparison of primary tumours and their synchronous metastases 
from the same patients by CGH revealed that both tumours share many common 
genetic events and that metastases, in some instances at least, not only 
accumulated additional genetic aberrations but contained other genetic defects that 
were not found in their primary tumours. This and other evidence suggests that 
primary tumours are heterogenous in their genetic composition and that, in some 
instances, the metastatic clone(s) could be a minor component in the genetic 
composition of primary tumours and, thus, could be easily masked in analysis. On 
the other hand, these additional or other genetic aberrations found only in 
metastases could have evolved within the metastases themselves. Nevertheless, 
tumour heterogeneity should be addressed whenever certain genetic event(s) are
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proposed as a prognostic marker for cancer progression or whatever clinical 
therapy is offered to patients. An important concept that has arisen from this work 
is that in, at least some patients, metastases to liver do not necessarily have 
accumulated more genetic aberrations than metastases to lymph nodes and that the 
genetic aberrations leading to liver or lymph nodes metastasis are significantly 
different. Thus, the genetic evolution of the two Dukes’ stages could be different 
and not necessarily consequential (Figure 35).
Metastasis is a complex process and the relevance of the genetic 
aberrations detected in this study to the evolution of metastatic clones will 
ultimately depend on thorough understanding of the effects of these changes at the 
molecular and cellular levels. This work represents a preliminary step in the 
ongoing war against cancer. As a pathologist, the work has offered me a unique 
privilege to realize the complexity of the metastatic process and the immense 
struggle that the clinicians and scientists together have to endure in the battles 
ahead.
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12.1. Future work
The result obtained in this work show valine-12, rather than aspartate-12, 
Ki-Ras protein to be associated with more aggressive tumours in vivo and cells 
expressing it with more invasive phenotype in vitro. To explain this different 
behaviour, a hypothesis, which suggests that valine-12 but not aspartate-12 Ki- 
Ras is able to bind Raf-1 or activate MAPK pathway, is proposed. This hypothesis 
is testable, and could be very rewarding indeed.
The results obtained using CGH also show certain chromosomal 
aberrations to be frequent in advanced colorectal cancer. I propose that future 
work should focus on narrowing the areas of interest using probes targetted 
against interesting genes within these areas. In particular, microarrays technology 
could be of immense benefit if properly applied to this type of work. Some genes 
of interest are listed in Table 13. It has to be noted, however, that the 
chromosomal aberrations found contain a large number of genes and that 
chromosomal areas found to be amplified or increased in copy number could 
potentially contain defective or deleted genes as well.
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Table 13: A summary of interesting genes for further persuit
Chromosome Current genes of interest
6p VEGF, P21, Cyclin D3, BAK, PIM-1, CDC5L
7p EGFR, PDGFA, TTIM1
8q c-MOS, c-MYC, FAK
9p ?16INK4, P14w
i i q Cyclin D l, BCL1, FGF4, FGF3, EMS1
13q DPI
17p P53
17q ERBB2, FGF1
18q SMAD2, SMAD4, DCC
20q AIB, BTAK, c-SRC, MMP-9
22 P300
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Figure 35: A simplified schematic representation o f clonal evolution in colorectal
cancer
Clonal evolution is represented rather like a tree with new clones 
hranshing from it. The thick red arrow represents the major clone in the primary 
tumour. A) Represents a scenario where by liver metastasis clones arise 
independently and at a different time from clones destined to colonise lymph 
nodes. B) Represents another scenario in which liver and lymph nodes metastatic 
clones evolve jointly but diverge at a later stage in the genetic evolution sequence.
Genetic
instability
Genetic
instability
Primary tumour 
clone
Liver metastatic 
clone
Liver metastatic  
clone
Primary tumour
c l o n e
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